A prolonged release in situ reconfiguring device for the delivery of drugs to solid tumors by Wadee, Ameena
A PROLONGED RELEASE IN SITU RECONFIGURING 
DEVICE FOR THE DELIVERY OF DRUGS TO SOLID 
TUMORS 
AMEENA WADEE 
 
A dissertation submitted to the Faculty of Health Sciences, University of the Witwatersrand, in 
fulfillment of the requirements for the degree of Master of Pharmacy 
Supervisor: 
Professor Viness Pillay 
Department of Pharmacy and Pharmacology, University of the Witwatersrand, South Africa 
Co-Supervisors:  
 Professor Yahya E. Choonara 
Department of Pharmacy and Pharmacology, University of the Witwatersrand, South Africa 
Ms Lisa C. du Toit 
Department of Pharmacy and Pharmacology, University of the Witwatersrand, South Africa 
and 
Doctor Clem Penny 
Department of Medical Oncology, University of the Witwatersrand, South Africa 
 
Johannesburg, 2012 
 
i 
 
DECLARATION 
I, Ameena Wadee, declare that this dissertation is my own work. It has being submitted 
for the degree of Master of Pharmacy in the Faculty of Health Sciences at the 
University of the Witwatersrand, Johannesburg. It has not been submitted before for 
any degree or examination at this or any other University. 
 
 
 
 
…………………………………. 
 
This …….. day of October 2012 
 
ii 
 
RESEARCH OUTPUTS 
1. Publications 
a. Ameena Wadee, Viness Pillay, Yahya E. Choonara, Lisa C. du Toit, Clement 
Penny, Valence MK Ndesendo, Pradeep Kumar and Caragh S Murphy. 2011. 
Recent advances in the design of drug-loaded polymeric implants for the treatment 
of solid tumors. Expert Opin. Drug Deliv. 8:1323-40. (Abstract in appendix A (I)) 
b. Determination of the effect of release of methotrexate from an in situ forming 
implant on colon carcinoma cells and in vivo studies in the rat model. 2011. 
Ameena Wadee, Viness Pillay, Yahya E. Choonara, Lisa C. du Toit, Clement 
Penny, Pradeep Kumar and Leith Meyer.  South African Pharmaceutical Journal. 
78:49-50. (Abstract in appendix A (II)) 
 
2. Conference Outputs : Poster Presentations 
a. Farhana Ravat, Ameena Wadee, Viness Pillay, Yahya E. Choonara and Lisa C. 
du Toit. Formulation approaches for interactive pH-responsive nanoparticles. 29th 
Annual Conference of the Academy of Pharmaceutical Sciences, 22-26 September 
2008, Rustenburg, South Africa. (Abstract in Appendix B (I)) 
b. Ameena Wadee, Palesa Sekano, Viness Pillay, Yahya E. Choonara and Lisa C. 
du Toit. The effect of gum arabic on the physicomechanical properties and drug 
release behaviour of thermoresponsive poly(methylvinyl ether) gels. 5th ICPPS 
conference, 23-26 September 2009, Potchefstroom, South Africa. (Abstract in 
appendix B (II)) 
c. Ameena Wadee, Viness Pillay, Yahya E. Choonara, Lisa C. du Toit, Clement 
Penny and Valence MK Ndesendo. An injectable in situ forming implant for the 
treatment of solid tumors utilizing a central composite design. International 
Symposium on Stimuli Responsive Materials, 26 and 27th October 2010. 
Mississippi, USA. (Abstract in appendix B (III)) 
 
3. Conference Outputs : Podium Presentations 
a. Ameena Wadee, Viness Pillay, Yahya E. Choonara, Lisa C. du Toit and Clement 
Penny. The development of an in situ forming implant for the treatment of 
osteosarcoma: Autoclaving as a sterilization method. Postgraduate Cross-
Symposium. September 2010, University of the Witwatersrand, Johannesburg, 
South Africa. (Abstract in appendix B (IV)) 
iii 
 
b. Ameena Wadee, Viness Pillay, Yahya E. Choonara, Lisa C. du Toit and Clement 
Penny. The development of an in situ forming implant for the treatment of solid 
tumors: Determination of the effect of methotrexate release on colon carcinoma 
cells and in vivo studies in the rat model. 6th ICPPS Conference, Adcock Ingram 
Young Scientist Competition, 25th- 28th September 2011, Umhlanga, Kwa-Zulu 
Natal, South Africa. (Abstract in appendix B (V)) 
 
4. Patent Application 
Ameena Wadee, Viness Pillay, Yahya E. Choonara, Lisa C. du Toit and Clement 
Penny. An implant for the controlled release of drugs. SA Patent Application No: 
2010/03745, 02-05-2008 (Preliminary filing).  
 
5. Accolades 
Postgraduate Merit Award, University of the Witwatersrand, 2008 and 2009 
TATA Africa Scholarship, 2010, 2011 
Winner of the Adcock Ingram Young Scientist Award: The development of an in situ 
forming implant for the treatment of solid tumors: Determination of the effect of 
methotrexate release on colon carcinoma cells and in vivo studies in the rat model. 
6th ICPPS Conference, 25th- 28th September 2011, Umhlanga, Kwa-Zulu Natal, 
South Africa. 
 
iv 
 
ABSTRACT 
The poor response of patients to high-dose chemotherapy commonly associated with 
the treatment of solid tumors has led to research efforts in the development of implants 
for the delivery of drug directly to solid tumors. In order to prevent surgical 
complications associated with the placement of an implant at the site of the tumor, 
efforts have been made to develop implants which form at the site of the tumor. 
This study aimed to develop an In Situ Forming Implant (ISFI) which was responsive to 
temperature and able to form an implant when injected into the body and to release 
drug over a period exceeding one month. To this end, a thermoresponsive polymer, 
poly(methyl vinyl ether) was selected and following preformulation studies to assess 
release and gelation temperature, a Design of Experiments approach was utilised to 
formulate an optimal formulation.  
Fourteen formulations were prepared according to a Face-Centred Central Composite 
Design selected and were assessed for gelation temperature, ease of injectability and 
Mean Dissolution Time. Utilising the experimental values obtained, regression models 
for each of the outcomes were generated. The optimal formulation was then 
determined by selecting the appropriate targets for each of the responses in the 
design. The optimal formulation was able to gel at body temperature, could be injected 
into the body and showed release of entrapped chemotherapeutic, methotrexate for a 
period exceeding one month.  
pH-responsive microparticles were also formulated and optimized using a Face-
Centred Central Composite Design.  Optimized particles were then loaded into the 
optimized ISFI and displayed faster release of the entrapped drug than with the 
dispersed drug.  
In vitro testing of the ISFI was conducted against solid tumor forming cells and in vivo 
testing was conducted in healthy Sprague-Dawley rats. A few rats developed toxicity to 
methotrexate after 6 days, however, low quantities of drug were found in the plasma. In 
addition, drug was present in the surrounding tissue in a high concentration even after 
10 days.  
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CHAPTER 1  
INTRODUCTION 
1.1.  The Burden of Cancer 
Cancer is the broad classification for a number of diseases characterised by the 
uncontrollable growth and spread of cells. It is a leading cause of death worldwide and 
it is estimated that deaths from cancer will continue to increase and cancer will be 
responsible for 7.9 million deaths by 2030 (Globocan, 2008, IARC, 2010). Cancer is 
estimated to be the cause of 1 in 8 deaths worldwide, more than HIV/AIDS, malaria 
and tuberculosis combined (American Cancer Society, 2010). Of all the deaths 
estimated to be caused by cancer in the United States of America for 2010, solid 
tumors account for approximately 90% (American Cancer Society, 2010).  
 
1.1.1.  The Pathology of solid tumors, barriers to treatment and current therapy  
Solid tumors are characterised by masses of abnormal cells often in sheets or nests 
surrounded by supporting stroma. This stroma contains connective tissue cells and 
other cells but is composed mainly of blood vessels (Murray and Carmichael, 1995) 
Solid tumors develop their own blood supply and it has been reported that a tumor 
cannot grow more than 1-2mm in diameter without causing angiogenesis (Folkman, 
1990). A highly perfused tissue would imply excellent drug delivery to the area. 
However, the problem lies in the structure of the vasculature. Angiogenesis is often 
erratic in solid tumors and tumors often consist of a well perfused outer region and a 
poorly perfused necrotic centre.  Hence, systemically administered drugs may reach 
the exterior layers but rarely reach the central area (Murray and Carmichael, 1995). 
This poor perfusion is mainly due to the low movement of drugs from the blood vessels 
into the stroma of the tumor and hence to the cancerous cells. Although the 
endothelium of the blood vessels in the area of the tumor does appear to “leak” more 
than normal cells due to large spaces between the endothelial cells, abnormally formed 
basement membrane and fenestration (Munn, 2003),  drugs are not taken up well into 
the stroma. This is thought to be due to the high interstitial hydrostatic pressure in the 
stroma or a diminished vascular pressure in the tumor region (Makrilia et al., 2009). 
The problem of erratic vasculature architecture is compounded by variable blood flow 
rates in the tumor region due in part to variable vessel sizes as shown in Figure 1.1. As 
Figure 1.1 also shows, blood flow may be high in some regions and low in others and 
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this pattern is not constant and can vary in minutes to hours (Patan et al., 1996). 
Further, Munn (2003) proposes that much of the systemically delivered drug which 
does diffuse into the stroma is shunted through the tumor and is reabsorbed by other 
blood vessels or enters the lymphatics of the tumor which are found mostly on the 
periphery of the tumor. Hence very little of the systemically delivered drug is actually 
delivered to the cells. 
 
 Another barrier to treatment is the 3-dimensional structure of the solid tumors, in that 
drug penetration into solid tumors is 5-10 fold less when compared to penetration into a 
single layer of cells (Au et al., 2001). 
 
 
Figure 1.1: Simplified schematic showing the barriers to effective therapy of solid 
tumors (venous blood drainage not shown). 
 
Current therapy of tumors involves surgical resection, the delivery of drugs mostly via 
the intravenous route (Wong et al., 2007) and the use of adjunctive radiotherapy. Oral 
therapy is often used following surgical resection or in hormone sensitive tumors. 
However, as discussed, oral and even intravenous drug delivery cannot successfully 
treat the majority of solid tumors. In order to overcome the problem of delivery of drugs 
to solid tumors as highlighted, high doses of drug are given to patients via the 
Areas of low perfusion
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Some drug in tumour area
Drugs with rapid plasma 
clearance do not reach  the 
tumour area in sufficient 
quantities
Very little systemic blood flow 
reaches the tumour site
Variable vessel sizes 
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of some drug molecules 
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effect on the tumour
Very few drug 
molecules diffuse into 
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interstitial pressure in 
the tumour or lowered 
hydrostatic pressure in 
vasculature
3 dimensional structure of 
tumour
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intravenous route. However, this worsens the problem as only a small portion of 
systemic blood flow reaches the tumor, and hence only a small fraction of the delivered 
dose is available at the site of the tumor (Weinberg et al., 2007). Instead most of the 
drug reaches healthy tissue and exerts its action resulting in numerous side effects. 
Hence the host (i.e. the patient) tolerability to the high doses of chemotherapy that are 
often used must also be considered (Gaze et al., 1995 and Schiller, 2008). Further, 
some drugs pose an additional barrier as they have rapid plasma clearance and as a 
result short exposure times to the tumor (Weinberg et al., 2007). 
 
1.1.2. Current methods proposed for overcoming barriers to effective solid tumor 
therapy 
One solution to the problems associated with the delivery of drugs to solid tumors is the 
development of novel drugs or other therapeutics which only target cancer cells. 
However, the time taken for a novel compound from development stage to reach the 
patient is a long one and the expense of such development is considerable (Adams 
and Brantner, 2010). Another simpler solution to the treatment of solid tumors is to find 
ways to deliver existing drugs such that the current problems faced are overcome. 
Hence focus has shifted to more targeted drug delivery systems (Hughes, 2005). 
Numerous methods of delivering drugs to solid tumors have been proposed and this 
includes the use of implants at the site of the tumor (Seong et al., 2003; Ruel-Gariépy 
et al., 2004 and Han et al., 2008).  
 
Carmustine loaded poly-lactic-co-glycolic-acid (PLGA) microparticles in an implantable 
wafer have shown exceptional results in the treatment of malignant glioma, a solid 
tumor of the brain (Seong et al., 2003). An implant of paclitaxel intended for injection at 
the tumor site has also been developed and shown to prolong the life of the tumor-
bearing rats considerably (Ruel-Gariépy et al, 2004). Han and co-workers (2008) 
synthesised a chitosan hydrogel which combined an anti-cancer drug (chemotherapy) 
and a vaccinia virus vaccine (immunotherapy). This device prolonged the lives of tumor 
bearing rats by approximately 60 days. An implanted drug delivery system at the site of 
the tumor offers solutions at many levels. The drug is not as systemically distributed as 
an intravenously administered drug and subsequently a lower dose can be 
administered and the chances of systemic side-effects are significantly reduced. 
Further some of the diffusion barriers are reduced as the drug is now at high 
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concentrations at the site of the tumor and hence would be able to diffuse more rapidly 
and penetrate the solid tumor effectively. Further, the implant can be formulated to 
release drug over a number of weeks or even months decreasing the need for the 
patient to return to the hospital for systemic treatment, or eliminating the need to take 
medication daily and hence improving patient acceptability and compliance (Vassileva 
et al., 2007 and Pulsipher et al., 2009). 
 
Drug delivery systems which are micro- or nano- enabled have also been designed for 
the treatment of solid tumors. Microparticles such as those formulated by Lin and co-
workers (2005), consisted of PLGA microparticles loaded with doxorubicin, a potent 
anti-cancer drug.  PLGA was also utilized to formulate paclitaxel loaded microparticles 
for the treatment of brain cancer by Elkharraz et al. (2006). As mentioned previously, 
PLGA microparticles were also formulated by Seong et al. (2003) and incorporated into 
wafers for the treatment of malignant glioma.  In terms of nanoparticles, Cegnar and 
co-workers (2004) have used poly(lactic-co-glycolic acid) (PLGA) nanoparticles 
containing a novel chemotherapeutic, cystatin and successfully showed the efficacy of 
nanoparticulate drug delivery to tumors. The advantages of nano-enabled devices are 
numerous and include the ability of these small particles to penetrate biological barriers 
(Hughes, 2005), and to be retained at the tumor site as per the enhanced permeation 
and retention effect (EPR) (Matsumura and Maeda, 1986). However, the problem with 
particles on the micro and nano level is the difficulties experienced in the scale up 
process and ultimate wide spread use. 
 
These systems are by no means the entirety of the research that has been done on 
solid tumor treatment. Chapter 2 of this dissertation expands on the numerous other 
systems that have been researched. 
 
1.1.3. The cost of cancer 
The costs of cancer are considerable. It is estimated by the US National Institute of 
Health that the overall cost of cancer in 2010 is $263.8 billion: $102.8 billion for direct 
medical costs, $20.9 billion for indirect morbidity costs such as the lost of productivity 
due to illness and $140.1 billion for indirect mortality costs such as lost of productivity 
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due to premature death (American Cancer Society, 2010). While exact South African 
statistics are not available, a similar pattern is expected.  
 
Considering medical costs and intravenous delivery of drugs, the following must be 
considered. Chemotherapeutics, especially newer modalities, are costly to manufacture 
and a further problem with intravenously delivered drugs is the costs involved: a 
pharmacist is often required to extemporaneously prepare the intravenous dose and 
nurses are required for administration. In South Africa, where public health care 
provides for many patients with various disease states, who cannot afford medical 
insurance, the healthcare system is overburdened. This may further complicate 
effective treatment of solid tumors as often patients may not be able to be treated 
appropriately due to lack of resources. It should also be noted that older drugs often 
have greater side-effect profiles. A study of drug sales in 25 countries was undertaken 
by Jönsson and Wilking, (2007) with 19 European countries and 6 countries outside of 
Europe including South Africa. The study showed the slow uptake of new drugs in 
South Africa (Jönsson and Wilking, 2007). 
 
Chemotherapeutics are often given weekly to patients and a factor cited by American 
patients (American Cancer Society, 2010) is the transport costs. In South Africa, the 
situation is expected to be the same with a further complication of rural living. Patients 
in rural areas must be expected to travel to urban areas to receive treatment at 
secondary or tertiary healthcare institutions. Naturally this provides a significant 
challenge. Patients failing to come in to the hospital run the risk of complications such 
as resistance of cancer cells to therapy thought to be influenced by subtherapeutic 
levels of drug (Weinberg et al., 2007).  
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Figure 1.2: Schematic showing 4 factors affecting the costs associated with 
intravenous chemotherapy. 
 
Another South African situation is that the overburdened health care system and the 
exorbitant cost associated with private health care means that some patients may not 
be diagnosed until later stages of cancer and treatment at that stage may be more 
extensive and costly. Considering the burden of other diseases in SA such as HIV, 
tuberculosis and malaria, cancer is neglected compared to these infectious diseases. 
 
Lastly, considering the side effects associated with cancer chemotherapy, treatment of 
these may add to costs as well. Complications such as neutropenic pneumonia which 
may arise in patients receiving chemotherapy must also be treated. In cases of severe 
neutropenia or anaemia or other complications, patients may require hospitalisation 
which has even more costs associated with it and may be associated with further 
complications such as nosocomial infections. Factors affecting the cost of 
chemotherapy are schematically represented in Figure 1.2. 
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Treatment of 
complications 
Drug cost 
Treatment of 
side effects 
Preparation 
and delivery 
of drugs: 
Specialised 
personnel 
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1.2. Rationale and Motivation for the Study 
Considering the challenges facing drug delivery to solid tumors such as poor blood flow 
and perfusion as outlined above as well as the costs involved in the treatment of solid 
tumors, the development of an effective method of drug delivery will prove beneficial.  
 
This study aimed to develop a novel stimuli responsive biodegradable In Situ Forming 
Implant (hereafter referred to as the ISFI). As mentioned previously, tumor sites are 
unique in their biochemistry and hence the microenvironment of a solid tumor varies 
from the environment surrounding healthy cells. Two of the microenvironmental 
characteristics selected for study in this dissertation were temperature and pH. The pH 
of interstitial fluid surrounding a tumor is approximately 6.75 which differs significantly 
from the interstitial fluid of normal body cells of approximately 7.23 (Martin and Jain, 
1994). An in situ forming implant would overcome the problems of poor systemic drug 
delivery and the reduction in side effects and complications would reduce costs.  
 
The ISFI was to be injected at the site of the tumor and would form an implant in this 
position due to its response to an inherent stimulus present at the tumor site. The ISFI 
was intended to treat solid tumors in general, by using colon cancer as a model for 
solid tumors.  
 
The ISFI as described in this study would exist as a sol at room temperature. Upon 
administration via an injection through an 18G needle to the site of the tumor, the sol 
would interconvert to a gel-state. The ISFI was hence expected to be responsive to 
temperature of the body. The ISFI would be injected into the tissue using conventional 
means to prevent further costs. The drug would be dispersed in the formulation and 
release from the implant would occur slowly, ideally over a period exceeding one 
month. The delivery over a month would reduce visits to the hospital hence decreasing 
costs.  
 
Should the ISFI release the drug too quickly, the use of particles (either micro- or nano- 
meters in size), as described in Figure 1.3 in the interests of improving the ISFI, was to 
be considered.  These particles were to be composed of a stimuli-responsive polymer 
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and were to serve to improve the release of drug from the implant. Firstly the particles 
would contain the drug and the response of the polymer, that forms the micro- or nano- 
particle, to the stimulus in the tumor environment would result in the release of the 
drug. Alternatively the particles would contain a substance, experimentally determined, 
hereafter referred to as the erosion controlling substance (ECS), which would influence 
the erosion of the polymer forming the hydrogel matrix by either increasing or 
decreasing the rate of erosion of the hydrogel. The stimulus for the particles was 
envisaged to be pH, and the micro- or nano- particles composed of a pH responsive 
polymer would respond to the pH at the tumor and release either the drug or the ECS 
(contained in the particles). 
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Figure 1.3: Proposed mechanism of the ISFI formation and drug release when loaded 
with microparticles 
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1.2.1. Rationale for the chemotherapeutic drug utilised in this study 
Folic acid acts as a coenzyme for a number of biochemical reactions in vivo. 
Dihydrofolate reductase is an enzyme requiring the presence of folic acid especially in 
the de novo synthesis of thymidylic acid and purine nucleotides and hence is important 
in the division of cells. Methotrexate inhibits the activity of this enzyme due to its 
structural similarity to folic acid (Chu and Sartorelli, 2004). As cancer cells are actively 
dividing, the drug inhibits the rapid division of the cells, leading to a decrease in the 
size of the tumor. It is widely used in the treatment of neoplastic diseases especially in 
combination treatment regimens (Avendaño and Menéndez, 2008).  Due to the high 
cost of chemotherapeutic drugs, methotrexate provides the ideal model due to its 
similarity to folic acid. Folic acid is a much cheaper and more readily available drug and 
as a result the majority of preliminary work conducted in this study was with folic acid. 
Methotrexate was only used in the optimized formulation and during in vitro cell line 
work and in vivo animal work conducted. 
 
1.3. Aims and Objectives of the Study 
The aim of this study was to formulate an ISFI for the treatment of solid tumors using 
colon cancer as a suitable model. Polymers used in the formulation of this implant 
would be stimuli-responsive and respond to specific stimuli around tumor site. The ISFI 
would be injected at the site of the tumor and form an implant in vivo. In this way the 
ISFI, containing a suitable drug, would release drug in a controlled manner- either from 
the micro- or nano- particles or directly from the implant at the site of the cancer lesion. 
In order to achieve this, the following objectives needed to be achieved: 
1. To select a suitable stimuli-responsive polymer in order to formulate an implant 
that will form in situ and to modify these polymers with the addition of excipients 
as necessary. 
2. To develop an implant that could release the model drug, folic acid over a 
period exceeding one month. 
3. To optimise the ISFI formulation using a Design of Experiments approach. 
4. To investigate the possibilities of a micro-enabled system. The microparticles 
would contain the drug or would serve as a way to enhance the biodegradation 
of the polymer and would also be optimized using an experimental design. 
5. To determine the physicomechanical properties of the various components of 
the optimized ISFI and microparticles, including the rheological properties of the 
ISFI and the morphology of the microparticles. 
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6. To load the implant with the cytotoxic drug, methotrexate and investigate the in 
vitro drug release. 
7. To determine an effective sterilisation method for the ISFI such that would not 
be detrimental to the either release or the formation of the implant in vivo.  
8. To investigate the effect of the release fractions on solid tumor cell lines. 
9. To perform in vivo studies in the Sprague-Dawley rat model, in order to 
determine the drug release behaviour from the ISFI and the biocompatibility of 
the implant. 
 
1.4. Novelty of the ISFI 
The novelty of the ISFI lies mostly in the use of a polymer which has not been used for 
such purposes before. In addition the following objectives were to be achieved in order 
to formulate a novel ISFI: 
1. Drug release would be over a prolonged period, ideally for at least one month.   
2. Micro- or nano- particles would be incorporated into the ISFI, if necessary. 
These particles would contain the drug or an erosion controlling substance 
(ECS).   
 
1.5. Overview of this Dissertation 
Chapter One serves as the introduction of the dissertation and describes the 
pathophysiology of solid tumors in order to highlight the problems preventing the 
successful treatment of solid tumors. The novelty of the work and the aims and 
objectives of this work are also discussed.  
 
Chapter Two is a literature review focussing on the work that has been conducted by 
other researchers in the development of polymeric implants for the treatment of solid 
tumors. It also provides insight into the use of stimuli responsive materials as implant-
forming systems. 
 
Chapter Three outlines the preformulation investigations undertaken in the 
development of the in situ forming system. Utilising this information, variables for an 
experimental design were obtained.  
12 
 
 
Chapter Four describes the utilization of a Face-Centred Central Composite Design in 
the determination of an optimum ISFI formulation. The formulations were tested for in 
vitro release behaviour, ease of injectability and gelation temperature. An investigation 
into the effects of autoclaving as a sterilisation method are also described. 
 
Chapter Five introduces the pH responsive particles, briefly describes preformulation 
of the particles and subsequent optimization of the particles using a Face-Centred 
Central Composite Design. The effect of some formulation variables on the response 
parameters (drug entrapment and drug release) was ascertained and utilised in the 
development of an optimal formulation. The combination of ISFI and particles was also 
investigated for rheological properties and drug release and are reported on. 
 
Chapter Six describes the in vitro testing of the implant and particles on various cancer 
cell lines. The use of flow cytometry and MTT assays are described and the results 
obtained from the two methods of viability testing of cells are compared. 
 
Chapter Seven reports on the in vivo work conducted on the Sprague-Dawley rat 
model. Ultra Performance Liquid Chromatography quantification of the amount of drug 
in the plasma is described and the results evaluated. The biocompatibility of the 
implant is also discussed. 
 
Chapter Eight lists shortcomings of the system and provides recommendations and 
suggestions for future work on this system. 
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CHAPTER 2  
RECENT ADVANCES IN THE DESIGN OF DRUG-
LOADED POLYMERIC IMPLANTS FOR THE 
TREATMENT OF SOLID TUMORS 
2.1. Introduction 
Implantable systems offer a number of advantages in the delivery of drugs to the 
human body. From a therapeutic point of view, high levels of drug can be achieved at 
the site of implantation. Considering conventional treatment methods for solid tumors 
often involve administration of high doses of chemotherapeutic agents (Gaze et al., 
1995 and Schiller et al., 2008) and chemotherapeutic agents such as cytotoxic drugs 
are limited by toxicity to healthy body cells (Vassileva et al., 2007 and Pulsipher et al., 
2009), an implant delivering high doses of drug only (or mostly) to the tumor area offers 
a clear advantage.  It has been shown that employing an implant at the site of the 
tumor instead of an intravenously delivered chemotherapeutic agent may overcome 
this problem (Vassileva et al., 2007 and Berrada et al., 2005). The chances of systemic 
side-effects are much reduced due to the localized therapy exerted by the implant.  
 
From a patient-centered viewpoint, implant systems in general, offer the advantage of 
compliance such as in the treatment of schizophrenia, where mental incapacitation 
may affect compliance or in the prevention of pregnancy where forgetting to take a 
single tablet can result in treatment failure. In the case of cancer where patient 
compliance is not usually a factor to be considered, implants offer convenience. An 
implant formulated to release drug over a number of weeks or even months decreases 
the need for the patient to return to the hospital weekly for systemic treatment, or 
eliminates the need to take medication daily and hence improves patient acceptability.  
 
A number of implants have been marketed for the treatment of cancer and are 
registered with Food and Drug Administration (FDA) USA are Zoladex®, Gliadel® and 
Eligard® (Table 2.1). Each of these implants is discussed more fully under the polymer 
utilised in the formulation of the implant. 
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Table 2.1: Currently available implant systems for the treatment of cancer. 
Product Condition Drug 
incorporated 
Year of 
approval 
by FDA 
Company 
Zoladex® Advanced 
prostate cancer 
Goselerin 1996 AstraZeneca PLC 
Gliadel® Malignant human 
glioblastoma 
BCNU 1997 Guilford 
Pharmaceuticals, 
Inc 
Eligard® Advanced 
prostate cancer 
Leuprolide 
acetate 
2002 Atrix Labs, Inc 
 
 
The use of implanted devices in the treatment of cancer can be divided into two 
therapeutic applications. Either the implant is intended for the delivery of 
chemotherapeutics as treatment or the implant is intended for “prophylaxis” following 
tumor resection (Jackson et al., 2000). The reasoning behind “prophylactic” 
applications is that there is often recurrence of the tumor within 2cm of the resected 
site (Jackson et al., 2000). Gliadel® is used for the treatment of malignant human 
glioblastoma and is placed at the site of the tumor. Zoladex® and Eligard® are used for 
the treatment of advanced prostate cancer and exert their action centrally by inhibiting 
central hormone production and are therefore not placed at the site of the tumor.  
 
Implants that are intended for the treatment of tumors are often in situ forming implants 
(Eliaz and Kost, 2001). These are injected into the body and form a solid implant at the 
tumor site often in response to a local stimulus. While an obvious advantage of such a 
system is that invasive surgery is not required and the system can be easily injected 
into the patient using conventional methods, a possible disadvantage is the use of a 
local stimulus for formation of the implant since patient variability in local tumor 
conditions may influence the formation of the implant. Implants used for prophylaxis are 
often pastes or pre-formed implants that are applied to or placed at the site during 
surgery (Brem, 1996 and Gopferich, 1997). These implants may be formed by a 
number of methods, including crosslinking and photo-polymerization. An advantage of 
such a system is that all implants are of the same size and shape while a major 
disadvantage is that surgical implantation is required. This review provides a critical 
assessment of the various attempts that have been made in the novel treatment of 
tumors using polymeric implants that are intended for the delivery of drugs directly to 
the tumor sites.  
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2.2. In situ Forming Implants 
In situ forming implants (ISFIs) exist as solutions (sol) at room conditions and convert 
into a gel like phase when exposed to a certain stimulus. Such a stimulus may be ionic 
or chemical crosslinking (Pezron et al., 1988) or photopolymerisation (Bosch et al., 
2000 and Wei et al., 2005) or a local environmental stimulus such as pH, ionic strength 
or temperature (Klouda and Mikos, 2008). There are also a number of in situ forming 
implants which are not based on stimuli-sensitive nature of the implant but rather form 
as a result of organic solvent diffusion (Pucetti and Leblanc, 1996). Figure 2.1 shows 
the main mechanisms of implant formation. 
 
 
Figure 2.1: Schematic depicting some of the mechanisms of formation of implants in 
situ. 
 
The stimuli-sensitive polymers which have been intensively investigated are those 
which respond to temperature change (Park and Song, 2006; Zhang and Misra, 2007; 
Lue et al., 2008 and Cole et al., 2009).This is due to the slightly higher temperature of 
most tumors (Babich, 2005). These polymers can form gels by two mechanisms. This 
is either through exhibition of an upper critical solution temperature (UCST) or a lower 
critical solution temperature (LCST). The UCST is exhibited by polymers which have 
some critical temperature below which they form a precipitated gel like phase whereas 
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heating the gel forms a homogenous solution (He et al., 2008) The LCST group of 
polymers exists as solutions below the LCST but form gels at temperatures exceeding 
the LCST (ten Brinke and Karasz, 1984; Geever et al., 2006; Zhou et al., 2007; Klouda 
and Mikos, 2008 and He et al., 2008). An example of such a polymer is poly(N-
isopropylacrylamide) (pNIPAAm).  The biggest advantage of thermal gelation is that it 
occurs almost instantaneously following the polymer reaching the LCST while other 
methods of chemical gelation take a few minutes (Hacker et al., 2008). The lag phase 
between the formation of a solid from the liquid phase may give rise to an undesirable 
initial burst effect (Schuetz et al., 2008). The pH of the interstitial fluid that surrounds 
the tumor cells is approximately 6.75. Thus, it differs quite considerably from the pH of 
the interstitial fluid that surrounds the normal body cells, which is approximately 7.23 
(Martin and Jain, 1994). This presents another stimulus at the site of the tumor that can 
be utilized to develop stimuli sensitive implants (Schmaljohann, 2006).  
 
As depicted in Figure 2.1, implants that form in situ may do so as a result of phase 
separation. In this case, the implant consists of a blend of a water insoluble polymer 
and a water-miscible solvent. This is then injected into the tumor area, the solvent 
diffuses out of the solution causing the polymer to precipitate out and an in situ implant 
is formed (Ravivarapu et al., 2000). The obvious downfall of such a system is the 
potential toxicity of the implant if the solvent used is toxic or not biocompatible. Eligard® 
is a registered product that utilizes this technology for the delivery of leuprolide acetate. 
The polymer that has been employed is poly (D,L-lactide-co-glycolide) and the 
pharmaceutically acceptable solvent is (N-methyl-2-pyrrolidone) (NMP). The PLG 
copolymer consists of a 75:25 ratio of D,L lactide to glycolide. Table 2.2 summarizes 
the attempts made by a number of researchers in the treatment of various tumors using 
in situ forming implants. 
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Table 2.2: Drug, type of tumor and the polymers employed for in situ forming implants. 
Polymer used Drug used Model and tumor 
line 
Reference 
Chitosan-GP Paclitaxel EMT-6 (mouse 
mammary tumor) 
Ruel-Gariépy et al., 
2004 
Chitosan-GP DOX and 
vaccinia viral 
vaccine 
Murine TC-1 (cervical 
cancer) 
Han et al., 2008 
Chitosan-GP Camptothecin RIF-1 (mouse 
fibroblastoma) 
Berrada et al., 2005 
Photcrosslinkable 
Chitosan 
Paclitaxel 3LL (Lewis lung 
tumor) 
Obara et al., 2005 
Acrylated 
Chitosan-
Poloxamer® 
Conjugated 
DOX 
A549 (Human Lung 
adenocarcinoma) 
Cho et al., 2009 
Albumin-TAD DOX WiDr (human colon 
carcinoma) 
Kakinoki and Taguchi, 
2007 
Collagen-
ephidrine 
5-FU/ DOX/ 
cisplatin 
BxPC-3 and PANC-1 
(human pancreatic 
cancer) 
Smith et al., 1995 
pNipaam-co-AA - SKOV-3 (human 
ovarian tumor) 
Meyer et al., 2001 
PEG Topotecan MAT BIII (breast 
cancer) 
Lalloo et al., 2006 
Atrigel® Cisplatin T4N2aMO(squamous 
carcinoma of 
supraglottic larynx) 
Chen et al., 2003 
Pluronic® 
F127/Poloxamer 
407 
Paclitaxel B16F1 (murine 
melanoma) 
Amiji et al., 2002 
GP: glycerophosphate; DOX: Doxorubicin; TAD: Tartaric acid derivative;5-FU: 5-flourouracil; 
AA: Acrylic acid; PEG: polyethylene glycol 
 
2.3. Implants Based on Natural Polymeric Sources 
2.3.1. Chitosan 
2.3.1.1. In situ forming implants  
Of all natural stimuli-responsive polymers, chitosan has been studied extensively in 
terms of its use for the treatment of cancer (Berrada et al.,2005; Ho et al., 2005 and 
Cho et al., 2009). The properties of chitosan, such as thermo- and pH- responsiveness 
as well as its biocompatibility, biodegradability, and mucoadhesiveness, make chitosan 
an ideal candidate for implant formation. In addition, chitosan can be used at low 
concentrations for the purpose of decreasing the chances of toxic effects in vivo 
(Berrada et al., 2005). A further advantage is that the chitosan solutions can be easily 
sterilized (Ruel-Gariépy and Leroux, 2004). Gelation of chitosan can be achieved 
through three mechanisms. Firstly, in the presence of salts such as glycerophophate, 
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chitosan can form a gel when exposed to body temperature (Chenite et al., 2000). 
Secondly, the formation of a chitosan hydrogel can be triggered by UV irradiation as 
already documented by Ono et al., (2000) who used azide-derived chitosan. Thirdly, 
chitosan is highly soluble at low pHs and poorly soluble at high pHs, thus forming 
viscous gels at physiological pH (Ganguly and Dash, 2004).  
 
Recently, Cho et al. (2009) conjugated doxorubicin (DOX) to acrylated chitosan and 
Pluronic® in an attempt to obtain sustained release of the chemotherapeutic agent. The 
hydrogels formed as a result of both photo-crosslinking as well thermoresponsiveness. 
As a result the formed hydrogels were mechanically robust and when compared to gels 
consisting of free DOX in a mixture of chitosan and Pluronic®, the release from the 
DOX-conjugated-chitosan-Pluronic® was significantly slower and over a longer period 
of time (40% DOX was released after 15 days) and the burst release that was 
established with the other hydrogel was not observed here. In vivo animal studies were 
conducted in athymic mice bearing human lung adenocarcinomas. The decrease in the 
tumor size appeared to mimic the obtained in vitro results as the size of the tumors 
decreased rapidly initially in mice receiving hydrogels containing free DOX (due to the 
burst release of drug) followed by an increase in tumor size indicating re-growth of the 
tumor due to the lack of further drug  release. In contrast, mice receiving the DOX-
conjugated-chitosan-Pluronic® showed a slow decrease in the size of the tumor initially 
but the tumor size at the end of 30 days was 22% less than the baseline tumor, 
indicating significant improvement. However, although the photo-initiator used was 
FDA approved, the use of photo-crosslinking can be detrimental to the drug and lead to 
degradation of the drug and must be performed for the minimum amount of time (Cho 
et al., 2009). This can potentially be a drawback to clinical application of the formulation 
as alteration of the required time for irradiation may lead to different release profiles.  
 
2.3.1.2. Pre-formed chitosan implants.  
Chitosan egg-Phosphatidyl (C-eP) implants were investigated by Ho et al., 2005 as 
well as Soo et al, 2008. Both implants were intended for the local treatment of ovarian 
cancer and contained paclitaxel. Ho et al., 2005 implants demonstrated in vitro zero 
order drug release over a period of 5 days. Soo et al., 2008 loaded the C-eP implant 
with PLA-b-PEG/PLA nanoparticles loaded with paclitaxel. They subsequently 
investigated the in vitro behavior of the implant in ascites fluid, of which a build up often 
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occurs in ovarian cancer. Furthermore, the effect of the implant in mice was 
investigated. The in vitro and in vivo results correlated well and the release of paclitaxel 
in vivo was over a period of 4 weeks (Soo et al., 2008). No local signs of toxicity were 
observed. Ho et al., 2005 investigated the effects of the implant on multi-drug 
resistance. The effect of the sustained release of paclitaxel from the implant was 
compared with the effect of intermittent intraperitoneal dosing with paclitaxel formulated 
in Cremophor EL®. The determination of multi drug resistance was carried out in vitro 
on cancer cell lines and in vivo on tumor bearing mice. After 14 days, cells that 
received paclitaxel- Cremophor EL® showed a two-fold increase in mRNA levels, an 
effect that was not observed with cells receiving the implanted device (Ho et al., 2005). 
In addition, there was also a significant induction of efflux activity of the drug 
transporter, PGP by the paclitaxel-Cremophor EL® dosing which was not seen with the 
implanted system. This indicates that the sustained delivery of drugs may be beneficial 
in reducing the development of multi-drug resistance. 
 
In another study, Vassileva et al., 2007 compared the overall toxicity as well as the 
anti-tumor effects of a paclitaxel loaded C-eP implant to paclitaxel formulated in 
Cremophor EL®. These studies revealed that the Cremophor EL®-paclitaxel formulation 
was associated with significant toxicity, lethality, abnormal peritoneal organ morphology 
and hepatic inflammation, whereas mice receiving the implanted device encountered 
no such problems (Vassileva et al., 2007). In addition, the maximum tolerable dose 
was much higher for the implant (up to 280 mg/kg/week) when compared to the 
Cremophor EL®-paclitaxel formulation (20 mg/kg/week) (Vassileva et al., 2007). A drug 
loading of 60 mg/kg in the implant had an enhanced cytotoxic effect compared to the 
same dose administered intraperitoneally as the Cremophor EL®-paclitaxel formulation 
indicating the potential of this implant system as a drug delivery device. 
 
2.3.2. Alginate 
2.3.2.1.  In situ forming alginate implants  
Alginate is a polysaccharide derived from seaweed. It is essentially a block copolymer 
consisting of β-d -mannuronic and α-L-guluronic acid which gels in the presence of 
divalent cations such as calcium (van Tomme et al., 2008). The polymer rapidly forms 
a gel by crosslinking in the presence of calcium ions and this gelation mechanism has 
been utilized by Hori et al. (2009) to develop an in situ forming implant. Calcium ions 
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were entrapped within alginate microspheres and dispersed in an alginate solution. 
Upon injecting this formulation into the body, calcium ions were released from the 
microspheres and assisted by the calcium concentration in vivo; the alginate solution 
took 60 minutes to form a stable gel (Hori et al., 2009). The implant was intended for 
the delivery of immunomodulators in the treatment of cancer. The soluble factor (IL2) 
was incorporated into the implant with ease by simple mixing with the alginate solution. 
Hori et al. (2009) also investigated the feasibility of attaching immunomodulatory 
oligonucleutides to the microspheres for delivery purposes. The IL2 was 95% bioactive 
after delivery via the alginic implant indicating the feasibility of this drug delivery 
system. Approximately 80% of the oligonucleotides were loaded to the microspheres 
and the release was slow (approximately 20% over one week). This study highlights 
the possibility of dual-functional microspheres and the potential for the effective 
treatment of cancer through delivery of immunomodulators to the tumor site. However, 
the delivery of other smaller chemotherapeutics may not be as effective as the time 
take for a stable gel to form is quite lengthy and this may lead to an initial burst effect 
(Hori et al., 2009).  
 
2.3.2.2.  Pre-formed alginate implants  
Bouhadir et al., 2001 made use of an alternate method of gelation by oxidising the 
alginate to form lower molecular weight oligomers and then crosslinked them using 
adipic dihydrazide. The alginate based implant was loaded separately with three drugs 
in different ways in order to demonstrate the different release profiles that could be 
obtained from this hydrogel. The three cytotoxics that were utilised were methotrexate 
(MTX), doxorubicin (DOX) and mitoxantrone (Bouhadir et al., 2001). Figure 2.2 depicts 
the loading mechanisms that were utilized for each drug as well as the mechanisms of 
release of the chemotherapeutic agents.  
21 
 
 
Figure 2.2: Schematic showing drug loading and release of the drugs from the 
modified alginate hydrogel (Adapted from data in Bouhadir et al., 2001). 
 
MTX was released over two days but this was extended to seven days with a higher 
concentration of the covalent crosslinker, adipic dihydrazide (Bouhadir et al., 2001). 
The reason for the prolonged release was the reduced swelling of the hydrogel that 
occurred with the higher concentration of the crosslinking agent, resulting in a slower 
diffusion-based drug release. The release of doxorubicin was over a period of days to 
weeks depending on the concentration of adipic dihydrazide. Likewise, the release of 
mitoxantrone was substantially controlled upon increasing the concentration of adipic 
dihydrazide. At high concentrations of adipic dihydrazide, the release of mitoxantrone 
was only 10% over a period of 22 days (Bouhadir et al., 2001). Thus, this system 
exemplifies that a number of drugs may be loaded into the hydrogel depending on the 
chemical nature of the drug. This allows specific loading for specific drugs and allows 
the implant to have many uses. Bouhadir et al. (2001) also investigated the release of 
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the three drugs when loaded simultaneously to determine whether the implant had 
potential to be used to deliver multiple drugs. In vitro release studies showed that MTX 
was released completely over 9 days, whereas DOX and mitoxantrone were released 
over 17 days. More than 20% of DOX was released over the first 13 days while 
majority of the mitoxatrone was released in the last 4 days. This sequential release of 
drug shows that the implant may be used to deliver multiple drugs which may prove 
useful in the treatment of drug resistant tumors (Bouhadir et al., 2001).   
 
2.3.3. Gelatin 
2.3.3.1. In situ forming gelatin implants  
Gelatin is derived from naturally occurring collagen and exhibits thermo-reversible 
behavior. At temperatures below 25˚C the polymer forms a gel while above 30˚C it 
reverts back to solution form (Klouda and Mikos, 2008). This is not favourable behavior 
for pharmaceutical preparations and therefore various attempts have been made to 
modify the temperatures of gelation-containing preparations to a more physiologically 
acceptable temperature range (Van Den Bulcke et al., 2000 and Klouda and Mikos, 
2008). Gelatin is also a pH responsive polymer (Gupta et al., 2002). In situ forming 
gelatin hydrogels for postoperative chemotherapy have been formulated by Okino and 
co workers (2002). Styrene derived gelatin together with the initiator camphorquinone 
was utilised and polymerisation in the presence of visible light irradiation occurred. This 
in situ forming hydrogel was intended for the delivery of drug to newly resected tumor 
sites. The formation of the hydrogel was investigated on the surface of rat liver and 
despite the potential toxicity of the free radicals produced by the initiator, the in vivo 
application of the hydrogel showed no necrotic damage to the hepatocytes (Okino et 
al., 2002). The mechanism of formation of these hydrogels is due to 
photopolymerisation and is not dependant on the temperature sensitivity of the gelatin. 
However, due to the application of UV light that is required; this formulation can only be 
used during surgical resection of the tumor or for tumors occurring on the skin. 
 
2.3.3.2.  Pre-formed gelatin implants.  
Liu et al., 2003 attempted to develop gelatin hydrogels for the treatment of cancer 
using a method previously developed by Tabata and Ikada (1999), Kang et al. (1999) 
and Hong et al. (2000) for producing gelatin hydrogels meant for purposes other than 
cancer treatment. The hydrogels contained Interleukin 12 (IL12) and were tested on 
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colon carcinomal cells implanted subcutaneously into the backs of rats. The effect of 
these hydrogels on the tumors was evaluated and the cytotoxicity of the IL12 was 
found to be higher in the subcutaneously administered gelatin hydrogel formulation 
than in the subcutaneously administered free IL12 (Liu et al., 2003). Konishi et al., 
(2003) have also studied the release of chemotherapeutic agents namely cisplatin from 
preformed gelatin hydrogels intended for implantation following tumor resection. They 
established that the release of the incorporated cisplatin was not via diffusion but rather 
a function of degradation of the hydrogel (Konishi et al., 2003). In 2005, the same 
group investigated the release of cisplatin and adriamycin from the hydrogel. 
Adriamycin was released at a quicker rate than the cisplatin and the combination 
showed a synergistic inhibition of tumor growth in vivo (Konishi et al., 2005). In 
addition, when adriamycin was injected percutaneously into the mice as a control, scar 
formation was noted at the injection site. Contrary to this, the adriamycin-loaded 
hydrogel did not induce such an effect in the mice (Konishi et al., 2005). The authors 
postulated that the lack of scar formation was due to the slow release of the drug from 
the hydrogel.   
 
2.3.4. Albumin 
2.3.4.1. In situ forming albumin implants 
Human serum albumin has been used to produce an in situ forming hydrogel which 
was combined with a tartaric acid derivative (TAD) (Kakinoki et al., 2007). TAD is a 
tissue adhesive that has the advantage of maintaining the position of the implant in the 
desired site (Kakinoki et al., 2007). The release of doxorubicin from this hydrogel was 
investigated and in vitro studies showed an initial burst effect due to surface drug 
followed by release from within the gel for up to 100 hours (4 days). A follow-up in vivo 
study by Kakinoki and Taguchi, 2007 tested the formulation in rats bearing the human 
colon carcinoma. They found that the size of tumors in rats had decreased to a greater 
extent in comparison to the tumors treated with free drug or the control. However, the 
drug was only detectable for 3 days, as expected from the in vitro results (Kakinoki and 
Taguchi, 2007). 
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2.3.5. Collagen 
2.3.5.1. In situ forming collagen implants.  
Collagen is a naturally occurring polysaccharide from which gelatin is derived. An 
injectable formulation containing collagen and ephedrine together with cisplatin as a 
drug registered as Intradose® (Matrix Pharmaceuticals) has provided some promising 
results in treating hepatocellular carcinoma (Mok et al., 2001; Wenig et al., 2002). 
Ephedrine serves to constrict blood vessels in the affected area thereby reducing the 
diffusion and hence loss of drug from the area. The delivery of these chemotherapeutic 
agents to tumors of the head and neck, trunk and liver for the treatment of 
hepatocellular carcinoma has been shown to be successful in humans (Mok et al., 
2001; Wenig et al., 2002). In addition, the collagen/ephedrine combined with cisplatin 
has also demonstrated efficacy in obstructive oesophogeal cancer in humans (Monga 
et al., 2000) while the gel in combination with 5-fluorouracil has proven good efficacy in 
pancreatic cancer of rats (Smith et al., 1995).  Collagen-poly(HEMA) hydrogels were 
synthesized by Jeyanthi and Rao (1990). The drug release from the gels was found to 
be independent of time and followed zero order kinetics. The maximum amount of drug 
release from the gels which followed zero order kinetics was 98% over 10 days for 5-
Flourouracil (Jeyanthi and Rao, 1990). The gels containing Mitomycin C and Bleomycin 
had zero order release of 52% over 12 days and 74% over 11 days respectively. This 
is longer than the release profiles obtained for collagen and ephedrine indicating that 
this formulation is superior to Intradose®. However, the drug release is still for a short 
period of time only. 
 
2.4. Synthetic, Biodegradable Mono-polymer and Co-polymers as Implant 
Sources 
2.4.1. Poly(N-isopropylacrylamide) (pNIPAAm) 
With the increasing interest in the polymers that are stimuli-sensitive, otherwise 
referred to as “smart polymers”, a number of studies have focused on pNIPAAm due to 
its thermosensitivity (Packhaeuser et al. 2004; Han et al, 2009). The polymer exists as 
a solution below its lower critical solution temperature (LCST) and gels at temperatures 
above LCST. The LCST of pNIPAAm is 32˚C (Winnik, 1990). This temperature can 
easily be increased to body temperature or the temperature of a tumor by co-
polymerisation of pNIPAAm with hydrophilic polymers (Jones et al., 2007). However, 
the problem with pNIPAAm is its lack of biodegradability (Yu et al., 2007). In an effort to 
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overcome this problem as well as improve the LCST of the hydrogel, researchers have 
polymerized pNIPAAm with various other polymers (often hydrophilic in nature) such as 
hydroxyethylmethacrylate (HEMA) (Jones et al., 2007), acrylic acid (Kim and Healy, 
2003; Yu et al., 2007), as well as gelatin and hyaluronic acid (Ohya et al., 2005). Co-
polymerization with polymers such as propylacrylic acid and poly(2-dimethyl 
amino)ethyl methacrylate (DMAEMA) leads to the formation of polymers that are pH- 
and thermoresponsive (Kim and Healy, 2003; Yu et al., 2007).  Although most of these 
polymeric hydrogels were not synthesized specifically for the treatment of cancer, they 
have shown promising potential for use in such applications. 
 
2.4.2. In situ forming Atrigel® implants  
Atrigel® (Atrix Laboratories, Inc) consists of biodegradable polymers such as polylactic 
acid (PLA) or poly(lactic-co-glycolic acid) (PLGA) together with a biocompatible 
hydrophilic solvent such as N-methyl-2-pyrollidone. The solvent renders the polymer 
soluble and when the system is injected into the body, the solvent dissipates into the 
surrounding tissue leaving behind a formed implant. This technology was initially 
designed for the treatment of periodontal disease (Packhauser et al., 2004). In 2000, 
Ravivarapu and co-workers developed a formulation of Atrigel® loaded with leuprolide 
acetate and showed the ability of the implant to suppress serum testosterone for a 3 
month period. A 6-month formulation has since been developed and Atrigel® is now 
used to deliver leuprolide acetate for the treatment of advanced prostate cancer in the 
product known as Eligard®. One of the problems facing the in situ forming implants is 
the quick initial release of drug (Packhauser et al., 2004). In order to overcome this 
problem, Astaneh et al., 2007 created a zinc-leuprolide complex which was loaded into 
a PLGA in situ forming implant. This implant was compared to Eligard® showing that 
the use of the zinc complex reduced the burst period slightly and also resulted in a 
continuous, zero-order release profile following the burst phase. Comparably, Eligard® 
showed a very rapid initial release of the drug (almost 40% over 24 hours) (Astaneh et 
al., 2007). Atrigel® has also been loaded with cisplatin for the potential treatment of 
head and neck cancers (Chen et al., 2003).  The efficacy of this system was 
investigated in a chimeric mouse model carrying the human head and neck squamous 
cell carcinoma (Chen et al., 2003).   Drug release was 80% at the 7th day. The ALZA 
Corporation, Inc. has also designed in situ forming implants that are very similar to the 
Arigel® technology (except for the solvents used) but they have not yet been 
investigated for use as anticancer formulations. 
26 
 
2.4.3. In situ forming poly(organophosphazenes) implants 
Recently Al-Abd et al., 2010 investigated the release of DOX from a 
poly(organophosphazene) hydrogel in vitro and in rats with human gastric tumor 
xenografts. Release of the drug was over 5 weeks and the hydrogel was retained for 7 
weeks. The concentration of polymer used was also relatively low (10%w/v). This group 
of polymers has shown a great potential for the development of an ideal implant system 
for cancer chemotherapy due to the ease with which they can be modified to serve the 
purpose of the respective drug delivery system (Al-Abd et al., 2010). 
 
2.4.4. In situ forming poly(ε-caprolactone fumarate) implants 
Poly(ε-caprolactone fumarate) is a relatively new photo-crosslinkable polymer which 
possesses both biocompatibility and good fluidity making it an ideal candidate for the 
development of an injectable in situ forming implant (Sharifi et al, 2009).  This polymer 
was used by Sharifi et al. (2009) to develop an in situ forming implant for the delivery of 
tamoxifen citrate to breast cancer patients. In vitro studies conducted showed 
extremely slow release of the drug (less than 5% of drug after 400 hours) and 40-60% 
of MCF-7 (breast cancer) cells incubated with the formulation were killed (Sharifi et al, 
2009). This formulation has potential for further development and in vivo work should 
be completed. 
 
2.4.5. Polyethylene glycol (PEG) 
2.4.5.1. In situ forming PEG implants 
Qiu et al., (2003) synthesized a PEG-based copolymer that was capable of in situ 
gelling. This was achieved as a result of chemical cross linking of the multiple thiol 
groups that lie on the polymer backbone. However, the polymer as well as the 
crosslinking agent must be injected into the area (Qiu et al, 2003).  Although hydrogel 
formation was achieved in vivo, the loaded hydrophillic anti-cancer drug, topotecan, 
was released very rapidly, probably due to the large pores in the hydrogel (Qiu et al, 
2003).  As a result, Lalloo et al. (2006) formulated a two phase drug release system. A 
portion of the drug was entrapped in the PEG hydrogel and some within liposomes 
which were then loaded into the hydrogel. The drug release profile showed a quick 
initial release followed by a longer controlled release over several days (Lalloo et al., 
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2006). Tumor masses (MAT BIII breast cancer cells) in rats were also significantly 
reduced with the use of this hydrogel (Lalloo et al., 2006).  
 
2.4.5.2. Pre-formed PEG implants  
Tauro et al. (2005) proposed a PEG hydrogel system for the treatment of Glioblastoma 
Multiforme. Highly invasive tumors are often associated with higher amounts of matrix 
metalloproteases (MMPs) in the area surrounding the tumor. These proteins cause 
tumor invasion as well as neovascularisation (Tauro et al., 2005). The developed 
system proposed the use of these proteases to control the release of the drug from the 
hydrogel matrix. The drug (cisplatin) was linked to the polymer backbone by means of 
peptide linkages. As the MMPs diffused through the hydrogel, the peptide bonds were 
cleaved by the MMPs and as the result the drug was released into the area 
surrounding the tumor. This allowed controlled release of the drug at the site of the 
tumor. The controlled release effect depended on the amount of MMPs present and 
hence the dose of drug delivered corresponded to the invasiveness of the tumor (Tauro 
et al., 2005). 
 
2.4.6. Pre-formed implants composed of poly(D,L-lactide-co-glycolide)  
Poly(D,L-lactide-co-glycolide) (PLGA) is a well known polymer, the use of which in the 
medical  field is well-documented. In the treatment of cancer, recent advances have 
been made into the use of this polymer as a foam or a nanofiber disc intended to be 
inserted intra- or peritumorally (Lee et al., 2009 and Ranganath et al., 2010). Lee et al., 
2009 formulated a micro-porous PLGA foam intended for the delivery of drug to the 
brain. The foams were loaded with paclitaxel and showed in vitro release of up to 8 
weeks. The foams were also placed intracranially in healthy mice and assessment after 
28 days revealed that therapeutic amounts of paclitaxel were found throughout the 
mouse brain (Raganath et al., 2010). Nanofiber discs were prepared by Ranganath and 
workers, (2010) and loaded with paclitaxel and implanted into the brains of mice 
bearing human glioblastoma. Paclitaxel was also found to have diffused from the disc 
to penetrate a large area of the brain and that the concentrations of paclitaxel were 
maintained for 42 days which exceeds the release obtained by previous researchers 
(Raganath et al., 2010). This formulation seems extremely promising for further 
development.   
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2.4.7. Pre-formed polyanhydride polymeric implants 
The most successful of the pre-formed implants are the Gliadel® implants intended for 
the treatment of malignant human glioma (Brem, 1996; Perry et al., 2007; Chopko, 
2009; Argyriou et al., 2009).  These implants have been developed with the intention of 
delivering anticancer drugs following at least partial resection of the tumor (Jain, 2005). 
A study that was conducted by Brem et al., 1995 using Gliadel® showed that patients 
who received the implant containing an anticancer drug had a 6 month survival rate 
50% greater than those who received a placebo implant. In 1996, the FDA (United 
States) approved this implant. However, the implant has only been shown to prolong 
the lives of patients by one year (Perry et al., 2007; Chopko, 2009; Argyriou et al, 
2009). Gliadel® consists of poly(carboxyphenoxypropane/sebacic acid) anhydride, 
20:80 (cPP-SA) (Biodel®) and the drug, carmustine (BCNU) co-dissolved in methylene 
chloride and spray dried into microspheres. The microspheres are then compressed 
into discs of dimensions 1.4cm in diameter and 1.0 mm in thickness. The discs are 
sterilized by gamma irradiation. 
 
Following the success of the Gliadel® implant, Göpferich (1997) aimed to develop an 
implant for release of at least two drugs, the release of one drug lasting two weeks and 
the second drug being released over the next week. This would decrease the 
resistance of cancer cells as they would be exposed to a number of different drugs 
over a certain period of time (Göpferich, 1997). A surface-eroding polymer, poly(1,3-
bis[p-carboxyphenoxy]propane-co-sebacic acid) (p(CPP-SA)) was used and two drugs 
were loaded into the implant. One drug was in the “core” and the other was in the 
“mantle”. Drug release from this implant was therefore a function of the erosion of the 
polymer. However, it was found that the release of the second drug occurred 
prematurely (Göpferich, 1997). Thus, instead of increasing the thickness of the mantle 
which would have caused the implant to be too large, a slow-eroding polymer namely 
poly (D,L-lactic acid) was used. A four layer device was formulated as depicted in 
Figure 2.3. With this implant release periods of up to four weeks were obtained 
(Göpferich, 1997). 
29 
 
 
Figure 2.3: Schematic depicting a longitudinal section through the disc shaped implant 
with the loading and release patterns of two drugs clearly illustrated (Adapted from data 
in Göpferich,1997). 
 
Although the implant devised by Göpferich (1997) was proven to allow release of drug 
from the core after two weeks, Vogelhuber et al. (2001) attempted to create an implant 
that had a greater lag phase before the release of the drug. This was meant to allow 
the implant to have more applications as a drug delivery system. Furthermore, this 
implant would also address the problem of the low survival rate of patients with human 
glioblastoma despite therapy with Gliadel®, as this implant would be capable of 
delivering a number of drugs to the tumor region in a controlled manner. This attempt 
registered some promising results (Vogelhuber et al., 2001). 
 
The greatest challenge that was faced during the attempt to improve the implant 
designed by Gopferich (1997) was the size of the implant. The implant had dimensions 
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of 8mm diameter and 4mm height and this made the in vivo testing in a rat model 
impossible (Vogelhuber et al., 2001).  As a result Vogelhuber et al. (2001) investigated 
the drug release from an implant consisting two layers one containing the drug (drug 
loaded core) and the other containing no drug (drug free mantle) (Figure 2.3). This 
reduced the size of the implant to a diameter of 2mm and a height of 1.8mm 
(Vogelhuber et al., 2001).   
 
 
Figure 2.4: Schematic depicting a cross-section through the implant (Adapted from 
data in Vogelhuber et al., 2001). 
 
The mantle consisted of either PLA or PLGA whilst the core consisted of 
polyanhydride, p(CPP: SA) 20:80 loaded with the drug. The effect of tempering the 
implant in silicon oil was also investigated. Delayed onset of drug release with this 
implant was achieved with the release being delayed by 10 days post-implantation 
when PLGA5017 was used and by 58 days when PLA5030 formed the mantle layer 
(Vogelhuber et al., 2001). Furthermore, it was shown that tempering of the implant 
allowed for erosion and drug release to be controlled by the type of polymer used and 
the effects of pores and other defects in the polymer mantle affected the release of the 
drug far more than the polymer erosion (Vogelhuber et al., 2001). 
 
More recently Hiremath et al. (2008) have synthesized cylindrical biodegradable 
implants intended for the delivery of tamoxifen citrate to breast cancers by the 
placement of the implant into the affected area. The employed polyanhydride polymer 
was poly(sebacic acid-co-rinoleic-ester anhydride) in a ratio of 70:30 w/w [poly(SA-RA) 
70:30 w/w]. The implants were prepared using the standard melt manufacturing 
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method and in vitro studies revealed that the release of drug from 10% and 20% 
loaded implants was 42.36 and 62.60% after 30 days indicating prolonged delivery of 
the drug to the tumor. It was also estimated that drug release would be complete after 
72 days for the 10% loaded implant and 100 days for the 20% loaded implant 
(Hiremath et al., 2008).  
 
2.5. Synthetic, biodegradable tri-block polymers used for implants 
2.5.1. Tri-block polymer from poly(lactic-co-glycolide and polyethylene glycol 
(PLGA-PEG-PLGA) 
ReGel® (MacroMed) is a tri-block polymer (ABA or BAB) whereby the A block is 
poly(lactic-co-glycolide) and the B block is poly(ethylene glycol).  The tri-block polymer 
is water soluble at room temperature but insoluble at body temperature (37˚C) (Zentner 
et al., 2001). It has been established that due to its insoluble gel state in vivo, the 
implant can remain intact at the site of application for at least 1 month (Jeong et al., 
2004). The implant is also biodegradable. The rate of degradation of the polymer, the 
permeability of the matrix of the hydrogel , the sol-gel transition temperature as well as 
the burst release rate depend on the molecular weight of the polymers and the ratio of 
PLGA to PEG (Jeong et al., 2000). In addition, the above mentioned polymer 
characteristics are also influenced by the ratio of lactide: glycolide as well as the 
concentration of these elements and the end group of the PLGA polymer component. 
Formulations of ReGel® containing paclitaxel have been trademarked OncoGel®. This 
tri-block polymer has also been used to develop a drug delivery system for the delivery 
of testosterone (Chen et al., 2005) and the delivery of interleukin 2 or cancer 
immunotherapy and this formulation is trademarked Cytoryn® (Madan et al., 2009).  
More recently, the polymer has been used in a formulation containing PEGlyated 
camptothecin (Yu et al., 2007). The purpose of adding a polyethylene glycol (PEG) 
group to the camptothecin was to enhance the release of the drug in a controlled 
manner. This was achieved and in addition the solubility of the drug was also enhanced 
(Yu et al., 2007). Furthermore, the sol-gel transition temperature was decreased and 
the viscosity of the implant with the PEGlyated drug was higher than that of the implant 
without the PEGylated drug. Ostensibly, this will improve the implants behavior in situ. 
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2.5.1.1. Poloxamers/Pluronics® 
These are triblock co-polymers consisting of poly(ethylene oxide)–b-
poly(propyleneoxide)–b-poly(ethylene oxide) (PEO–PPO–PEO). Poloxamers have also 
been investigated as potential implant-forming systems due to their thermoreversible 
nature (Jeong and Gutowska, 2002). Sol to gel transitions occur at 5-30˚C and gel to 
sol transitions at 35-50˚C (Jeong and Gutowska, 2002). Alteration of the molecular 
weights, composition and concentration of the polymer results in a change in the sol to 
gel transition (gelation) temperature of the polymer (Klouda and Mikos, 2008). 
However, the actual formation of the gel phase is poorly understood (Klouda and 
Mikos, 2008). Pluronic products include Pluronic® F127, P85 and L61. The cytotoxicity 
of these polymers has been investigated and the study revealed that F127 had no 
cytotoxic potential while both P85 and L61 decreased the growth of the tumor cells 
(Exner et al., 2005). Amiji et al., 2002 created a paclitaxel containing implant using 
Pluronic® F127, which was administered to melanoma bearing mice. The results were 
promising as 91% of rats survived up to 15 days post-implantation compared to 58% in 
the control group (Klouda and Mikos, 2008). This study seems to be an exception as 
other formulations containing Pluronics rarely released drugs for more than a period of 
a few days (Ruel-Gariépy and Leroux, 2004).  
 
2.6. Synthetic non-biodegradable polymers 
2.6.1. Silicone 
The use of silicone in the formulation of implants has not been investigated extensively 
as silicone is not biodegradable (He et al., 2003). He et al., 2003 investigated the 
effects of silastic implants loaded with 5-Flourouracil (5FU) - a drug which has an 
extremely short half life (10 minutes). The dimensions of the implants were 2mm (outer 
diameter), 0.5mm (wall thickness) and 25mm in length. Each pellet contained 13.2mg 
of 5FU. These implants were surgically implanted into the livers of Wistar rats bearing 
Walker-256 carcinosarcoma. When the implant was placed in the left lobe of the liver at 
the site where the tumor had been implanted, the tumor inhibition was found to be as 
high as 96.3%, with one of the animals in this group surviving the entire length of the 
experiment and no viable tumor was detected in this animal (He et al., 2003). 
Biodistribution results showed a high concentration of 5FU in the tissues adjacent to 
the area in which the implant was placed but the amount of 5FU found in other tissues 
was lower, indicating a lower toxicity of this implant than when administered parentally. 
In addition, 5FU was found in the blood for 1 to 8 weeks, despite its short half life, 
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indicating that there was a controlled release of the drug from the implant (He et al., 
2003).  Pathological studies were also carried out on the tissue surrounding the implant 
and no fibrous capsule was found around the implant, indicating the lack of 
immunological attack on the implant (He et al., 2003). While these results seem to 
indicate the feasibility of the system for cancer treatment, the lack of biodegradability 
potential in silicone cannot be ignored. Non-biodegradation necessitates the removal of 
the implant following the drug release. This is not likely to have high patient 
acceptability and also multiple operations may lead to further complications.   
 
2.7. Surgical pastes 
Most of the pastes developed for use in cancer have been formulated prior to 2005 and 
include those developed by Dordunoo et al. (1997), Winternitz et al. (1996) and 
Jackson et al. (2000, 2004). Dordunoo et al. (1997) investigated the impact of a 
paclitaxel-containing surgical paste composed of poly(caprolactone). This polymer has 
a biodegradation lifetime of between 6-9 months, making it an ideal polymer for 
sustained drug release. The paste was to be delivered by heating of the paste to 
temperatures of between 50-55oC and delivering it via injection or application to the 
tumor area following the resection of the tumor. This paste showed tumor regression in 
63% of the mice treated (Dordunoo et al., 1997). The same polymer and drug was 
used by Hunter et al. (1997). The application of this paste was carried out on a murine 
tumor model. The results indicated that the implant delayed the re-growth of tumors 
that were not resected entirely (Hunter et al., 1997).  Blends of PCL and 
methoxypolyethylene glycol were also investigated by Winternitz et al., 1996, obtaining 
drug release over a number of days. 
 
2.8. Other implants 
Numerous other implants also exist which are intended for the treatment of cancer but 
cannot be implanted locally. These include: Zoladex® (AstraZeneca PLC), which 
consists of PLGA rods containing goselrelin, a LHRH analogue which is injected 
subcutaneously and is used in the treatment of advanced prostate cancer (Dijkman et 
al., 1990). Results from clinical studies have revealed that the implant may be effective 
over at least 14 weeks when injected into the upper arm of patients (Dijkman et al., 
1990). An implant of a gonadotropin releasing hormone agonist namely histrelin, 
(administered subdermally) has also shown efficacy in the treatment of prostate cancer 
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(Chertin et al., 2000). Implanted devices which carry radiopharmaceuticals to the site of 
the tumor have also been synthesized (Sofou et al., 2008).  
 
2.9. The ideal implantable system 
When considering implants in the treatment of solid tumors, in situ forming implants 
have an advantage over pre-formed implants as they rule out the need for surgical 
interventions and hence have both the benefit of higher patient acceptability and 
reduction of a multitude complications which may occur during surgery. These implant 
systems also allow delivery of the drugs intratumorally rather than peritumorally as is 
the case with pre-formed implants. The ideal characteristics of an ideal polymer for an 
implant include responsiveness to a stimuli such as temperature, pH (~6.75) or light 
(photopolymerizable); biocompatibility, biodegradability, low cytotoxicity, 
mucoadhesivity, low concentration effectiveness, easily sterilizable, long storage 
capability, the ability to form mechanically robust hydrogels, easily modifiable and 
lastly, the polymer should have an LCST around body temperature. An appropriately 
designed and defined implant should provide a sustained delivery of drugs (beneficial 
in reducing the development of multi-drug resistance), retention of activity of the 
bioactives such as IL2, controlled rate of degradation of the polymer, desirable 
permeability of the hydrogel matrix, desirable sol-gel transition temperature and finally 
feasibility of the drug delivery system which also depends on the chemical nature of the 
drug. The most commonly cited problems with the polymer/polymeric implant include: i) 
quick burst release or release of the bioactive at a lower pH (pH 5-6); ii) negatively 
charged entities which may interact with bioactive components once in the body; and 
iii) formation of turbid gels thus necessitating the need of stabilizers during 
lyophilization. Quite often this results in the formation of hydrogel with very low strength 
which are also expensive to manufacture. The use of photo-crosslinking can as well be 
detrimental to the drug e.g. leading to degradation of the drug. Such shortcomings of in 
situ forming implants are described in Table 2.3. 
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Table 2.3: Comparison of the advantages and disadvantages of in situ forming 
implants.  
System Photocrosslinkable 
systems 
Local stimuli 
responsive 
systems 
Solvent diffusion 
systems 
Mechanism of 
operation 
Use of an initiator in the 
implant and an external 
light source  
Responds to local 
environment e.g. 
pH or temperature 
Contains an organic 
solvent which 
diffuses into 
surrounding body 
tissue leaving 
implant in situ 
Advantages Do not require surgical implantation and removal 
Cost of production (manufacturing is lower than for similar targeted 
systems e.g. micro- or nano- particles) (Packhauser et al., 2004) 
Can be used in the delivery of “sensitive ” molecules e.g. proteins 
(Packhauser et al., 2004) 
Disadvantages 1. Area of injection 
limited by penetration of 
the light source 
(Packhauser et al., 
2004) 
2. Possibility of toxicity 
of the initiator (Okino et 
al., 2002) 
3. Drug may be 
damaged when 
crosslinking occurs 
(Cho et al., 2009) 
1. Inter-patient 
variations 
2. Differences in 
injection 
techniques can 
result in 
differences in 
release kinetics 
3. Sterilization 
technique may 
pose challenge 
4. Initial burst 
release may occur 
(Schuetz et al., 
2008 and Kakinoki 
and Taguchi, 2007) 
1. Possibility of 
toxicity of the 
solvent 
2. Initial burst phase 
release (Schuetz et 
al., 2008 and 
Astaneh et al., 
2007) 
 
2.10. Concluding Remarks 
A few of the systems described in this chapter such as Intradose®, Atrigel®, , Eligard®., 
Gliadel®, ReGel®, Cremophor EL®-paclitaxel, OncoGel®, Cytoryn® and Zoladex® have 
shown great potential but further development of these systems is warranted for the 
effective treatment of solid tumors. This chapter served to summarise the various 
attempts that have been made in the development of an ideal implant system for the 
treatment of solid tumors. The advantages of an implant system have been highlighted 
and the opportunities offered by in situ forming implants mentioned. Challenges 
associated with in situ forming implants have also been clearly delineated. Subsequent 
chapters of this dissertation will attempt to overcome the associated challenges and 
develop an in situ forming implant capable of delivery a chemotherapeutic drug to solid 
tumors over prolonged periods of time.  
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CHAPTER 3  
PREFORMULATION STUDIES CONDUCTED FOR 
DESIGNING THE IN SITU FORMING IMPLANT 
3.1.  Introduction 
Thermoresponsive polymers as described in Chapter 2 of this dissertation are useful 
for the formation of in situ forming implants as these polymers are able to reconfigure 
from a sol state, at some defined temperature to a gel state, with a change in 
temperature. Some polymers such as poly(acrylic acid) exhibit an Upper Critical 
Solution Temperature. At low temperatures the polymer solution exhibits phase 
separation whereas at higher temperatures, homogeneity is achieved (He et al., 2008). 
In contrast, polymers exhibiting a Lower Critical Solution Temperature (LCST) undergo 
a phase separation following heating. Alteration from a homogenous solution to a two 
phase system consisting of a solid phase and a liquid phase is typically observed 
(Bokias et al., 2000). The formation of the solid phase in LCST polymers was of 
interest as this could be used for the formation of an In Situ Forming Implant (ISFI).  
  
Poly(methylvinyl ether) (PMVE) is a water soluble, biocompatible polymer which 
displays thermoresponsiveness and is reported to have a LCST of 32-38˚C (Karayanni 
and Staikos, 2000; Madbouly and Ougizawa, 2005; Nurkeeva et al., 2005). Drug 
delivery systems using PMVE in combination with maleic acid have been investigated 
for the delivery of various drugs such as pilocarpine (Urrti, 1985) and tetracaine 
(Woolfson et al., 1998). PMVE-co-maleic anhydride is also used commercially as a 
denture fixative.  However, these systems and products do not utilise the 
thermoresponsive behaviour of PMVE. Currently there is no literature on the use of 
PMVE in the formulation of a thermoresponsive drug delivery system for the site 
specific treatment of solid tumors. 
 
PMVE was selected as it offers two significant advantages for its use as an implantable 
system for drug delivery. Firstly, the polymer converts from a solution into a gel 
instantaneously upon heating to its LCST (Figure 3.1) and secondly, the polymer is 
biocompatible (Nurkeeva et al., 2005). The “sharp” transition from solution phase to the 
precipitated gel-like phase was considered a distinct advantage as it would stop a 
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significant burst release of drug as observed in other in situ forming implants (Astaneh 
et al., 2007and Schuetz et al., 2008).  
 
 
Figure 3.1: Digital images showing the transition of PMVE from a) a solution to b) a gel 
following heating to 37˚C. 
 
Many other in situ forming systems take a few minutes to form in situ and as a result 
the drug has sufficient time to be released from the formulation and into the 
surrounding tissue (Hacker et al., 2008 and Schuetz et al., 2008). 
 
Gelation of PMVE is thought to be as a result of its hydrophilic (ether oxygens) and 
hydrophobic (vinyl backbone and methyl side groups) regions as shown in Figure 3.2 
(Karayanni and Staikos, 2000).  
 
25˚C 37˚C
a) b)
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Figure 3.2: Chemical structure of PMVE showing the hydrophilic oxygen that is 
responsible for the solvation of the polymer at room temperature. 
 
As a result the polymer is solvated at room temperature (surrounded by water 
molecules) due to the presence of the ether oxygens on the polymer. However, at 
temperatures exceeding the LCST of the polymer, the hydration sheath surrounding 
the polymer chains is damaged and the interactions between the hydrophobic areas of 
the polymer such as the vinyl backbone and methyl groups on the polymer, become 
more important and as a result the water molecules are forced out, resulting in the 
“collapse” of the polymeric strands (precipitation of the sol or gel formation) (Karayanni 
and Staikos, 2000). 
 
Other polymers displaying thermosensitivity, such as hydroxypropylcellulose and 
methylcellulose in combination with other additives, were also investigated, but are not 
discussed further in this dissertation, since results obtained with these polymers were 
not as desirable as those obtained with PMVE.  
 
In order to control the initial burst release from the PMVE formulations, other polymers 
were added to the formulation. The burst effect was postulated to be related to the 
syneresis of water on formation of the implant and hence various water absorbable 
polymers were selected to minimise this effect. Gum arabic, a polysaccharide extracted 
from the gum of the acacia tree (Phillips et al., 1996), carrageenan, a polysaccharide of 
seaweed origin (Usov, 1998) and polyacrylamide (PAAm) a polymer able to imbibe 
large amounts of water (Martínez-Ruvalcaba et al., 2008) were investigated. An 
additional reason for the selection of carrageenan was due to the research conducted 
by Tomšič et al., 2008 on the thermogelation properties of κ-carrageenan. As the 
n
CH3
Hydrophilic 
oxygen
Methyl group
O
Hydrophobic 
backbone 
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polymer available was of mixed composition, i.e. it contained all forms of carrageenan 
and not solely κ-carrageenan, the results obtained would be of interest. 
 
The effect of a salt, calcium chloride in addition to the polysaccharides was also 
investigated due to the influence of calcium ions on the gelation characteristics of 
polysaccharides such as carrageenan (Usov, 1998).  
 
Other polymers investigated included alginate, hydroxypropylcellulose and gellan gum. 
However these results are not reported on due to undesirable results obtained. 
Polyacrylic acid (PAA) was also used and the results are reported here. Other salts 
investigated included potassium chloride and sodium bicarbonate. Sodium bicarbonate 
showed promising results and is discussed further. 
 
3.2. Materials and Methods 
 
3.2.1.  Materials 
Poly(methyl vinyl ether) (PMVE) (50%wt in water), folic acid (pteroylglutamic acid,98% 
purity), polyacrylamide (PAAm) (Mw= 5-6x10
6g/mol), carrageenan, sodium alginate 
(with a viscosity of a 2% solution at 25˚C reported to be ~3500cP) and dialysis tubing 
(MWCO 12kDa, flat width 33mm) were purchased from  Sigma-Aldrich (Steinheim, 
Germany). A sample of hydroxypropylcellulose (Klucel®, Type EF) was obtained from 
Hercules Incorporated (DE, USA). Sodium hydroxide pellets (NaOH, Mw=40g/mol), 
calcium chloride dihydrate (CaCl2, Mw=147.02g/mol) and gum arabic powder were 
obtained from Rochelle Chemicals (Johannesburg, South Africa). Sodium dihydrogen 
phosphate (NaH2PO4, Mw=141.96g/mol), and sodium bicarbonate (NaHCO3, 
Mw=84.01g/mol) was purchased from Merck, Wadeville, Gauteng, South Africa. 
Potassium chloride (KCl, Mw= 74.56g/mol), potassium dihydrogen phosphate (Mw= 
136.09g/mol) and sodium chloride (NaCl, Mw= 58.44g/mol) were obtained from ACE 
Chemicals (Southdale, South Africa).  Double deionised water (Milli-Q Gradient, 
Millipore, MA, USA, electrical conductivity 18.2MΩ.cm at 25˚C) was used to prepare all 
solutions of the polymer and all other buffered solutions. 
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3.2.2. Preparation of PMVE solutions  
Solutions of PMVE were diluted to 10, 20 or 30%w/v using double deionised water. 
Since the high viscosity of the supplied PMVE (50%w/v) made accurate measuring of 
the polymer as a liquid challenging, Equation 3.1 was utilised to determine the volume 
of solutions. Briefly, the polymer was weighed (m) and the density of PMVE (ρ=1.03) 
was used to determine the volume (v) of polymer solution. Using the volume obtained, 
dilutions were then made using deionised water to yield polymeric solutions of the 
correct concentration. 
 
ρ=
m
v
 ..............................................................................................................Equation 3.1 
 
In order to adjust the pH, a standard quantity of 100μL of NaOH (1M) was added to 
10mL of each solution prepared. This altered the pH of the solution to ~ 6.75.  
 
3.2.2.1. Preparation of formulations to minimise the burst release of drug 
PAAm combinations with PMVE were prepared. Briefly, a solution of PAAm (1% or 
5%w/v) was prepared and added to 20% PMVE formulations in ratios of 1:10 or 10:1. 
 
Other formulations were prepared as shown in Table 3.1. Gum arabic, carrageenan 
and the salts were added as powders with the correct weight to appropriately diluted 
PMVE solutions to produce formulations with concentrations as listed in Table 3.1. 
When the effect of a combination of both CaCl2 and gum arabic was investigated, 
formulations were prepared as follows. Briefly, to produce the formulation containing 
0.1M CaCl2 and 4%
w/v gum arabic: 0.284g of CaCl2 was added to 20mL of a PMVE 
solution diluted to the correct concentration. The solution was mixed until the salt had 
dissolved in the polymer solution. Gum arabic (0.8g) was then added to the solution to 
yield a formulation as described in Table 3.1. The solution was then physically stirred 
using a glass rod until a homogenous solution formed. The model drug, folic acid was 
added to the solutions at a concentration of 5mg/mL per formulation.  
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Table 3.1: Composition of ISFI formulations formulated for investigation 
Formulation Concentration of 
PMVE 
(%w/v) 
Concentration of 
Gum Arabic  
(%w/v) 
Concentration of  
Carrageenan  
(%w/v) 
Concentration of 
CaCl2 
(M) 
Concentration of  
NaHCO3 
(M) 
1 10 0 0 0 0 
2 20 0 0 0 0 
3 30 0 0 0 0 
The effect of gum arabic 
4 20 1 0 0 0 
5 20 4 0 0 0 
6 20 10 0 0 0 
The effect of carrageenan 
7 20 0 1 0 0 
8 20 0 5 0 0 
9 20 0 10 0 0 
The effect of gum arabic and CaCl2 
10 20 4 0 0.05 0 
11 20 4 0 0.1 0 
12 20 4 0 0.2 0 
The effect of CaCl2 
13 20 0 0 0.05 0 
14 20 0 0 0.1 0 
15 20 0 0 0.2 0 
16 20 0 0 0.3 0 
17 10 0 0 0.2 0 
The effect of NaHCO3 
18 20 0 0 0 0.05 
19 20 0 0 0 0.1 
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3.2.3. Determination of the gelation temperature of the polymeric formulations 
utilising oscillatory rheology 
The study of the flow properties was considered extremely significant to this study as it 
is central to the mechanisms by which the ISFI functions. At room temperature the 
implant remains in the liquid state to allow delivery via a 18G needle and at body 
temperature (37˚C) the implant forms a solid-like structure. In order to characterise and 
analyse the flow behaviour and determine the LCST or gelation temperature of the ISFI 
formulations, rheology studies were conducted using a Haake Modular Advanced 
Rheometer System (ThermoFisher Scientific, Germany). As the polymeric material acts 
as a viscoelatic solid, some background on viscoelastic solids is provided.  
 
3.2.3.1. Viscoelasic solids 
Polymer solutions often exhibit viscoelastic properties. The term “viscoelastic” implies 
that they behave neither like a liquid which flows when a force is applied and do not 
return to their original shape (as depicted by the dashpot, Figure 3.3(a)) nor like an 
elastic material which when a force is applied to it, deforms and upon removal of the 
force returns to its original shape (much like a spring: Figure 3.3(b)). Instead, a 
viscoelastic solid exhibits properties of both these materials Figure 3.3(c) (Marriott, 
2004).  
 
Figure 3.3: Schematic showing a model to aid in the understanding of viscoelastic 
materials (Adapted from Marriott, 2004). 
 
a) b) c)
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For elastic materials, Hook’s Law of Elasticity is used to characterise the flow 
properties and the term shear modulus (G) is used to relate the relationship between 
the shear stress ( ) and the deformation ( ) (Equation 3.2). Liquids are defined by 
Newton’s Law of Viscosity (Equation 3.3) whereby the shear stress ( ) is proportional 
to the shear rate of the liquid (
  
  
).  
 
    ............................................................................................................Equation 3.2 
 
   
  
  
..........................................................................................................Equation 3.3 
 
In order to characterise viscoelastic solids, the use of oscillatory rheology is required. 
The principle of oscillatory rheology can be explained as the induction of a sinusoidal 
shear deformation in the sample being analysed and the measurement of the resultant 
stress. As shown in Figure 3.4 the application of a sinusoidal strain results in different 
resultant stress patterns in elastic solids, viscous fluids and a viscoelastic solid. The 
viscoelastic solid shows a phase shift that lies between the phase shift of 0 for an 
elastic solid and π/2 for a viscous fluid (Wyss et al., 2007).  
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Figure 3.4: Phase shifts in different materials following application of a sinusoidal 
strain (Adapted from Wyss et al. 2007). 
 
For viscolelastic solids, as the behaviour of the sample is between the extremes of 
elastic and viscous behaviour, additional terms are required for definition relating the 
elastic modulus component or storage modulus, G', and the viscosity modulus or loss 
modulus, G'', to the angular frequency, ω. The complex modulus, G represents the 
total resistance of the substance to oscillatory shear and is determined using Equation 
3.4. The complex viscosity (η’) is the flow resistance of the sample and is determined 
using Equation 3.5 and Equation 3.6.   
 
Strain
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   .........................................................................Equation 3.4 
  
        
  
  
.....................................................................................................Equation 3.5
  
And      
 
 
................................................................................................Equation 3.6 
Where δ is the phase angle, G’ is the storage modulus, G“ is the loss modulus, η’ is the 
complex viscosity and ω is the angular frequency. 
 
3.2.3.2. Determination of the viscoelastic region 
Viscoelastic solids should be tested for their properties within the viscoelastic region. In 
order to determine the viscoelastic region of the formulation samples, each sample was 
placed on the lower plate of the rheometer and the yield stress of the formulation was 
first determined, as this is the point at which a minimum critical shear stress is 
exceeded and hence the point at which a viscoelastic substance begins to flow. Stress 
sweeps at 0.01Hz, 1Hz and 10Hz were then conducted using an applied strain of 0.1-
70Pa ensuring that the minimum strain applied was less than the yield stress value 
obtained. The stress sweep plots were then analysed and the plateau or linear 
viscoelastic region where both G' (storage modulus) and G'' (loss modulus) were 
independent of the stress amplitude, was used as the viscoelastic region. The first 
point of deviation from the plateau and the frequency at which it occurred was used for 
subsequent temperature ramping tests. 
 
3.2.3.3. Determination of the gelation temperature of the polymer 
In order to determine the lower critical solution temperature (LCST) and hence the 
gelation temperature of the ISFI formulation, the temperature of samples was ramped 
from 20-50˚C at a rate of 0.25˚C/min while applying the predetermined stress obtained 
from the stress sweeps previously described, at the frequency observed in that test.  
The gelation temperature was determined as the temperature at which the cross-over 
of G' and G'' occurred i.e., the point at which the formulation was no longer acting as a 
liquid (G'') but as a solid (G'). In all cases a solvent trap was used to prevent sample 
evaporation. 
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3.2.4. Construction of a standard curve for the quantification of folic acid release 
from ISFI using ultraviolet spectroscopy 
A stock solution of folic acid in phosphate buffered saline (PBS) was prepared at a 
concentration of 2%w/v. Serial dilutions were then made to yield a concentration range 
of (0.0018-0.15mg/mL). The solutions were then assayed using a UV 
Spectrophotometer (Specord 40, Analytik Jena, AG, Germany) using a wavelength of 
280nm. Assays were conducted in triplicate and on two different days, to determine 
whether the results obtained were reproducible.   
 
3.2.5. Release of folic acid from the formulations under conditions mimicking 
those at the tumor site 
Drug release studies were conducted in an orbital shaker bath (Orbital Shaker 
Incubator, LM-530, Yihder, Taiwan) (37˚C, 25rpm). A dialysis tubing method similar to 
that described by Graves et al. (2007) was used. Briefly, the dialysis tubing was 
thoroughly rinsed to remove preservative fluid and then cut into 10cm pieces. One end 
of the tubing was tied and the tubing was filled with 5mL of dissolution fluid (PBS, 6.75, 
37˚C). The formulation being tested (3mL) was injected into the dialysis tubing and the 
other end of the tubing was also tied. The dialysis bags were then placed into vessels 
filled with 100mL of PBS (pH 6.75) as shown in Figure 3.5 and the vessels were placed 
into the shaker bath. Samples of 10mL were drawn at: 1 hour, 4.5 hours and 1, 2, 3, 5, 
7, 12 and 17 days. Pre-warmed buffer (10mL) was replaced at each time interval to 
maintain sink conditions. Samples were analysed using a UV spectrophotometer 
(Specord 40, Analytik Jena, AG, Germany) at the wavelength for folic acid, 280nm. 
PBS was prepared in accordance with tissue culture requirements with the following 
molar quantities: 137mM NaCl, 2.7mM KCl, 10mM NaH2PO4, 2mM KH2PO4 (Sambrook 
et al., 1989). The solution was adjusted to pH 6.75 in order to mimic conditions of the 
tumor site (Martin and Jain, 1994). 
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Figure 3.5: a) Schematic showing the drug release method used to determine the 
release of folic acid from the ISFI, b) digital image showing the actual drug release 
vessel with the suspended implant within the dialysis tubing clearly shown. 
 
3.3. Results and Discussion 
 
3.3.1. Construction of a standard curve for the quantification of folic acid 
released from the ISFI 
Beer Lamberts Law (Equation 3.7) describes a linear relationship between the 
absorbance (A) of a dilute substance (<0.01M) and its concentration (c), provided that 
the pathlength of the light (b) through the solution remains constant. It also describes 
some absorptivity value that is specific for the substance being assayed. This specific 
absorptivity can be used on the determination of concentration of released drugs 
utilising the constructed standard curve relating absorbance to concentration. 
 
         ....................................................................................................Equation 3.7 
 
As shown in Figure 3.6, a straight line through the origin was obtained. Regression 
coeffients obtained for the calibration curves conducted on two consecutive days were 
0.998 and 0.991 with the absorptivity values only differing slightly from each other. The 
standard deviations between absorbance values obtained for solutions having the 
same concentration on the same day was < 0.025 and the standard deviation between 
absorbances of the same solution on consecutive days was 0.045. These results 
Dialysis tubing tied at 
either end
Vessel filled with 100mL 
PBS
ISFI
a) b)
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indicate the precision of the instrument and allowed the usage of the UV 
spectrophotometer in subsequent tests. 
 
 
Figure 3.6: Calibration curve of the absorbance of folic acid in PBS (pH 6.75) using UV 
spectroscopy at 280nm (in all cases n=3 and SD<0.025). 
 
3.3.2. Determination of the viscoelastic region of PMVE and gelation 
temperatures 
In accordance with the process described in Chapter 3, Section 3.2.3.2 the viscoelastic 
region of PMVE was first determined. As shown in Figure 3.7, the yield stress of the 
polymer was determined. Using this data, subsequent tests were run at stress values 
which did not exceed this value. Consequently stress sweeps were run from 0.1-70Pa, 
with the yield stress value within the minimum and maximum stresses. Results of the 
stress sweeps as shown in Figure 3.8 clearly depict the plateau phase associated with 
the viscoelastic phase and the point of first deviation from the plateau was used for 
subsequent tests. As the stress sweep at 10Hz showed the most horizontal plateau, it 
was therefore used for subsequent tests, together with a stress of 13.4Pa.  
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Figure 3.7: Rheological plot of deformation vs. stress showing the yield stress of 
PMVE. 
 
Figure 3.8: Stress sweeps obtained for PMVE at various frequencies. 
 
Points of  deviation from 
plateau
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As shown by the gelation temperatures in Figure 3.9, the gelation temperature of 
PMVE changes with a change in concentration. However as can be seen the storage 
modulus varies with the higher concentration of the polymer and the effect is highest 
when the concentration of polymer is highest.  
 
 
Figure 3.9: Gelation temperatures of different concentrations of PMVE.  
 
3.3.3. The effect of increasing polymer concentration on the release of folic acid 
from the ISFI 
As can be seen in Figure 3.10, the 10%w/v formulation showed a significant burst 
release over 3 days, whereas the other formulations showed less of an initial burst 
release.  
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Figure 3.10: Drug release profiles of formulations with increasing amounts of PMVE 
(n=2, SD< 0.09). 
 
The erratic release of drug from the 10%w/v formulation coupled with the initial burst 
release excluded it from further analysis. The 20%w/v PMVE formulation showed 
prolonged release, however, about 50% of the drug was released in 24 hours. The 
30%w/v formulations showed prolonged release and a very low burst effect. However, 
the increase in PMVE in the 30%w/v also increased the viscosity of the formulation 
considerably. As a result, the 20%w/v PMVE containing formulation was chosen for 
further modification. Of concern was the burst release from the 20%w/v formulation that 
occurred over 24 hours and attempts were made to decrease this burst release through 
the addition of various polymers. 
 
3.3.3.1. The effect of carrageenan, gum arabic, PAAm and other polymers on the 
release profile of the ISFI formulation 
As shown by Figure 3.11a, the addition of carrageenan to the formulation did not 
change the burst release of the ISFI and actually appeared to have increased the burst 
effect while the addition of gum arabic (Figure 3.11(b)) also had very little impact on 
decreasing the burst release of drug from the polymer (24 hour profile shown). 
Increasing amounts of either gum arabic or carrageenan in the formulation decreased 
the release (i.e. a 10%w/v carrageenan formulation had lower release than a 1%
w/v 
formulation). However, the increasing quantity of polymer naturally increased the 
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viscosity, an unwanted effect as this would cause difficulty in administration of the ISFI. 
The possible lack of effect of these two polymers on the drug release is possibly due to 
the large size of the polysaccharide molecules which did not interact with the PMVE 
and hence did not decrease the burst effect from the formulations perhaps indicating 
that the burst release is not in fact due to the syneresis of water from the formulation or 
that the gum arabic and carrageenan polymers were unable to absorb this water with 
the drug. It is a possibility that the burst release of the drug was caused by surface 
deposition of the drug. Rheological characterization was performed but results were 
unremarkable. 
 
The addition of PAAm, a non-ionic polymer did not prove fruitful either as upon 
standing formulations separated into two distinct phases indicating immiscibility. PAAm 
is classified as a proton acceptor (Koussathana et al., 1997) and as a result the phase 
separation and lack of interaction is possibly a result of the fact that PMVE is also a 
proton acceptor rather than a proton donator due to its –OCH3 group(Nurkeeva et al., 
2005). The interaction between a proton donator and a proton acceptor was clearly 
seen when attempts were made to add PAA to PMVE solutions. The addition of PAA 
even at low concentrations (0.05%w/v) caused precipitation of PMVE. This is in 
accordance with the literature as reported by Cowie et al. (1989), and is a result of 
hydrogen bond formation between PAA and PMVE due to the proton donating groups 
of PAA.  
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Figure 3.11: a) Drug release profiles obtained from the carrageenan containing ISFI 
formulations  (n=2, SD< 0.1) b) The effect of gum arabic on the drug release profile of 
PMVE (25 hour profile). (37˚C, pH 6.75, n=2, SD< 0.069). 
 
3.3.3.2. The effect of gum arabic and CaCl2 on drug release from the ISFI formulation 
Following unsuccessful results with carrageenan and gum arabic, CaCl2 was then 
investigated in addition to the gum arabic and carrageenan, in the hope that the salt 
would increase the viscosity of the polysaccharide polymers (Uosv,1998) and hence 
decrease the release from the ISFI. However, the addition of CaCl2 to carrageenan 
formulations did not appear to affect the release tremendously while the addition of the 
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salt to gum arabic-containing formulation proved more successful as shown in Figure 
3.12. 
 
 
Figure 3.12: PMVE-gum arabic and CaCl2 (0.1M) compared to a combination of 
PMVE-CaCl2 (0.1M) on the drug release profile (37.5˚C, pH 6.75). (37˚C, pH 6.75, n=2, 
SD< 0.04). 
 
The addition of both gum arabic and CaCl2 caused an initial slower release of folic acid. 
However, as the effect of gum arabic minimal as described previously, the effect of the 
salt on drug release was then investigated and found to be as effective in reducing the 
burst effect as the combination of gum arabic and CaCl2 (Figure 3.12). For this reason, 
gum arabic was no longer utilised and the effect of differing concentrations of CaCl2 
were investigated. 
 
3.3.3.3. The effect of CaCl2 on the release profile of the ISFI formulation and on the 
gelation temperatures of the ISFI 
Following the discovery that the salt was responsible for the decrease in the burst 
release of drug from the polymer, CaCl2 was added to formulations in different 
concentrations and drug release and rheological assessment was performed. 
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As shown in Figure 3.12, the addition of CaCl2 slowed the release of folic acid from the 
ISFI and the increasing quantity of CaCl2 decreased the release further (Figure 3.13). 
However, increasing the concentration of CaCl2 to concentrations above 0.3M caused 
immediate precipitation of PMVE in the formulation. In addition, it was intended that the 
quantity of salt used would be kept to a minimum due to concerns of local toxicity. A 
discussion of the possible effect of CaCl2 on PMVE follows in Chapter 4, Section 4.3.5. 
 
 
Figure 3.13: The effect of increasing the quantity of CaCl2on the release of drug from 
ISFI formulations (37˚C, pH 6.75, n=2, SD< 0.051). 
 
The effect of CaCl2 on formulations containing 10%
w/v PMVE was also investigated and 
showed a decreased burst release although still present. Unfortunately while 
decreasing the burst release of drug from the ISFI, CaCl2 also decreased the gelation 
temperature of the polymer. Formulations containing 0.3M CaCl2 had a gelation 
temperature of 26.0˚C (±0.3˚C) and this was counter-productive as this temperature 
was too close to ambient temperatures which could result in gelation of the ISFI prior to 
administration or while handling. For this reason 0.3M formulations of CaCl2 were not 
considered ideal and higher concentrations of PMVE were not investigated. As can be 
noted in Figure 3.14, the Gʹ values for the formulations also increased with an increase 
in CaCl2 concentration.  
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Figure 3.14: The effect of CaCl2 on PMVE with regards to gelation temperature. 
 
Following the success of CaCl2, the effect of other salts were also investigated. Of 
these NaHCO3 showed promising results. The addition of NaHCO3 increased the 
release of drug from the polymer and on visual inspection of the formulation in the 
dissolution medium appeared to have increased the breakdown of the polymer 
formulation (Figure 3.15). Higher concentrations of NaHCO3 proved detrimental as they 
caused immediate precipitation of the polymer. This formulation was considered to be 
of interest as it increased the rate of folic acid release a great deal and hence could be 
considered for use as the “erosion controlling substance” mentioned in Chapter 1, 
Section 1.2 of this dissertation. While the mechanism of increased release from the 
formulations containing NaHCO3 have not been elucidated, and hence it is unknown 
whether NaHCO3does in fact increase the erosion of the polymer, addition of NaHCO3 
increased the release of the drug. While data on PMVE is not readily available, studies 
have been performed on the PMVE-maleic anhydride copolymer. Finne et al. (1989) 
explained that the alteration of the pH in that polymer by the addition of salts caused an 
increase in the pH of the polymer surface and consequently lead to an increase of the 
entrapped drug. Without the addition of the basic salts, H+ ions accumulated on the 
surface of the polymer inhibiting polymer dissolution (Finne et al., 1989).  However, the 
source of the H+ ions is the carboxylic esters (maleic anhydride esters) (Heller, 1985) 
on the polymeric chain and hence this effect is not possible with PMVE. 
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Regardless of the mechanism of increasing the drug release from the polymer, a faster 
release indicated that the salt be investigated further. For this reason it was further 
investigated in microparticles and results obtained are reported in Chapter 5 of this 
dissertation. 
 
 
Figure 3.15: Release of folic acid from the sodium bicarbonate containing implant 
(37˚C, pH 6.75, n=2, SD<0.5). 
 
Rheological analysis of formulations containing NaHCO3 also proved interesting as the 
gelation temperature of the formulations also decreased exactly as noted with CaCl2 
containing formulations. However the Gʹ value was much lower than both the 
formulation containing an equivalent amount of PMVE and a CaCl2 containing 
formulation. This is an interesting discovery as the addition of CaCl2 caused a 
decrease in gelation temperature but an increase in the storage modulus. It is possible 
that the ionic nature of NaHCO3 caused a decrease in the gelation temperature and the 
decrease in the storage modulus was caused by the effect of pH change on the 
polymer. 
 
3.4. Concluding Remarks 
A preliminary ISFI formulation was developed, rheologically tested and drug release 
from the formulation was determined. It was established that PMVE was a viable 
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choice of polymer for the formulation of an ISFI. However, there was a slight burst 
effect observed when the polymer was used in isolation especially at lower 
concentrations.  CaCl2 was investigated and showed promise in decreasing the release 
of folic acid from the ISFI. An experimental design was selected for the determination 
of a statistically optimal ISFI formulation and input formulation variables were therefore 
as follows: PMVE concentration (10-30%w/v) and CaCl2 concentration (0.05M-0.2M). 
Chapter 4 describes the Design of Experiments (DoE) strategy selected and the 
process of determining the optimal ISFI formulation. 
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CHAPTER 4  
STATISTICAL OPTIMIZATION OF THE IN SITU 
FORMING IMPLANT 
4.1. Introduction 
Statistical optimization has gained popularity due to the numerous advantages that are 
associated with the use of such a process (Singh et al., 2005). Traditionally, the design 
of a drug delivery system has been based on trial and error. This method generally 
involves variation of one variable at a time in the formulation and can be a time 
consuming process. In addition success depends on characteristics of the formulator 
such as previous experience, knowledge base, and intuition (Singh et al., 2005).  Using 
this method a satisfactory formulation which satisfies the desired outcomes can be 
achieved, however the optimal formulation is rarely achieved (Singh et al., 2005). 
Design of Experiments (DoE) fits experimental data to statistical equations and then 
utilizes these models in the prediction of formulation performance and in the 
optimization of the formulation. DoE hence offers a rational method of connecting 
various experiments and obtaining information from fewer experiments (Singh et al., 
2005). Essentially it is the rationality of such an approach that makes it a useful tool in 
the scientific method. Some advantages of design of experiments (Lewis et al., 1999, 
Singh et al., 2005 and Furnaletto et al., 2006) are shown in Figure 4.1. 
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Figure 4.1: Some advantages of utilizing a design of experiments in the development 
of an optimal formulation. 
 
As concluded in Chapter 3, two variables or factors had been identified to be of interest 
in the design of an ISFI. The aim of this phase of the study was to employ an 
experimental design to develop a thermoresponsive implant which would be easily 
injectable into human tissue, form in vivo in response to the temperature of the human 
body and would be capable of providing release of drug for at least one month. As the 
response i.e. the effect of the variable on these measured outcomes described was not 
expected to be linear and response surface plots were required, a Face-Centred 
Central Composite Design was chosen rather than a factorial design. 
 
Face-Centred Central Composite Designs contain an embedded 2k (where k= number 
of factors) factorial design but with the addition of a group of star points and a central 
point as shown graphically in Figure 4.2. The star points serve to estimate curvature of 
the response of the variables to the outcome hence providing an idea of the response 
surface and allowing estimation of interactions. A response surface is a graphical 
representation of the mathematical data obtained from the design of experiments and a 
response surface plot shows the relationship of two variables on an outcome. This 
provides valuable information in understanding the contributions of variables on a 
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single outcome (Singh et al., 2005). The 9 points as shown in Figure 4.2 constitute the 
experimental runs. In this study the centre-points were run 6 times, giving a total of 14 
formulations.  
 
 
Figure 4.2: Diagramatic representation of a Face-Centred Central Composite Design 
with two factors (X1 and X2) showing the centre point, 4 factorial points and four axial 
points (Adapted from Verseput, 2000). 
 
4.2. Materials and Methods 
 
4.2.1.  Materials 
Materials used were as described in Chapter 3, Section 3.2.1 of this dissertation. 
Methotrexate (≥95% purity) was purchased from Sigma-Aldrich, Steinheim, Germany.  
 
4.2.2. Design and optimization of the formulations using a Central Composite 
Design 
A two-factor Face-Centred Central Composite Design (FCCCD) was employed for the 
determination of the effect of the two formulation variables (PMVE concentration and 
CaCl2 concentration) on the gelation temperature, force of injectability and Mean 
Dissolution Time (MDT) of the ISFI.  
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The ISFI was designed to be easily injectable using standard injection methods and for 
this reason the force of injectability was minimized to ensure that the optimal 
formulation would be easily injectable (i.e. less force would be required to inject the 
formulation in vivo). The release of the entrapped chemotherapeutic was to be over a 
period of one month (> 30 days) which was demonstrated in preliminary results. 
Finally, the ISFI was intended to form in vivo at around the temperature of the body (37 
±0.5˚C). As preliminary studies revealed that the addition of CaCl2 contributed to a 
decrease in the gelation temperature and the ISFI was not to form at temperatures 
approaching room temperature as this would contribute to difficulty in injecting the 
polymer solution, the ISFI was optimized within the design by maximizing the gelation 
temperature. For each of the two parameters selected, two factors were fixed, an upper 
and a lower level as summarized in Table 4.1 and these values were obtained from 
preliminary studies undertaken. Also shown in Table 4.1 are the responses and the 
optimization constraints for each variable. The design was both generated and 
analysed using Minitab V15 software (Minitab® Inc, PA, USA) and for the design 14 
experimental formulations were obtained as summarized in Table 4.2. 
 
Table 4.1: Formulation variables and responses applied in design. 
 Levels Objective 
 Upper Lower  
Parameters    
PMVE (%w/v) 30 10  
CaCl2 (M) 0.20 0.05  
Responses    
Gelation Temperature (˚C)   Maximize 
MDT*   Minimize 
Force of Injectability (N)   Minimize 
*MDT: Mean Dissolution Time 
 
4.2.3. Preparation of in situ forming implant (ISFI) solutions  
The experimental design template provided by the FCCCD was utilised to prepare 14 
formulations containing varying quantities of polymer and salt. Compositions of the 
formulations prepared are shown in Table 2. All formulations were prepared in 
duplicate. Briefly, to produce the formulation a 30%w/v PMVE formulation containing 
0.1M CaCl2: 15g of PMVE (50%
w/v) (density, ρ=1.03g/mL) was diluted with 9.71mL 
deionised Milli-Q water to give a 30%w/v solution. CaCl2 (0.142g) was then added to 
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10mL of the 30%w/v PMVE solution. The solution was then placed under magnetic 
stirring until a homogenous solution formed. NaOH (1M, 150μL) was added to each 
formulation while the pH was measured to ensure that the pH of the implant was 
approximately 7.2. When drug release studies were conducted, folic acid or 
methotrexate (MTX) (for the optimized formulation) was added to the solutions in a 
concentration of 15mg/3mL of formulation.  
 
Table 4.2: Compositions of ISFI solutions formulated in accordance with the FCCCD 
design template. 
Formulation 
Number 
Concentration of PMVE (%w/v) Concentration of CaCl2 (M) 
1 30 0.200 
2 10 0.200 
3 20 0.125 
4 20 0.125 
5 10 0.050 
6 30 0.050 
7 20 0.125 
8 20 0.200 
9 30 0.125 
10 20 0.125 
11 20 0.125 
12 20 0.125 
13 10 0.125 
14 20 0.050 
 
 
4.2.4. Determination of the viscoelastic behavior and the gelation temperature 
utilizing oscillatory rheology  
A Haake Modular Advanced Rheometer System (ThermoFisher Scientific, Germany) 
fitted with a 2˚ Titanium probe was used for these studies. Stress sweeps at 0.1Hz, 
1Hz and 10Hz were conducted on the samples to determine the linear viscoelastic 
region for the formulations. Using the information obtained, samples were then 
exposed to a fixed strain and oscillation (18Pa, 10Hz) while the temperature of the 
sample was increased from 20-40ºC in a ramped temperature flow curve (0.042˚/min). 
The LCST was defined as the temperature at which there was a significant increase in 
the storage modulus (G') and dynamic viscosity (η'). All tests were conducted in 
duplicate.  
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4.2.5. Determination of the force of injectability of the ISFI 
A Textural Analyser (TA.XTplus Texture Analyser, StableMicroSystems, England) was 
fitted with a 2mm cylindrical steel probe and a 5kg load-cell and the samples were 
tested for the ability to be easily injected. The maximum force required to depress the 
plunger of a syringe filled with the implant formulation was determined and compared 
with the force required to depress the plunger of a water filled syringe. An 18G needle 
was fitted at the end of the syringe.  Figure 4.3 shows the setup of the equipment used 
to determine the force of injectability. A typical test involved advancing the probe at a 
predetermined velocity onto the plunger of the sample-filled syringe in accordance with 
the following parameters: pre-test and post-test speeds 1mm/s and 3mm/s 
respectively; test speed 2mm/s; maximum compression force 40N; trigger force 
0.001N. Data acquisition was performed at 200 points/sec via Texture Exponent for 
Windows software, V3.2.  
 
 
Figure 4.3: Textural analysis instrument set-up used to determine Force of Injectability 
of the ISFI through syringe fitted with a 18G needle. 
 
4.2.6. Determination of drug release from the ISFI at a simulated tumor site  
Drug release studies were conducted in an orbital shaker bath (37±0.5˚C, 25rpm). As 
described in Chapter 3, Section 3.2.5 of this dissertation a dialysis tubing method 
similar to that described by Graves et al., (2007) was used. 30mL samples were drawn 
at the following intervals: 6 hours, 1 day, 3 days, 5 days, 9 days, 13 days and 17 days, 
22 days, 27 days, 32 days and 40 days. Pre-warmed buffer (30mL) was replaced at 
each time interval to maintain sink conditions. Large volumes were extracted to 
compensate for the poor solubility of the drug. Samples were passed through a 0.22μm 
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pore size filter (Cameo Acetate membrane filter, Millipore Co., Bedford, MA, USA) and 
analysed using a UV spectrophotometer (Specord 40, Analytik Jena, AG, Germany) at 
the wavelength for methotrexate (MTX), 306nm or for folic acid (FA), 280nm and the 
amounts of MTX or FA were quantified using a calibration curve for each of the drugs. 
Each ISFI formulation was tested in triplicate. The Mean Dissolution Time (MDT) as 
described by Pillay and Fassihi (1998) at 32 days was calculated for each of the 
formulations using Equation 4.1 and a maximum MDT is the fastest drug release rate 
achievable (Govender et al., 2005). 
 


M
M
tMDT t
n
1i
i
.........................................................................................Equation 4.1 
Where Mt is the fraction of dose released in time (ti = ti +ti-1)/2 and M∞ corresponds with 
the loading dose. 
 
4.2.7.  Computational modelling to determine the effect of the addition of a salt to 
PMVE 
Computational and structural modeling was performed to determine the effect of the 
addition of a highly water soluble salt to solutions of PMVE. Predictive models were 
created using ACD/I-Lab V5.11 (Add-on) software (Advanced Chemical Development 
Inc., Toronto, Canada, 2000).  
 
4.2.8. Determination of an effective method of sterilization for the ISFI 
In order for the implant to be tested in the animal model an effective method of 
sterilization had to be determined. Two types of sterilization exist: terminal sterilization 
and aseptic processing. Terminal sterilization is of the greatest benefit as it involves 
sterilization of the final product only. However, methotrexate is a thermo-labile drug and 
therefore terminal sterilization could not be considered. It was therefore proposed that 
the polymer solution be sterilized and the drug added to the formulation aseptically.  
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Approved methods for sterilization according to the United States Pharmacopoeia 
(1999) involve the following: steam sterilization, dry heat sterilization, gas sterilization, 
sterilization by ionizing radiation, sterilization by filtration and aseptic processing. 
Filtration of the implant would prove difficult due to the viscous nature of the 
formulation, and irradiation of polymeric materials can lead to the formation of reactive 
species such as free radicals. Irradiation of polymers can be detrimental in two ways: it 
can cause an increase in molecular weight (cross linking) or it can cause chain scission 
and degradation (decrease in molecular weight) (Andriola Silva Brun-Graeppi et al., 
2009). Nurkeeva et al, 2004 have reported the use of gamma irradiation in the 
crosslinking of PMVE. Oven sterilization (dry heat) was not considered due to the 
length of time required for sterilization. Instead autoclaving (steam sterilization) was 
selected. Autoclaving utilizes high steam pressures to kill viable microorganisms. 
  
4.2.8.1.  Materials and methods 
Materials utilised were as described in Chapter 3, Section 3.2.1 of this dissertation. 
Blood agar was purchased from Oxiod, UK, sterilized appropriately and then poured 
into sterile petri dishes.  
 
4.2.8.2. Preparation of formulations 
Formulations were prepared according to the centre point of the design (PMVE 20%w/v 
and CaCl2 0.125M) as this would give 5 previous runs obtained from the design for 
comparison purposes. Samples were bottled into amber glass bottles with screw tops 
and placed in a Butterworth HD158 autoclave and allowed to run at 121˚C for 15 
minutes. This is the minimum time allowed by the British Pharmacopoeia (British 
Pharmacopoeia, 1993). Samples were removed following autoclaving and allowed to 
reach room temperature. Samples were then opened aseptically and previously 
autoclaved double deionised water was added to the make up the volume lost during 
autoclaving. 
 
4.2.8.3. Determination of polymeric structural variations 
Fourier Transformed Infrared Spectroscopy (FTIR) was utilized in order to determine if 
any variations in vibrational frequencies had occurred following autoclaving of the 
formulations. Differences in vibrational frequencies would be indicative of bond 
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formation or loss and hence structural variations on the polymeric structure. FTIR was 
conducted on samples using a Perkin Elmer Spectrophotometer (Perkin Elmer 
Spectrum 100, Beaconsfield, United Kingdom). Formulations were air dried before 
testing to remove excess water. 
 
4.2.8.4. Determination of the gelation temperature of the ISFI 
The gelation temperature of the autoclaved formulations was determined as per 
Section 4.2.4 of this chapter.   
 
4.2.8.5. Determination of the release of folic acid from the formulation 
Drug release studies were performed as per Chapter 4, Section 4.2.6 of this 
dissertation. Folic acid was utilized as the model drug and was added to the 
formulations aseptically. 
 
4.2.8.6. Determination of the sterility of the formulations 
Once formulations had been autoclaved and reconstituted to correct volume under 
aseptic conditions (discussed further in Chapter 6, Section 6.2.2 of this dissertation), 
formulations were streaked onto blood agar plates using a sterile spatula as depicted in 
Figure 4.4 and incubated at 25˚C and 37˚C for 24 hours. As can be noted in Figure 4.4, 
each time the formulation was streaked onto one half of the plate and the other half 
was left untreated to serve as a negative control i.e. to ensure that the agar was not 
contaminated. Incubation at 25˚C was to determine the presence of fungal growth 
whereas incubation of the plate at 37˚C was to test for the presence of bacteria. 
Remaining formulations were capped and placed in a refrigerator (4˚C) and retested in 
the same way after one month.  
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Figure 4.4: Schematic representation of agar plate and the streaking of the autoclaved 
formulation.  
 
4.2.9. The Effect of Different Temperatures on the Release Profile of the Implant 
Considering that the temperature in the tumor region, especially a rapidly growing 
tumor, is slightly higher than the temperature of normal tissue (Babich, 2005), the 
release of folic acid from formulations was determined at higher temperatures. While 
the release of entrapped drug from the implant prove satisfactory, the effect of ice on 
the release profile of the ISFI was examined in an attempt to increase the release of 
drug from the implant should that prove necessary.   
 
4.2.9.1. Materials and Methods 
Materials utilized were as described in Chapter 4, Section 4.2.1 of this chapter. 
 
4.2.9.2. Determination of the release of drug from ISFI formulations under different 
temperature conditions 
Drug release studies were conducted as per Chapter 4, Section 4.2.6 of this 
dissertation with some modifications. For studies determining the impact of an increase 
in temperature studies, vessels prepared as described in Chapter 4, Section 4.2.6, 
were placed in a rotating water bath (Labex SBS40) maintained at 38.5±0.5˚C and set 
at a rotation speed 25rpm. For the determination of the impact of ice on the release 
profile, vessels were placed in a shaker bath as described in Chapter 4, Section 4.2.6. 
Unlike in Chapter 4, Section 4.2.6, samples drawn were taken directly from the dialysis 
bag rather than from the exterior fluid as described previously. This made the 
application of ice for short periods of time possible without having the effect of waiting 
for the dissolution fluid to heat up following the application of ice. The following 
procedure was carried out. A 22G needle was attached to the dialysis bag, as shown in 
Figure 4.5 and the fluid surrounding the implant was drawn directly from this point. 
Samples were taken before and after the application of ice. At each time point: 6 hours, 
Autoclaved 
formulation
Untreated
control surface
Sterile petri
dish containing
blood agar
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1 day, 4 days and 10 days, 3mL of PBS was withdrawn through the needle and 
replaced with prewarmed buffer. The dialysis tubing was then removed from the vessel 
and placed in a beaker on a bed of crushed ice. After the given time interval: 2 minutes 
or 5 minutes, a 3mL sample was withdrawn from the tubing through the needle and 
replaced with prewarmed buffer. The dialysis tubing containing the implant was then 
returned to the vessel which was placed in the shaker bath maintained at 37˚C. 
Adjustments for the different volumes of the samples were made. 
 
 
Figure 4.5:  Figure showing the method used for drug release during experimental 
determination of the effect of ice on the implant. 
 
4.3. Results and Discussion 
 
4.3.1. Analysis of the Face-Centred Central Composite Design  
Regression (ordinary least squares) was used to fit the experimental data by estimating 
the effects of each of the variables on an outcome such that the sum of squared 
differences between predicted and observed responses was minimized. The standard 
error of the model(S) and the R2 value of the model indicate the fit of the model and are 
summarized in Table 4.3. Regression equations generated for gelation, force of 
injectability and MDT are as described by Equations 4.2, 4.3 and 4.4. Response 
surface plots describing the effect of each variable on the outcomes are discussed 
under each of the outcomes (Figure 4.9, Figure 4.11 and Figure 4.13). 
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Gelation=33.6410-0.02633 PMVE -1.9367 CaCl2 -1.1353 PMVE*PMVE -0.1353 CaCl2*CaCl2  
+0.075[PMVE*CaCl2 …………………...............................................................…….Equation 4.2 
 
Force of Injectability=28.7086+9.8433[PMVE -1.0967[CaCl2 +3.8967[PMVE*PMVE -1.6633[CaCl2 
*CaCl2 +5.2625[PMVE*CaCl2 ……………………......................................................Equation 4.3 
 
MDT=18.4370+0.4485[PMVE -1.9718[CaCl2 +2.1155[PMVE*PMVE +4.2038[CaCl2*CaCl2  
+0.6254[PMVE*CaCl2 …………………….................................................................Equation 4.4 
 
Table 4.3: Table summarizing the standard error of the model (S) and the coefficient of 
determination (R2) values obtained for the regression equations. 
 Gelation (˚C) Force of 
Injectability (N) 
MDT* 
S 0.1501 4.196 2.720 
R2 99.4 85.8 69.4 
* MDT= Mean Dissolution Time 
 
The lower the standard error of the model (S) the better the fit of the model. The 
standard error for gelation is fairly low and the R2 value also shows the good fit of the 
model. Force of injectability has a less desirable fit with a slightly lower R2 value and 
MDT has a satisfactory fit. The model also predicts the confidence intervals of the 
variables and a significant value (p≤0.05) indicates that the predicted effect of the 
variable can be considered to be of importance (Table 4.4). These p-values together 
with the response surface plots describing the effect of each variable on the outcomes 
are discussed under each of the outcomes (Figure 4.9, Figure 4.11 and Figure 4.13). 
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Table 4.4: Probabilities of the effects of the variables on the outcomes.  
Term p-value 
 Gelation (˚C) Force of 
Injectability (N) 
MDT 
PMVE 0.004 0.001 0.698 
CaCl2 0.000 0.542 0.119 
PMVE*PMVE 0.000 0.169 0.240 
CaCl2*CaCl2 0.180 0.534 0.038 
PMVE*CaCl2 0.923 0.040 0.660 
 
 
4.3.1.1. Analysis of Variance (ANOVA) 
Variance or how widely the data is distributed can provide valuable information. 
ANOVA was employed in the further examination of the models and data obtained for 
regression and the residuals is as summarized in Table 4.5. 
 
Table 4.5: Analysis of variance for regression and residual errors. 
Source DF Adj SS Adj MS F P 
ANOVA for Gelation 
Regression 5 27.3802 5.4760 243.14 0.000 
Residual Error 7 0.1577 0.0225   
Total 13 27.9807    
ANOVA for Force of Injectability 
Regression 5 740.941 148.188 8.42 0.007 
Residual Error 7 123.229 17.604   
Total 13 865.347    
ANOVA for MDT      
Regression 5 116.033 23.207 3.14 0.084 
Residual Error 7 51.802 7.400   
Total 13 169.393    
DF= degrees of freedom, Adj SS= Adjusted Sum of Squares, Adj MS= Adjusted Mean 
squares. 
 
The sum of squares for regression is the sum of the deviations of the fitted response 
values from the mean response value whereas the residual sum of squares is the sum 
of deviations of the observed response values from the fitted values. In all the 
outcomes, the adjusted sum of squares for regression exceeds that of the adjusted 
sum of squares for the residual error indicating that regression accounts for most of the 
data. This is confirmed by the F statistic value which is the ratio of mean squares of 
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regression to the mean squares of the residual. The p value is significant (p≤0.05) for 
gelation and slightly higher for force of injectability and much higher for MDT indicating 
that at least for gelation the coefficient is not 0.    
 
4.3.1.2. Examination of the residual error in the design 
Of important consideration in the determination of the efficacy of an experimental 
design is the assessment of the residual error. Figure 4.6 presents the various residual 
plots that require examination. The normal probability plots (a-c) for all the responses 
showed approximately straight lines indicating a normal distribution of residuals. The 
residuals versus  fitted value scatter plots (d-f) showed random scatter of the residuals 
around 0 as expected. This plot serves to detect non-constant variance, missing higher 
order terms and outliers. None of these were observed in the plotted graphs. The plots 
of the residuals versus the order of the data are used to determine the time 
dependence of the residuals. The plotted curves (g-i) showed no clear pattern 
indicating a lack of dependence. Histograms, plotting residuals against frequency (j-l), 
should be bell shaped curves. However the graphs obtained were not bell shaped and 
this seemed to indicate the presence of outliers (data points with large residuals). 
However, as the sample size is very small (<50) a histogram is not considered the best 
choice in the examination of normality and the normal probability plot is far more 
sensitive (NIST/Sematech, accessed 2012-02-06). 
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Figure 4.6: Residual plots of the data for gelation temperature, force of injectability and MDT for the ISFI formulation.
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4.3.2. The use of oscillatory rheology in the determination of the thermal gelation 
temperatures of the ISFI formulations  
All the formulations tested exhibited the typical pattern expected of a thermoresponsive 
system displaying a Lower Critical Solution Temperature (LCST) (Figure 4.7). As 
clearly annotated in Figure 4.7, the crossover of the storage and loss modulus was 
considered  the gelation temperature (T˚g) for the formulation. The storage modulus 
(G′) of a viscoelastic solid is associated with the solid properties or the elastic energy 
storage properties which indicated that the sample would return to its original state 
following removal of the deformational energy, while the loss modulus (G′′) explains the 
behavior of the viscoelastic solid when it is acting as a liquid i.e. the viscous properties 
of the sample representing the dissipation of energy after the application of the 
deformational stress. Hence at the point at which the storage modulus exceeded the 
loss modulus, the formulation was behaving more like a solid than a liquid and hence 
this was used to determine the thermal gelation temperature.  
 
 
Figure 4.7: Typical profile obtained during rheological testing of samples. The black 
circle demarcates the crossover between the storage modulus (G′) and the loss 
modulus (G′′) and hence the value that was used as the gelation temperature. 
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The T˚g of the formulations ranged from 30.18 to 35.44˚C and seemed to vary with the 
amount of CaCl2 that had been added (Figure 4.8). This was confirmed by the surface 
response curve (Figure 4.9) which displayed the variation of gelation with both CaCl2 
and PMVE concentrations. Both these factors were found to have significant effects on 
the gelation of the implant formulations (p=0.000, Table 4.4), however the interaction 
between the two was not significant. As can be seen in the response surface plot the 
T˚g decreased with the increased amount of salt in the formulation. As explained by the 
computational modeling (Chapter 4, Section 4.3.5), this effect was expected due to the 
CaCl2 acting as a dessicant.  
 
 
Figure 4.8: The effect of CaCl2 on the gelation temperature of formulations (n=3, SD< 
0.35). 
 
The effect of salts on thermoresponsive polymers has been recorded by Kundu and 
Kundu (2001) in their work on methylcellulose where a decrease in gelation 
temperature has also been decreased with the addition of various salts. 
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Figure 4.9: a) Bar chart for gelation temperature showing the experimental versus the 
predicted values (R2=0.9971) and b) Response surface plot correlating the Gelation 
temperature with the concentration of PMVE and CaCl2 present in the formulation. 
 
4.3.3. Determination of the force of injectability: The force required to inject the 
ISFI formulations 
In order to develop a formulation which will be clinically beneficial, the formulations 
must be easily injectable. PMVE, as supplied (50%w/v solution), is highly viscous and 
for this reason the force of injectability of the formulations was tested. The formulations 
all showed the typical profile displayed in Figure 4.10. Also shown is the comparison of 
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the test formulation to that of an air filled syringe. The maximum force recorded was 
used as the maximum injectability force. 
 
 
Figure 4.10: Typical profile obtained for a formulation filled syringe versus that of an 
air-filled syringe. 
 
As expected, only the PMVE had a significant effect on the force of injectability 
(p=0.001, Table 4.4), while CaCl2 had no significant effect (p=0.542, Table 4.4). As can 
be seen in the surface plot for force of injectability (Figure 4.11) the increase in the 
force of injectability has a very close relationship with the PMVE concentration. As 
expected the increase in PMVE concentration caused an increase in the force required. 
The CaCl2 concentration had no apparent effect. 
78 
 
Formulation Number
1 2 3 4 5 6 7 8 9 10 11 12 13 14
In
je
c
ta
b
ili
ty
 (
N
)
0
10
20
30
40
50
Experimental
Fitted
 
 
Figure 4.11: a) Graph showing the experimental values obtained for force of 
injectability compared to the predicted or “fitted” values (R2=0.9164) and b)  Response 
surface plot correlating the force of injectability with the concentration of PMVE and 
CaCl2 present in the formulation. 
 
4.3.4. Release of folic acid from the ISFIs over 32 days 
As illustrated in Figure 4.12 the release of drug from all formulations exceeds a month. 
Further, the release appears dependant on the polymer concentration in the 
formulation, as shown in the figure the release is slowest from  F1 (which is composed 
of 30%w/v PMVE) and quickest from the formulation containing 10%
w/v  PMVE (F5) 
(Figure 4.12(a)). 
a) 
b) 
79 
 
 
 
 
Figure 4.12: Drug release profiles from formulations over a period of 40 days where a) 
represents formulations 1-5 b) represents formulations 6-10 and c) represents 
formulations 11-14 (37˚C, pH 6.75, n= 3, SD< 0.1). 
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As determined in preformulation studies, the addition of CaCl2 results in a slower initial 
release of the drug, perhaps due to the lowering of the gelation temperature. However, 
this effect only appears important when the ISFI contains lower concentrations of 
PMVE. For formulations containing 10%w/v PMVE: the higher the concentration of 
CaCl2, the slower the release of folic acid from the formulation. As shown in Figure 
4.12(a), F5 contains PMVE 10%w/v and 0.05M of CaCl2 and shows a significant burst 
effect, whereas F2 which also contains 10%w/v of PMVE but 0.2M CaCl2 shows almost 
no burst effect. This can also be seen in the response surface graph (Figure 4.13) 
obtained for MDT for the formulations. As can also be noticed in Figure 4.13, the same 
effect was not as pronounced with formulations having a higher concentration of 
PMVE, indicating that at low concentrations of the polymer, the amount of CaCl2 in the 
formulation affected drug release whereas at higher concentrations of polymer, the 
concentration of polymer in the formulation was more important. As shown by the 
response surface plot (Figure 4.13) there exists a concentration at which the MDT was 
at its lowest point, indicating that at this point of a certain concentration of PMVE and 
CaCl2 there is an optimal interaction between the polymer and the salt which delays the 
release of drug from the implant.  
 
Figure 4.13: Response surface plot showing the relationship between MDT and the 
PMVE and CaCl2 concentration in the ISFI formulations. 
 
4.3.5. Computational modeling of the method of gelation and the effect of the 
addition of CaCl2  
PMVE consists of both hydrophobic (vinyl backbone and methyl side groups) and 
hydrophilic (ether oxygens) regions (Karayanni and Staikos, 2000). As a result the 
polymer is solvated at room temperature (surrounded by water molecules) due to the 
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presence of the ether oxygens on the polymer. However, at temperatures exceeding 
the LCST of the polymer, the hydration sheath surrounding the polymer chains is 
damaged and the interactions between the hydrophobic areas of the polymer such as 
the vinyl backbone and methyl groups on the polymer, become more important and as 
a result the water molecules are forced out, resulting in the “collapse” of the polymeric 
strands (precipitation of the sol or gel formation) (Richter, 2004; Karayanni and Staikos, 
2000). As shown in Figure 4.14 the addition of the soluble salt is thought to have a 
“dehydrating” effect on the polymer as the salt interacts with the water molecules 
previously associated with the polymer. This would explain the decrease in gelation 
temperature observed in formulations with higher amounts of salt as the dehydration of 
the surrounding water sheath can occur at lower temperatures in the presence of 
CaCl2. It is thought that this is the reason for the prolonged release of the entrapped 
drug as the drug is lipophillic by nature and hence has the tendency to become 
entrapped in the core hydrophobic region of the gel. Figure 4.14 shows this 
hypothesized interaction using molecular models. 
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Figure 4.14: Computational modeling showing a) The PMVE Chain with R-
representing chain elongation on both ends, the R is represented by large balls b) 
Water associated PMVE chains in the aqueous medium, only part shown, chain 
elongation R is shown in olive green. The -OCH3 are in water association, red dots 
represent water molecules and oxygen atoms in the polymer chain as well. In c) CaCl2 
(the slate-green balls) in the medium, with water and PMVE chain as associated with 
water molecules, and around the polymer chain. Figure denotes size relationship of the 
salt with the polymer chain atoms (and not chain length and size). d) CaCl2 in 
association with water molecules which are itself in association with the PMVE polymer 
methoxyl’s oxygen and hereby giving a compacted matrix where in all the entities are in 
close proximity as well as in the limits of inter-atomic distances required for the 
physicochemical interaction. The salt, CaCl2 is also in layered state between the two 
polymer strands and could not be inter-wined/embed into the polymer chain itself. 
 
4.4. Optimization of ISFI Formulation Responses 
The ISFI was optimized using Minitab V15 (Minitab® Inc, PA, USA) to determine the 
optimal level for each variable as summarized in Table 4.1. Table 4.6 summarises the 
a) b)
c) d)
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obtained values for the responses with the optimized formulation as well as the 
predicted values and desirability. The overall desirability for the all the responses in the 
design was 0.965. The optimal formulation was predicted to consist of 16.87%w/v 
PMVE and 0.1482M CaCl2. 
 
Table 4.6: Summary of the obtained values for each of the responses and the 
predicted values and desirability.  
Response Obtained Predicted Desirability 
Gelation Temperature 32.46˚C 33.0˚C 1.0000 
Force of Injectability 24.7N 25.0N 1.0000 
MDT* 21.23 (folic acid) 18.2357 0.89759 
*MDT=Mean Dissolution Time 
 
4.4.1. The release of MTX from the optimized formulation 
Studies conducted thus far had been completed using the drug, folic acid due to its 
similarity with the chemotherapeutic drug methotrexate. With the determination of an 
optimized formulation, the release of MTX from the formulation had to be ascertained. 
To this end, a calibration curve of MTX was prepared in order to quantify the amount of 
drug that had been released using standard UV spectroscopy. A stock solution of 
methotrexate in phosphate-buffered saline was prepared at a concentration of 0.2%w/v. 
Serial dilutions were then made to yield a concentration range of (0.00018-0.007 
mg/mL). The solutions were then assayed using a UV Spectrophotometer (Specord 40, 
Analytik Jena, AG, Germany) using a wavelength of 306nm.The optimized formulation 
consisting of 16.87%w/v PMVE and 0.1482M CaCl2 was prepared and loaded with 
methotrexate (5mg/mL). Release studies as per Chapter 4, Section 4.2.6 of this 
chapter were conducted.  
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Figure 4.15: a) Calibration curve obtained for MTX and b) drug release profile from the 
optimized formulation containing MTX over a period of 50 days. (pH=6.75, n=3, SD< 
0.024).  
 
The calibration curve obtained showed a linear relationship between the concentration 
of MTX and the absorbance with the coefficient of determination being 0.9988. The 
release of MTX from the formulation followed a pattern similar to that obtained for folic 
acid, however the MDT was 20.65 whereas formulations containing folic acid had a 
slighter higher MDT of 21.23. The pattern of release was also considered satisfactory, 
in that the formulation appears to have a fast release initially and then a steady release 
Concentration (mg/mL)
0.000 0.002 0.004 0.006 0.008
A
b
s
o
rb
a
n
c
e
 a
t 
3
0
6
n
m
0.0
0.1
0.2
0.3
0.4
0.5
Standard curve
Linear regression curve 
95% Confidence Band 
95% Prediction Band 
y= 45.169x
r2= 0.9998
Time (Days)
0 10 20 30 40 50
F
ra
c
ti
o
n
a
l 
D
ru
g
 R
e
le
a
s
e
0.00
0.05
0.10
0.15
0.20
0.25
0.30
Optimised: MTX
a) 
b) 
85 
 
of drug followed by rapid release. Weinberg et al. (2007) have suggested that a 
formulation would prove the best for the delivery of drug to solid tumors if it is able to 
provide an initial burst release at the site and then show continuous slow release of 
drug. The ideal slow release of methotrexate in particular is also described by Kumar et 
al. (2008). Kumar and co-workers (2008) suggest that as MTX has a “time effect” i.e. 
the sensitivity of cells towards MTX increases with a time an implant releasing drug 
slowly will also be beneficial. The release of the drug in vivo will be discussed further in 
Chapter 6. 
 
4.4.2. Further rheological characterisation of the optimized ISFI. 
In addition to the determination of the gelation temperature of the optimized formulation 
using methods as described in Chapter 4, Section 4.2.4, a frequency sweep was also 
conducted. Briefly samples were exposed to fixed stress values of 1, 10 or 18Pa. as 
frequencies were ramped from 0.1 to 100Hz.  
 
 
Figure 4.16: Rheological profile of the optimized ISFI at different stress values. 
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As shown in Figure 4.16, the formulation showed an increase in both Gʹ and Gʺ in 
response to an increase in frequency, indicating a dependence on frequency.   
 
4.4.3. Modelling of the release of drug from the implant 
In order to postulate the mechanism of release of the drug from the implant various 
predictive models were considered. Table 4.7 shows the model as well as the 
coefficient of determination obtained when fitting the experimental data to the release 
model. 
 
Table 4.7: Value of R2 for different models of mechanisms of drug release  
Model R2 
Zero Order 0.1348 
First Order 0.2295 
Higuchi 0.7395 
Hixson Crowell 0.1993 
Korsmeyer-Peppas 0.9474 
 
Higuchi’s model showed the highest R2 value (0.7395) and hence the data was fitted to 
the Korsmeyer-Peppas equation (Equation 4.5) which showed a R2 value of 0.9474. 
 
 F =  
Mt
M
  = kmt
n
..............................................................................................Equation 4.5 
 
Where F is the fraction of drug released at time t, Mt is the amount of drug released at 
time t, M is the total amount of drug in the dosage form, Km is the kinetic constant, t is 
the time, and n is the diffusion or release exponent. n was estimated from linear 
regression of log  
  
 
  vs log t (Peppas and Sahlin, 1989, Jain et al., 2004 and Kabir et 
al., 2009). The diffusion or release coefficient (n) can be used to determine the type of 
release. When n<0.45 this indicates release by fickian diffusion, while 0.45>n<0.89 
indicates anomalous diffusion and values of n exceeding 0.89 indicate release due to 
erosion of the polymer chain.  
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The value of n was found to be 0.231 for the release of MTX, indicating that the release 
of the drug occurred via diffusion of the drug out of the polymeric matrix and this also 
explains the relatively high value obtained for Higuchis model, a model explaining 
release of drug via diffusion (Equation 4.6). Two factors explain the less than ideal fit of 
the drug release to the Higuchi model. Firstly the model describes release from a film 
and secondly the model describes release from a formulation containing undissolved 
drug (i.e. a dispersed system) (Siepmann and Siepmann, 2008). 
 
Q =KHt
1
2..........................................................................................................Equation 4.6 
 
4.4.4. The effect of autoclaving on the properties of the ISFI 
4.4.4.1. Vibrational transition analysis 
There was no difference observed between autoclaved and un-autoclaved formulations 
in terms of FTIR spectra as can be seen in Figure 4.17. This seems to indicate that the 
structure of the polymer did not change following autoclaving. 
 
 
Figure 4.17: FTIR spectra comparing the autoclaved and unautoclaved formulations. 
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4.4.4.2. Rheological determination of the gelation temperature of the autoclaved 
formulation 
Autoclaving did not appear to change the gelation temperature of the formulation either 
as depicted in Figure 4.18.  
 
 
Figure 4.18: Rheological determination of gelation showed no apparent change 
between autoclaved and un-autoclaved formulations. 
 
The gelation temperature of the formulations were very similar, 33.51˚C for the un-
autoclaved and 33.65˚C for the autoclaved formulation. However this difference is well 
within the difference found between un-autoclaved formulations. 
 
4.4.4.3. Release of folic acid from autoclaved formulations   
Autoclaving of the formulations required the addition of water prior to the addition of the 
drug. As can be noticed in Figure 4.19, the release from the autoclaved formulation 
was faster than that from an un-autoclaved comparison formulation. Although the 
difference was only slightly greater than that observed between equivalent un-
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autoclaved formulations, a possible reason for the difference is poor reconstitution of 
the formulation and indicative of the care that had to be taken during reconstitution. 
 
Figure 4.19: Release profiles showing the release of folic acid from autoclaved and un-
autoclaved formulations (n=3, SD<0.067). 
 
4.4.4.4. Sterility of the formulations by examination of agar plates 
Agar plates were examined after 24 hours following incubation at 25˚C and 37˚C. 
Neither of the plates showed the presence of colonies indicating that the formulations 
were sterile. Plating of the formulations one month after autoclaving also showed the 
achievement of sterile formulations.  
 
4.4.5. The effect of different temperatures on the release profile of folic acid from 
ISFI formulations  
Formulations showed a slightly faster release at higher temperatures at least initially 
(Figure 4.20), while a markedly higher release at each point was obtained when the ice 
was applied. The faster release of drug following the application of ice is easily 
explained as the return of the formulation to a more liquid like phase and hence the 
drug is released. A further observation to be noted is that as the responsiveness of the 
implant to the ice appears to decrease with an increase in time. Release from the ISFI 
at higher temperatures is more of a challenge to explain and it is hypothesized that the 
increased release could be due to the lower viscosity shown by formulations at higher 
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temperatures. As shown in Figure 4.7 the viscosity of the implant drops slightly after 
the gelation temperature is achieved and this could possibly be the reason for such 
behaviour.  
 
  
  
Figure 4.20: a) The effect of increased temperature on the release profile of folic acid 
from the ISFI over 10 days (pH 6.75, n=2, SD< 0.039) and b) the effect of ice 
application on the release profile from the ISFI over 10 days (pH 6.75, n=2, SD< 0.06).   
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4.5. Concluding Remarks 
A thermoresponsive ISFI system was developed and the effect of CaCl2, on the 
physicomechanical properties of the polymer poly(methylvinyl ether) was examined. A 
Face-Centred Central Composite Design was used to optimize the formulation and 
proved to be quite effective in the selection of an optimized formulation which would be 
easily injectable, gel around body temperature and release drug from the formulation 
over a period exceeding 30 days. These drug release results demonstrated promise for 
the use of the ISFI for the prolonged delivery of drug in the treatment of solid tumors. In 
order to investigate improvement of the system, microparticles which were responsive 
to pH were developed as will be described in Chapter 5 of this dissertation.   
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CHAPTER 5  
THE DESIGN AND OPTIMIZATION OF PH-
RESPONSIVE MICROPARTICLES 
5.1. Introduction 
The use of responsive polymers in drug delivery systems has received much attention 
recently (Anal, 2007; Bajpai et al., 2008 and Bawa et al., 2009). Of the environmentally 
responsive polymers, pH responsive polymers in particular offer a multitude of 
advantages as they allow the controlled delivery of drugs at a certain pH. This is of 
considerable importance in the delivery of drugs to solid tumors as there are different 
pH conditions at the site of a solid tumor. The pH external to the solid tumor is 
approximately 6.75 whereas the pH within the tumor is about 5.6. The pH of normal 
tissue is about 7.4 (Martin and Jain, 1994). A combination of two pH responsive 
polymers allows the exploration of delivery of drug at different pHs.  
 
Chitosan (CHT) is an abundant natural polysaccharide obtained from the deacetylation 
of chitin, a component of the external skeleton of many crustaceans and insects. It is a 
cationic polysaccharide that has one amino group and two free hydroxyl groups in 
every monomer unit (Sinha et al, 2004). The presence of the amino groups gives the 
molecule an overall positive charge.  Poly(methacrylic acid-co-methyl methacrylate) 
(PMMA)- commercially available as Eudragit S100® and Eudragit L100®- has both 
carboxyl groups and ester groups. Eudragit S100®, the polymer utilised in this study, 
has a ratio of carboxyl groups to ester groups is 1:2. The polymer hence carries an 
overall negative charge (Hilbrig and Freitag, 2007 and Huanbutta et al., 2008). In this 
study CHT and PMMA (Figure 5.1) were selected to formulate particles able to deliver 
drug at different pHs based on the interaction between the two polymers as a result of 
their opposing charges. 
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Figure 5.1: Chemical structure of a) chitosan and b) poly(methacrylic acid-co-methyl 
methacrylate. 
 
The interaction that takes place between these two polymers was used to formulate 
microparticles. The aim of this study was to develop particles which were able to show 
different release profiles in response to different pHs. As outlined in Chapter 4 of this 
dissertation there are numerous benefits for utilising Design of Experiments to guide 
the formulator and to provide a method of statistically optimising a formulation. Once 
again a Face-Centred Central Composite Design was selected as two variables had 
been chosen for further investigation during preformulation studies.  
 
5.2. Materials and Methods 
 
5.2.1. Materials 
Chitosan (medium molecular weight) (CHT), Glacial acetic acid, and methotrexate 
(>95% purity) were purchased from Sigma-Aldrich, Steinheim, Germany. Sodium 
hydroxide pellets (NaOH, Mw=40g/mol) were purchased from Rochelle Chemicals, 
South Africa. Poly(methacrylic acid-co-methyl methacrylate) (PMMA) in the form of 
Eudragit S100® was purchased from Evonik Röhm Pharma Polymers,Darmstadt, 
Germany. Other materials used were as described in Chapter 3, Section 3.2.1.  
 
5.2.2. Preliminary investigations into the formulation of microparticles 
5.2.2.1. Preparation of microparticles  
Various methods of formulating particles were attempted and formulation A as 
described in Table 5.1 was the initial formulation found to provide desirable results. 
a) b)
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Briefly, to produce formulation A the following method was used: a solution of medium 
molecular weight chitosan (0.2%w/v) was prepared by adding 0.2g of chitosan to 100mL 
of a 1% acetic acid solution. An equivalent solution of PMMA (0.2%w/v) was then 
prepared by dissolving 0.2g of PMMA in 100mL of a 0.01M NaOH solution. To 10mL of 
the PMMA solution, 30mg of folic acid was added. 10mL of the CHT solution was 
placed under a sonicator (Vibra-Cell Ultrasonicator, Sonics, USA) and 10mL of the 
second solution (PMMA and folic acid) was added to the chitosan solution during 
sonication. The following variables were then investigated as shown in Table 5.1.  
 
Table 5.1: Investigation of variables for the formation of microparticles 
Formulation Chitosan(%w/v) PMMA(%
w/v) Amplitude (%) Time (mins) 
A 0.2 0.2 60 30 
A1 0.1 0.2 60 30 
A2 0.2 0.1 60 30 
A3 0.1 0.1 60 30 
A4 0.5 0.5 60 30 
A5 1 1 60 30 
A6 0.2 0.2 30 30 
A7 0.2 0.2 50 30 
A8 0.2 0.2 80 30 
A9 0.2 0.2 60 5 
A10 0.2 0.2 60 15 
A11 0.2 0.2 60 40 
 
 
5.2.3. Statistical optimization of the microparticles 
5.2.3.1. Design and optimization of the formulations using a central composite design 
Preformulation studies identified polymeric concentration and sonication time to be two 
variables contributing to drug entrapment. A two factor Face-Centred Central 
Composite Design (FCCCD) was therefore employed for the determination of the effect 
of the two parameters (polymeric concentration (0.1- 0.5% w/v) and sonication time(5-40 
seconds) on the drug entrapment of the particles and on the mean dissolution time 
(MDT) at two pH values as described in Table 5.2.  
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Table 5.2: Formulation variables and responses applied in design 
 Levels Objective 
 Upper Lower  
Parameters    
Polymer concentration (%
w
/v) 0.5 0.1  
Sonication time (minutes) 5 40  
Responses    
MDT*
1
 (pH 6.75)   Maximize 
MDT*
1
  (pH 7.4)   Minimise 
DEE*
2
   Minimize 
*
1
 MDT: Mean Dissolution Time; *
2
DEE: Drug Entrapment Efficacy 
 
The Face-Centred Central Composite Design provided the 14 formulations that were 
prepared as summarized in Table 5.3.  Formulations were prepared as described in 
section 5.2.2.1 of this chapter. After the formulations were prepared, they were left for 
12 hours to cure. The particles settled to the bottom and the supernatant was 
discarded. The particles were collected via centrifugation at 1000rpms for 3 minutes 
(Model TD5A-WS, Shanghai Luxiangyi Centrifuge Instrument Co., Ltd., Shanghai, 
China) and resuspended in deionised water. The particles were centrifuged once more 
and collected. Particles were resuspended in deionised water and frozen for 24 hours. 
Hence the particles were only washed once as there was no need to remove organic 
solvents and the drug had been in solution and un-entrapped drug was likely to have 
been discarded in the initial supernatant. Formulations were then lyophilised 
(Labconco, Missouri, USA) for 48 hours. 
 
Table 5.3: Composition of microparticle formulations in accordance with the FCCCD 
Formulation CHT / PMMA (%w/v) Time (minutes) 
1 0.5 40 
2 0.1 40 
3 0.3 22.5 
4 0.3 22.5 
5 0.1 5 
6 0.5 5 
7 0.3 22.5 
8 0.3 40 
9 0.5 22.5 
10 0.3 22.5 
11 0.3 22.5 
12 0.3 22.5 
13 0.1 22.5 
14 0.3 5 
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5.2.4. Determination of percentage of drug entrapped by the particles 
To determine the quantity of drug entrapped within the microparticles, accurately 
weighed amounts of each sample (approximately 25mg) were placed in 100mL of 
0.01M NaOH.  Samples were left for 48 hours to ensure complete breakdown of the 
particles. Aluminium foil was used to cover the vessels to prevent degradation of the 
entrapped drug (Lund, 1994). Following centrifugation, the supernatant was assayed 
using UV spectrophotometry (λ=280nm) and drug concentration was determined. 
Equation 5.1 was used to determine Drug Entrapment Efficacy (DEE). 
 
DEE = 
Actual amount of drug in microparticles
Theoretical amount of drug in microparticles
  100 …………………….............Equation 5.1 
 
A calibration curve of folic acid in sodium hydroxide (0.01M) was also constructed to 
determine amounts of drug entrapped in the particles. A stock solution was prepared 
by dissolving 1.65mg of folic acid in NaOH (50mL) in a volumetric flask. Serial dilutions 
were made and a UV spectrophotometer was used to measure the absorbance at a 
wavelength of 280nm.  
 
5.2.5. Determination of the release of drug from the microparticles at various pHs 
In order to determine the pH sensitivity of the particles, drug release studies were 
conducted using a dialysis tubing method as described by Moebus et al, 2009. Briefly, 
accurately weighed amounts of microparticles (~50mg) were placed in 6cm strips of 
dialysis tubing (molecular weight cut off: 12kDa) and the ends of the tubing were tied. 
The tubing was then placed into 100mL of phosphate buffered saline at an appropriate 
pH (6.75 or 7.4). At pre-determined time intervals, 10mL sample were drawn and 
replaced with an equal amount of pre-warmed buffer. In order to ascertain the fraction 
of drug being released at each time point a calibration curve of folic acid in PBS (7.4). 
The calibration curve for pH 6.75 can be found in Chapter 3, Section 3.3.1 of this 
dissertation. The Mean Dissolution Time (MDT) as described by Pillay and Fassihi 
(1998) was calculated for each of the formulations using Equation 4.1. 
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5.2.6. Examination of the morphology of the particles 
In order to assess the size and shape of the prepared formulations, electron 
microscopy was undertaken using a scanning electron microscope, Phenom (FEI, 
USA). Samples were mounted onto stubs using carbon tape and sputter coated with 
gold under an argon atmosphere using a sputter-coater (SPI, USA) for 90 seconds. 
 
5.2.7. Determination of the zeta potential of the optimised particles 
In order to determine the stability of the microparticles, zeta potential was ascertained 
using a Zetasizer NanoZS (Malvern Instruments Ltd. Worcestershire, UK).  The sample 
was diluted to less than a 1%w/v solution with deionised water and placed in a capillary 
cell. Measurements were undertaken in triplicate. 
 
5.3. Results and Discussion 
 
5.3.1. Calibration curve of folic acid conducted to ascertain concentrations of 
folic acid entrapped in particles 
A calibration curve was obtained as shown in Figure 5.2 and was utilised in the 
determination of the amount of drug entrapped in the microparticles. 
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Figure 5.2: Calibration curve of folic acid in NaOH  
 
5.3.2. Drug entrapment efficacy of preformulation microparticle formulations 
The calibration curve was utilised together with the absorbances obtained in order to 
determine the drug entrapment efficacy of the various formulations of microparticles as 
shown in Table 5.4: Table listing formulations as well as the drug entrapment efficacy 
obtained for each formulation 
 
Table 5.4: Table listing formulations as well as the drug entrapment efficacy obtained 
for each formulation (SD< 9.4) 
Formulation DEE 
A1 45 
A2 42 
A3 61 
A4 38 
A5 48 
A6 40 
A7 62 
A8 67 
A9 62  
A10 84 
A11 81 
 
 
Concentration (mg/mL)
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1.0
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2.0
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Linear regression curve
95% Confidence Band 
95% Prediction Band 
y= 56.716x
r2= 0.996
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The DEE of the formulations prepared during preformulation revealed some interesting 
trends and resulted in the variables being selected for experimental design. Altering the 
ratios of chitosan to PMMA (A1,A2) did not reveal desirable results. Increasing the 
amount of chitosan in the formulation decreased the DEE and although an increase in 
PMMA had a higher DEE, it was elected that the ratio of chitosan and PMMA would 
remain at 1:1 for the purposes of the design. Increasing the amounts of polymer in the 
formulation decreased the amount of drug being entrapped (A3-5), hence polymer 
concentrations were maintained between 0.1-0.5%w/v. Although the higher amplitude 
(80%; A8) showed a high DEE, concerns for safety resulted in exclusion of this 
amplitude. For the purposes of the design the amplitude was maintained at 60%. 
Increased sonication time caused an increase in the DEE (A10-11). However, this was 
chosen as a variable as ideally the time was to be minimized. Hence, two variables 
were selected for further investigation and optimization of the particles formed. The 
concentration of the two polymers was to be varied between 0.1-0.5%w/v and the 
sonication time was varied between 5-40 minutes. These values were then inputted 
into the two-factor Face-Centred Central Composite Design as described in Section 
5.2.3 of this chapter.  
 
5.3.3. Regression equations and examination of the FCCCD 
The regression model for drug entrapment efficacy generated by the FCCCD showed 
very poor values for both the standard error of the model (S=5.938) and the coefficient 
of determination (R2= 17.9). Slightly better values were obtained for the MDT6.75 (S= 
0.6003, R2 = 72.4) and MDT7.4 (S= 0.6388, R
2=53.3). These values are indicative of 
poor model fitting. Regression equations were generated (Equation 5.2, 5.3 and 5.4)  
 
DEE = 65.7214 - 0.5543 CHT - 2.1317 Time + 2.55 CHT*CHT + 0.5150 Time*Time   
– 0.4775[CHT*Time ......................................................................................Equation 5.2 
 
MDT6.75 = 66.7366 - 0.2121 CHT  + 0.3940 Time + 0.5396 CHT*CHT + 0.4241 Time*Time   
– 0.0712[CHT*Time]......................................................................................Equation 5.3 
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MDT7.4 = 37.4789 - 0.1558 CHT  + 0.3823 Time + 0.5179 CHT*CHT + 0.8353 Time*Time   
– 0.0168[CHT*Time]......................................................................................Equation 5.4 
 
5.3.3.1. Residual error in the design 
Figure 5.3 presents the various residual plots associated with the design and 
responses. The normal probability plots (a-c) for all the responses showed 
approximately straight lines indicating a normal distribution of residuals. Some outliers 
can be observed in graphs (a) and (b). The residuals versus fitted value scatter plots 
(d-f) showed random scatter of the residuals around 0 as expected. The plots of the 
residuals versus the order of the data (g-i) showed  somewhat of a dependence for the 
early observation points.  Histograms, plotting residuals against frequency (j-l), are bell 
shaped although somewhat skewed to the left (j) and (l). 
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Figure 5.3: Residual plots obtained for the responses examined in the design. 
DEE MDT 7.4MDT6.75
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5.3.4. Entrapment of drug within the design microparticles 
Most of the formulations showed desirable entrapment ranging from 55-74%. As 
shown in the response surface plot (Figure 5.4) the DEE was higher at the extremes 
of polymer concentrations. Higher polymeric concentrations may allow more efficient 
entrapment of the drug within the formed particles. Higher entrapment efficacies 
observed with lower polymer concentrations could be due to surface adherence of 
the drug rather than entrapment within the polymeric complex.  
Formulation number
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Figure 5.4:  a) Bar graph showing the DEE: experimental and predicted values and 
b) response surface plot showing the relationship between the polymer concentration 
and DEE. 
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Interestingly a decrease of entrapment efficacy is noted with an increase in 
sonication time and the effect appears larger at high concentrations rather than lower 
ones. This could possibly be due to the heat generated by sonication. Following 
sonication, temperatures of the beaker were found to be 70˚C. It is a possibility that 
this influenced the entrapment of the drug.  It also possible that at these high 
temperatures some degradation of the drug occurred (Lund, 1994) 
 
5.3.5. Release of folic acid from the optimised microparticle formulation 
As shown in Figure 5.5, release of folic acid from the particles was conducted in 
buffered saline solutions, pH 6.75 and pH 7.4 and showed slightly different profiles. 
Release of the drug from the particles appeared to be pH responsive with the release 
of drug faster at pH 6.75 and slower at pH 7.4. The enhanced permeation and 
retention (EPR) effect was first described by Maeda et al.,2000. Observed in solid 
tumors, this effect describes the accumulation of macromolecules and particles at the 
site of the tumor for up to 100 hours (Matsumara and Maeda et al., 1986) and is a 
result of hyper-permeability of the tumoral vasculature and poor lymphatic drainage 
as described in Chapter 1 of this dissertation. Hence although release of the drug 
does occur at pH 7.4, it is not expected that much of the drug will reach the 
circulation as most of the particles are likely to be retained at the site of the tumor 
due to the EPR effect. Table 5.5 shows the various MDT values obtained for the 
formulations and demonstrates the faster release obtained at pH 6.75 compared to 
pH 7.4. Furthermore, it must also be noted that there are very small differences 
between the values. 
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Figure 5.5: a) Calibration curve of folic acid in PBS, pH 7.4 and b) typical release 
profile obtained from a microparticle formulation. 
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Table 5.5: MDT values obtained for the formulation generated by the FCCCD 
Formulation MDT pH 6.75 MDT pH 7.4 
1 68.84 36.47 
2 68.24 37.46 
3 67.14 37.70 
4 67.32 36.83 
5 67.75 37.97 
6 68.07 37.05 
7 66.13 35.83 
8 67.02 37.10 
9 66.76 38.26 
10 66.60 37.95 
11 67.27 38.13 
12 66.63 37.75 
13 66.41 37.29 
14 65.92 37.02 
 
 
Response surface plots as summarized in Figure 5.6 show the effect of the 
concentration of the polymers and the sonication time on the mean dissolution time 
at two pH values. At low sonication times the concentration of polymers does not 
appear to affect the MDT6.75 as much as at high sonication times. Further MDT6.75  
appears to increase with sonication time with maximal release occurring at high 
sonication times and high polymer concentrations. The response plot for MDT7.4 
appears to be the inverse of MDT6.75. A maximal release from formulation would be 
obtained at medium sonication times and with high polymer concentrations.  As both 
the polymers were being used at the same concentrations, it is difficult to attribute the 
results to one polymer. However, the release profile suggest that the release is more 
dependent on the chitosan component. PMMA dissolves at pH 7and as a result the 
release should have occurred rapidly from the formulations at this pH if PMMA was 
playing a larger part in the release. As these results appear to indicate, the release of 
folic acid is faster at lower pH values. This is concurrent with the reported pKa of 
chitosan (approximately 6.5), as at pH values below this value the polymer is soluble 
and above this pH the polymer is insoluble (Dehousse et al., 2010).  
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Figure 5.6: Response surface plots generated by the FCCCD analyzing the effect of 
CHT/PMMA concentrations and sonication time on the responses a) mean 
dissolution time at pH 6.75 and b) mean dissolution time at pH 7.4. 
 
5.3.6. Determination of the morphology of the microparticles using SEM 
As seen from the scanning electron micrographs (Figure 5.7) the microparticles had 
peculiar spindle like morphology. Note the single spindles in the lower micrograph as 
well as the clumps in the first micrograph. The size of the spindles ranged from 
1.64μm-9.88μm in length and widths ranged from 0.29-0.6μm. The reason for the 
formation of these spindle like particles has been hypothesized to be a result of the 
increasing crystalline structure of the particles.  
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Figure 5.7: Electron micrographs showing the spindle like morphology of the 
microparticles. 
 
5.4. Response optimization 
The particle formulations were optimized using Minitab® V15 (Minitab Inc, PA, USA) 
to determine optimal levels of formulation components. The optimal formulation was 
found to consist of 0.4315%w/v of PMAA and CHT with a sonication time of 40 
minutes. Desirability values were satisfactory and obtained values were in close 
agreement with predicted values.  
 
Table 5.6: Values obtained for each response as well as the model predicted values 
and the desirability. 
Response Obtained (folic 
acid) 
Predicted Desirability 
DEE 64.89 64.60 1.00000 
MDT6.75 67.45 67.9745 0.99149 
MDT7.4 37.87 36.3717 0.82134 
 
 
5.4.1. Loading of the optimised microparticle formulation with methotrexate 
As mentioned in Chapter 1, Section 1.2.1 of this dissertation formulations were 
prepared with folic acid due to the high cost of the chemotherapeutic drug, 
methotrexate. Hence, only optimized formulations were loaded with methotrexate.  
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5.4.1.1. Determination of the drug entrapment efficacy of the microparticle 
formulation 
To determine the amount of drug entrapped within the microparticles, 25mg of each 
sample (approximately) were placed in 100mL of 0.01M HCl.  Samples were left for 
48 hours to ensure complete solubilisation of the particles. Following centrifugation, 
the supernatant was assayed using UV spectrophotometry (λ=306nm) and drug 
concentration was determined. Equation 5.1 was used to determine the amount of 
drug entrapped in the formulation. A calibration curve of methotrexate in HCl (0.01M) 
(Figure 5.8) was also conducted to determine quantity of drug entrapped in the 
particles. Drug entrapment efficacy was very high for the optimized formulation with a 
DEE value of 95.28%.  
 
 
Figure 5.8: Calibration curve of MTX in hydrochloric acid. 
 
5.4.1.2. Release of methotrexate from optimized microparticle formulations 
Release of MTX from the optimized particles was conducted at three pH values. 
Although the size of the particles excluded use of the particles for intracellular 
targeting, the effect of the pH on the release was of interest.  Figure 5.9 shows the 
release profile obtained from the optimized particles at three pH values. 
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Figure 5.9: Release of MTX from the optimized formulation at three different pH 
values (37˚C, n=3, SD<0.03). 
 
As can be observed the pattern of release is similar to that observed for the design 
formulations with increasingly rapid release with a decrease in pH values. However 
the effect is not as great as that observed with folic acid. Had the size of the particles 
been smaller, the particles could have provided release of the drug intracellularly. 
However, at the present sizes as shown in the electron micrographs (Figure 5.7), it is 
unlikely that the particles would be taken up by cells. In addition, the MTX-loaded 
particles show a large burst release and it is possible that the washing step described 
in section 5.2.4., was not sufficient especially with the methotrexate loaded particles 
and hence a larger burst release was noted with these particles at all pHs possibly 
indicating the presence of surface drug.  
 
5.4.1.3. Determination of the zeta potential of the particles 
Zeta potential is used to refer to the cloud of charge surrounding particles. The 
charge around a particle is an important determinant of its stability. Weak surface 
charges (+30mV or -30mV) cause repulsion between the particles inhibiting 
aggregation. High forces between the particles or neutral charges cause attractive 
forces between particles leading to aggregation of the particles.  
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Figure 5.10: Zeta potential distribution obtained for the optimized formulation. 
 
The results (Figure 5.10, -23mV n=3, SD=5.03) indicated that particles had a 
moderately high electrostatic charge associated with them indicating that the 
particles were unlikely to aggregate.  
 
5.5. Investigation of the effect of microparticles in the ISFI 
Optimized ISFI formulations were prepared as per Section 4.4 of Chapter 4 of this 
dissertation. Microparticles were loaded with MTX and prepared as described in 
Chapter 5, Section 5.2.2 with concentrations as per the optimized formulation 
described in Chapter 5, Section 5.4.  
 
5.5.1. Determination of the release of MTX from the combination of MTX-loaded 
particles and the ISFI 
The optimized ISFI (3mL) was mixed with 50mg of the optimized MTX-loaded 
particles. The formulation was then tested for drug release as described in Chapter 4, 
Section 4.2.6. It should be noted that contrary to the observed zeta potential values 
aggregation of the particles did occur and it was deemed unlikely that the formulation 
would pass through a 18G needle, making the injectability of the formulation a 
challenge.  
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Figure 5.11: Release of MTX from drug loaded particles in the ISFI (37˚C, pH 6.75, 
n=2, SD< 0.04)   
 
Release of the drug occurred rapidly with the addition of the particles (Figure 5.11). 
However, as mentioned there was significant clumping of the particles observed 
upon addition of the particles to the ISFI solution i.e. clumping occurred at room 
temperature and before thermal gelation temperatures were reached. It is possible 
that when gelation did occur, the “clumps” of particles were pushed to the edges of 
the ISFI and hence release rate was increased. Another hurdle for utilization of the 
implant formulation containing drug-loaded microparticles, is the low amount of drug 
entrapped. The amount of drug that can be loaded is limited by the concentration of 
microparticles that can be added without creating a slurry. As a result 50mg of 
microparticles were added. This equates with the addition of 1.86mg of MTX. As a 
result this formulation cannot be used solely for the delivery of the drug to the solid 
tumor. Should the particles not create aggregation in the formulation, the possibility 
of a double loaded implant exists, i.e. an implant containing drug loaded in the 
implant and within the particles dispersed in the implant. This would offer a number of 
interesting possibilities such as the loading of the same drug with two rates of release 
or the loading of two different drugs. However, the significant clumping, the lowered 
gelation temperature and the difficulty of injecting the microparticle containing implant 
preclude use of this formulation. 
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5.5.2. Rheological investigation of the formulation 
Rheological tests were carried out as first described in Chapter 3, Section 3.2.3 of 
this dissertation. As shown in Figure 5.12, the gelation temperature of the formulation 
is much lower than expected. This gelation temperature would been that samples 
would have to be refrigerated as normal handling could lead to gelation. 
 
 
Figure 5.12: Rheological profile of the optimized implant containing MTX loaded 
particles. 
 
5.6.   Investigation of the effect of bicarbonate loaded microparticles 
 
5.6.1. Preparation of the formulation 
Particles were prepared as described in Chapter 5, Section 5.2.2. However, instead 
of adding the drug, 50mg of sodium bicarbonate as an erosion controlling substance 
as described in Chapter 3 of this dissertation, was added to the formulation. ISFI was 
prepared as described in Chapter 4, Section 4.4 as per the optimized formulation. 
Folic acid (15mg) was added to the ISFI and then the bicarbonate loaded particles 
(50mg) were added to create the formulation. 
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5.6.2. Determination of the effect of bicarbonate particles on the release of drug 
entrapped within the implant  
Release from the implants loaded with bicarbonate particles and drug showed 
promising results (Figure 5.13). When the release from this formulation is compared 
to the addition of sodium bicarbonate directly to the implant as shown in Chapter 3, 
Figure 3.15 of this dissertation, a more pronged release was seen from the 
microparticle loaded formulation. Release from this implant must also be compared 
to that of the optimized ISFI (Figure 4.15) which showed release of approximately 
25% of the drug after 50 days.  
 
 
Figure 5.13: Release of folic acid from the ISFI loaded with sodium bicarbonate 
particles (37˚C, pH 6.75, n=2, SD< 0.09). 
 
It is possible that unlike observed with the addition of the salt in the powder form, the 
particles are not dissolved in the polymer matrix but rather remain suspended 
changing the pH surrounding the area and this could be the reason why the release 
of drug is more sustained. However the amount of bicarbonate that was entrapped 
within the particles could not be ascertained. This is a clear disadvantage and if the 
particles are to be utilised further, additional testing on these particles is required. 
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5.7. Concluding Remarks 
This chapter described the development of microparticles for the enhancement of 
drug release from the ISFI. A FCCCD was utilized to achieve the optimization of the 
microparticle formulation. However, the FCCCD showed poor fitting indicating that 
the models generated were not ideal. Microparticles showed relatively high 
entrapment of the drug and pH responsive release of the drug. Particles were then 
optimized and loaded into the optimized ISFI. Two challenges were encountered, 
firstly the release of drug occurred rapidly and secondly the delivery of the 
combination of implant and microparticles proved difficult considering microparticle 
aggregation. For these reasons, particles were not tested in vivo although in vitro 
testing on cells was performed as described in Chapter 6 of this dissertation.  
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CHAPTER 6  
IN VITRO TESTING OF THE ISFI AND 
MICROPARTICLES AGAINST VARIOUS CELL LINES 
6.1. Introduction 
Chapters 4 and 5 described the in vitro release of the cytotoxic drug methotrexate 
from the implant and the microparticles respectively. This chapter aimed to determine 
the effect of MTX incorporated within the ISFI on a cancer cell line in order to 
determine whether the drug was being released in sufficient quantities over time to 
result in the death of the cancer cells. The optimised ISFI containing MTX as 
described in Chapter 4 of this dissertation and the optimised particles as described in 
Chapter 5 of this dissertation were selected for in vitro testing on the cell lines. In 
addition, the effect of the polymer, PMVE on the viability of the cancer cells was also 
determined. In order to achieve these aims, colon carcinoma cell lines (HT29 and 
DLD1) and a breast cancer cell line (MCF7), which were to serve as models for solid 
tumors for the purpose of this study, were grown. Both a MTT assay and flow 
cytometry were used to determine the percentage of living cells after treatment with 
elutes from the implant or from the particles. 
 
MTT assays are colourimetric assay providing a measurement of cell viability by 
providing a measure of the proliferation of the cells. The tetrazolium salt, MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is added to the cells and 
is subsequently reduced to a purple formazan in the mitochondria of metabolically 
active (living) cells (Figure 6.1) Singh et al., 2007. A solubilisation solution such as 
dimethyl sulfoxide is then added to the cells to dissolve the formazan product to yield 
a coloured solution.  Comparison of the treated cells with the untreated control wells 
provides an indication of the cell viability. Treated cells showing higher absorbances 
than the control cells is indicative of enhanced proliferation of the cells and lower 
absorbance values indicate of a reduction in cell growth. 
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Figure 6.1: Yellow MTT is reduced to purple formazan crystals in the mitochondria of 
living cells.  
 
Flow cytometry is a highly accurate way of determining the viable and dead cells in a 
population of cells. The fluidics system in a flow cytometer allows for individual 
characteristics of each cell to be determined as it causes the cells in a particular 
sample to flow in a single stream past the machine’s detection system. The fluidics 
system (Figure 6.2) consists of two parts: A central core through which the sample 
will be aspirated via the application of pressurised air and a sheath surrounding the 
core through which sheath fluid flows. As the sheath fluid flows faster, this creates a 
drag effect on the narrowed central core and forcing the fluid and hence the cells to 
flow in a parabolic manner with faster flow in the centre and slower flow along the 
edges, hence forcing the cells into a single stream. This process is called 
hydrodynamic focusing. A higher sample pressure than sheath fluid pressure 
ensures that no mixing of the sample with the sheath fluid occurs 
(http://www.bdbiosciences.com/support/training/index.jsp, Accessed 2011-05-31). 
 
Reduction in mitochondria
MTT (yellow) MTT formazan (purple)
117 
 
 
Figure 6.2: Schematic showing the principle of hydrodynamic focusing utilised by the 
flow cytometer within the flow cell to allow the flow of single cells past the detector. 
 
Following hydrodynamic focusing, cells then flow past laser beams which are the 
light sources for scatter and fluorescence as shown in Figure 6.3. The light is then 
gathered by the optic system (consisting of various filters) and received by the 
detectors which convert the information from light intensity into voltage. Light that is 
scattered in the forward direction is collected by the forward scatter channel diode 
(FSC). As the amount of forward scatter produced by the cells is determined by the 
size of the cells, the forward scatter is a measure of the size of the cells. The light 
collected by the side scatter channel serves as a measure of the complexity of the 
cells as the granularity and structural complexity within the cell causes it to be 
scattered at larger angles. In order to gain information about the viability of the cells, 
fluorescent dyes are added to the cell sample. When laser light of the correct 
wavelength strikes the fluorescent dye, excitation occurs and the resulting 
fluorescence emission light is detected by the appropriate wavelength detector 
(http://www.bdbiosciences.com/support/training/index.jsp, Accessed 2011-05-31). 
 
7-Amino-actinomycin (7-AAD) is a nucleic acid dye commonly used in flow cytometry 
and was selected for its ability to penetrate the cell membranes of dying or dead cells 
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and intercalate with DNA. It is effectively excluded by viable cells. Its fluorescence is 
detected in the far red range of the spectrum (650nm long-pass filter).  
 
 
Figure 6.3: Figure showing a simplification of the fluidics and optic systems of the 
FACSCalibur (BD Biosciences, New Jersey, USA), the flow cytometer used in this 
study (adapted from: http://www.bdbiosciences.com/support/training/index.jsp). 
 
6.2. Materials and Methods 
 
6.2.1. Materials 
HT29, MCF-7 and DLD1 cells were obtained from the ATCC (American Type Culture 
Collection). Dulbelccos Minimum Essential Medium (DMEM), fetal bovine serum 
(FBS), Penicillin-Streptomycin Mixture (Pen-Strep), Trypan Blue (0.4%v/v solution), 
Trypsin-Versene® (0.5g/L trysin1:250 and 0.2g/L Versene® (EDTA)) and 
cryoprotective medium (15%v/v DMSO)  were all purchased from Whitehead 
Scientific, Brackenfell, South Africa. Phosphate buffered saline tablets were 
purchased from Sigma Aldrich (Steinheim, Germany) and once prepared were 
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autoclaved before use on the cells. Trypan Blue Solution (0.4%), MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and dimethyl sulphoxide 
(DMSO) were also purchased from Sigma Aldrich (Steinheim, Germany). Tubes used 
during flow cytometry analysis (BDTM Falcon tubes (5cm) with polypropylene lids) 
were purchased from The Scientific Group, Randburg, South Africa. Tissue cell 
flasks and other cell culture equipment was purchased from Lasec (South Africa).  
 
6.2.2. Methods 
6.2.2.1. Aseptic technique 
Aseptic technique was utilised at all times in the culturing of cells. Briefly all surfaces 
of the horizontal laminar flow unit (Labotec, Midrand, South Africa) were wiped with 
70% ethanol before commencing work. Laminar flow units are validated bi-annually. 
Gloves were worn at all times and were periodically sanitised with ethanol and when 
leaving the laminar flow unit. All tissue culture bottles and flasks were sanitised with 
70% alcohol prior to placing them in the unit and were flamed on opening and 
closing. All used disposable flasks, pipettes and culture equipment was sent for 
incineration, and all non-disposable items were treated with bleach for 2 hours before 
being discarded to the drain with copious amounts of water. Cell medium was 
periodically tested for contamination by incubating media at 37˚C for 24 hours. 
 
6.2.2.2. Culturing and counting of cells  
Standard methods were employed for the culturing of all cell lines. Cell lines were 
grown using DMEM (with 4.5g/L glucose and L-glutamine) supplemented with 10%w/v 
fetal bovine serum and 0.2%w/v Pen-Strep
® in 25cm3 flasks. When cells had reached 
confluency, media in the culture flask was discarded and 3mL Trypsin-EDTA was 
added to each flask and the flasks were placed in the incubator for 3-4mins. When 
cells had detached, 3mL of fresh media was added and the entire volume was 
centrifuged at 1000rpm for 3 minutes. The supernatant was discarded and the cell 
pellet was resuspended in 10mL of fresh media and plated into two flasks. When 
necessary, cells were frozen in a 1:1 mixture of cryoprotective medium (15%v/v 
DMSO) and media at -70˚C.  
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6.2.2.3. Cell counting using the trypan blue exclusion assay and a haemocytometer 
Following trypsination as described in Chapter 6, Section 6.2.2.2., and the discarding 
of the supernatant, the cell pellet was resupended in 3mL of fresh media. The 
number of cells per mL of media was then calculated using the trypan blue exclusion 
assay. Briefly, the cell suspension (10μL) was added to 20μL of trypan blue. The 
chamber of a disposable haemocytometer was then filled and the chamber was 
examined using light microscopy (Olympus CKS microscope, Olympus, Japan). The 
haemocytometer allowed the counting of the cells. Trypan blue is a stain which is 
taken up by dead cells and excluded by living ones and hence by counting stained 
cells as well as unstained cells allowed the estimation of dead cells in the sample. 
Only samples that showed viability of greater than 95% were utilised in subsequent 
testing.  
 
6.2.2.4. The inclusion of controls into test runs 
The use of controls is essential during the testing of samples especially when living 
cells are being utilised. For this reason positive and negative controls were used 
during the testing of samples. Table 6.1 summarises the types of controls used and 
the reason for the addition. 
 
Table 6.1: Summary of the controls used in the study. 
Type of control Method Reason for addition 
Positive Addition of a standard solution 
of MTX to cells 
Determination of sensitivity of 
the cells to MTX 
Negative 1. Cells allowed to proliferate 
without the addition of other 
substances 
 
2. Incubation of blank medium 
with no cells 
To ensure that cells are viable 
and that the tested substance is 
responsible for the death of the 
cells  
To verify that the media is 
uncontaminated 
 
 
6.2.2.5. MTT assay 
6.2.2.5.1. Preparation of the MTT solution 
A 0.5%w/v of MTT was prepared by adding 5g of MTT to 1000mL of phosphate 
buffered saline, pH 7.4. The solution was filtered through 0.22μm filters and stored in 
the fridge (4˚C) in a foil covered flask until further use.   
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6.2.2.5.2. Calibration curve of HT29 cells using the MTT assay 
A calibration curve for the MTT assay was conducted by starting with a cell 
suspension of 1x106 cells/mL. Serial dilutions in culture medium were then made 
yielding concentrations ranging from 1x106 cells/mL to 1x103 cells/mL. Cell 
suspension (100μL) was plated out in triplicate in the wells of a 96 well plate 
(NunclonTM Surface 96-well plates, sterile, NuncTM, Roskilde, Denmark). Media 
(200uL) was added to each well of the plate. The plate was incubated for 48 hours in 
an incubator (37˚C, 5% CO2). MTT (40μL of a 0.5%
w/v solution) was added to all the 
wells and the plate was incubated for a further 4 hours. The plate was then 
centrifuged at 3000rpm for 5 mins. The supernatant (200μL) was removed and 
DMSO (150μL) was added to each well to dissolve the formazan crystals. Plates 
were maintained at 37˚C and shaken for 5 minutes using an orbital plate shaker 
(MRC Thermo-Shaker, Hagavish, Israel). Plates were then read using a Labsystems 
iEMS Reader MF (Helsinki, Finland) with Ascent PC software at 540nm with a 
reference wavelength of 690nm. Figure 6.4 shows the obtained calibration curve for 
HT29 cells which was subsequently used to determine the number of cells to add to 
each well. 
 
 
Figure 6.4: MTT calibration curve obtained for HT29 cells 
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6.2.2.5.3. Determination of the effects of the drug release elutes and microparticles 
on HT29 cells utilising the MTT assay 
6.2.2.5.3.1. Preparation of test samples 
As the amount of solution that can be tested when using an MTT assay is typically 
100μL or less, direct elutes from drug release studies were not used. Instead the 
amount of drug which was determined to have been released at each period of time 
was prepared aseptically and added to the wells of the 96-well plate. Solutions of the 
polymer which had been autoclaved as described in Chapter 4, Section 4.4.4 of this 
dissertation were added directly to the wells of the plate in a concentration range of 
8.435g/mL to 0.263g/mL. Microparticles were suspended in media at 2mg/100μL 
media. Solutions of the amount of drug believed to have been released after 6 hours 
and 24 hours were also prepared. A control formulation was prepared in accordance 
with the literature at a concentration of 55nM for HT29 cells (Leteurtre et al., 2004). 
However, at this concentration cells (examined using the trypan blue assay) did not 
show susceptibility. For this reason the concentration of MTX used as a control in this 
study against HT29 cells was 5.5μM. 
 
6.2.2.5.3.2. Testing of samples 
Culture media (100μL) was added to each well of the 96 well plate. As per the 
calibration curve obtained (Figure 6.4), cells were plated at a density of 6250 
cells/well (62500 cells/mL) as this would result in a maximum possible absorbance of 
approximately one. Cells were allowed to attach and grow for 24 hours in an 
incubator (37˚C, 5% CO2). Test samples (100μL) prepared as described in Chapter 
6, Section 6.2.2.6.1 were then added to the wells and the plate was incubated for 24 
hours. Microparticles were added in two sets. The first set (24 hours) was added 
when the implant test samples were added. The second set was added 6 hours 
before the addition of MTT.  
 
Positive and negative controls were used as described in Table 6.1. However, in this 
assay the negative control also served to compensate for background absorbance. In 
addition, to ensure that the media was uncontaminated, three wells were filled with 
media containing no cells. As outlined in Section 6.2.2.5.1 of this chapter, MTT was 
added to all the wells and the procedure of centrifuge, addition of DMSO, plate 
shaking and plate reading  as described there was carried out. 
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6.2.2.6. Determination of the effects of the drug release elutes and microparticles on 
HT29 cells, MCF7 cells and DLD1 cells utilising flow cytometry 
6.2.2.6.1. Preparation of test samples and controls 
Drug release was conducted in sterile media as described by Decker et al., (1999). 
Briefly for each of the cell lines, four formulations of the optimized ISFI containing 
MTX and four formulations with no drug were placed in 4mL of sterile media each. 
The media was removed from the respective vessels at day 1, 7, 15 and 30 and 
added to the flasks containing cells. Microparticles (6mg) were added directly to the 
flasks containing cells. A control formulation was prepared at the following 
concentrations: 5.5μM for HT29 cells, 0.28μM for DLD1 cells (Calabresi, 1981) and 
4.4μM for MCF-7 cells (Kohler et al., 2005). 
 
6.2.2.6.2. Testing of samples  
Cells were counted as outlined in Section 6.2.2.3 of this chapter and plated at a 
density of 220, 000 cells and placed in prepared media in a 25cm3 tissue cell culture 
flask. The flask was placed in a humidified incubator (37˚C, 5% CO2 atmosphere) 
and cells were allowed to attach and grow for 24 hours. The media in the flasks was 
discarded and replaced with elute containing media (4mL) and 1mL of sterile media. 
Elutes from the placebo implant were similarly treated, and microparticles (6mg) were 
added directly to the media and into the flasks. Control flasks received either the 
media containing methotrexate at the concentrations outlined in Section 6.2.2.6.1 of 
this chapter (positive control) or received sterile media (negative control). Cells were 
subcultured 24 hours later using standard trypsination methods. 7AAD (BD Via-
ProbeTM,BD Biosciences, CA, USA) (10μL) was utilised as the stain for flow 
cytometry (FACSCalibur, BD Biosciences, New Jersey, USA). Counting beads 
obtained from BD Biosciences, CA, USA (BDTM Liquid Counting Beads) were also 
utilised so that exact numbers of dead cells could be determined. The beads were 
vortexed and a fixed volume of bead solution (50μL) was added to a fixed volume of 
cells (500μL). Equation 6.1 was used to calculate the number of viable and non-
viable cells in the test sample, where NCI is the number of cells of interest. 
 
NCI  
Number of events in region
Number of beads in region
   
Number of beads(theoretical)  
Sample size
……………………Equation 6.1 
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The number of events in the region refers to the number of events in the region of 
interest, i.e. the region where cells have not taken up the 7AAD dye and are hence 
viable could be the region of interest or alternatively the region where cells have 
taken up the dye and are therefore considered non-viable. These regions are shown 
with more clarity in Figure 6.8 in Chapter 6, Section 6.3.2 of this dissertation. The 
percentage of non-viable cells was then calculated as a percentage of all the cells 
tested. 
 
6.3. Results and Discussion 
 
6.3.1. The effects of methotrexate, polymer and microparticles on HT29 cells 
using the MTT assay 
The MTT assay showed a decreasing viability of cells as expected (Figure 6.5). 
However two observations are of importance. Firstly it is important to note that the 
reported IC50 did not in fact reduce the viability of the cells by 50%. This is 
suggestive of a cell line displaying some resistance and hence it should be noted that 
the effect of MTX might be higher in a different cell line. Secondly, the cumulative 
release was utilised in the determination of concentrations and the release of MTX 
from the implant is high initially and then slows as the implant reaches the plateau 
phase.  
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Figure 6.5: Bar graph illustrating the reduction in viability of the HT29 cells when 
treated with the drug release elutes of the optimized ISFI 
 
The effect of the polymer on the HT29 cells was more difficult to determine than the 
effect of MTX. As demarcated in Figure 6.6, once the polymer solutions were 
incubated at 37˚C, they formed solid deposits at the base of the wells. These could 
not be re-dispersed following the addition of DMSO despite vigorous shaking using 
an orbital plate shaker. Low concentrations of the polymer (0.451 and 0.263mg/mL) 
formed deposits that could be dispersed and showed absorbance that was equal or 
slightly higher than the negative control, indicating that the cells were viable. 
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Figure 6.6: Digital image showing an MTT plate following addition of DMSO as the 
solubilising agent for formazan crystals. Note the highlighted area indicating the 
presence of undispersable polymer deposits and the final four wells showing no 
deposit.  
 
An interesting observation was noted on the addition of microparticles directly to the 
cells. These appeared to show a greater cytotoxic effect when compared with the 
release elutes and with viability of the cells being decreased by a considerable 
amount as shown in Figure 6.7. While the size of the particles is too large for entry 
into the cells as discussed in Chapter 5 of this dissertation, perhaps the presence of 
the particles themselves caused some disruption in the formation of a confluent cell 
layer. 
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Figure 6.7: Plot showing the decrease in the viability of the cells following treatment 
with the particles versus treatment with the elutes prepared (n=3, SD< 0.1). 
 
6.3.2. The effect of drug elutes, placebo elutes and microparticles on HT29, 
MCF7 and DLD1 cells determined using flow cytometry 
Flow cytometry results correlated well with the MTT assay and showed that the 
amount of drug that was released over the 30 days was sufficient to cause toxicity to 
the cancer cells at the site. Figure 6.8 shows the dot plots obtained and the toxicity of 
the elutes against HT29 cells.  
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Figure 6.8: a) Typical dot plot obtained showing the viable cells (region R2), and 
cells which have taken up the 7AAD stain (region R4) b) counting beads are shown 
in region R3 and c) toxicity of elutes on HT29, MCF7 and DLD1 cells.  
 
As observed with the MTT assay, the reported IC50 was not achieved with the HT29 
cells. Hence the percentage of non-viable cells both with the positive control and with 
the actual elutes was low. However, a notable difference was observed with the 
DLD1 and MCF7 cells. This is ascribed to the greater sensitivity of the DLD1 and 
MCF7 cells to the MTX.  
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The placebo elutes showed no cytotoxicity towards the cancer cells with values of 
non-viable cells being similar to non-treated controls. Due to the settling of the 
microparticles in one region at the base of the flask, the true toxicity of the particles 
could not be determined using flow cytometry. The MTT assay provides a more 
comprehensive account of the toxicity of the microparticles.  
 
6.4. Conclusion 
In conclusion, this study attempted to determine the effect of release of drug from the 
implant and microparticles on cancer cells using two different techniques of 
measuring cell viability. Both flow cytometry and the MTT assay showed that the 
release of MTX from the optimised ISFI was sufficient to cause cell death. In addition, 
the implant did not appear to cause any major cytotoxicity towards the cell lines. The 
testing of the pH-responsive microparticles showed that the particles were more toxic 
than the release elutes. Although this is promising, the particles were not utilised 
further mainly due to the clumping that occurred when the particles were added to 
the ISFI formulation. For this reason only the implant was tested in vivo as described 
in Chapter 7.  
130 
 
CHAPTER 7  
IN VIVO TESTING OF THE ISFI IN THE SPRAGUE-
DAWLEY RAT MODEL 
7.1. Introduction 
Animal ethics approval for in vivo studies described in this chapter was obtained 
from WITS Animal Ethics Screening Committee, AESC Number: 2009/37/05 
(Appendix C). 
 
Although animal experimentation remains controversial, the testing of 
pharmaceuticals in animal models provides valuable information to researchers by 
allowing the study of formulations in vivo and hence providing important information 
which cannot be ascertained in vitro. A number of animals are commonly used for 
laboratory research such as rats, mice and larger animals such as primates, dogs 
and pigs. The majority of the animals used in research are mice and rats (80-95% of 
total animals used) (Lachman, 1992) Rats and mice are commonly used as they are 
readily available, associated with low cost due to their short gestation period and 
large litters. In addition they are small animals and hence easy to handle and easy to 
take care of both in terms of feed and housing. In particular Sprague-Dawley rats are 
calm and easy to handle (Sprague Dawley Rats, Harlan Laboratories, 
http://www.harlan.com/models/spraguedawley.asp, Accessed 2011-06-18). Due to 
the ease in obtaining large numbers of rats compared to larger animals and the 
larger volumes of blood obtained from rats versus mice, Sprague-Dawley rats were 
chosen for this study.  
 
7.1.1. Biocompatibility of implanted materials 
Essentially, a biomaterial is considered one if it is able to exist in the body without 
causing an unacceptable amount of harm (Williams, 2008). Determination of 
biocompatibility of an implant in vivo is of utmost importance in the avoidance of 
damage to the body. When a material is introduced into the body a number of 
responses may occur (Table 7.1). 
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Table 7.1: Responses to a foreign body that may occur (Williams, 2008) 
Protein adsorption and desorption characteristics 
Generalised cytotoxic effects 
Neutrophil activation 
Macrophage activation, foreign body giant cell production, granulation tissue formation 
Fibroblast behaviour and fibrosis 
Microvascular changes 
Tissue/organ specific cell responses (e.g. osteoclasts and osteoblasts for bone, endothelial proliferation) 
Activation of clotting cascade 
Platelet adhesion, activation, aggregation 
Complement activation 
Antibody production, immune cell responses 
Acute hypersensitivity/anaphylaxis 
Delayed hypersensitivity 
Mutagenic responses, genotoxicity 
Reproductive toxicity 
Tumor formation 
 
 
Besides the damage caused at the site, implants being used for the delivery of a drug 
may be adversely affected by the response of the local tissue surrounding the area of 
implantation.  The presence of inflammation and the associated oedema may cause 
an increase or a decrease in the release of the drug from the implant. Presence of 
granulation tissue and formation of a fibrous capsule will lead to a decrease in the 
amount of drug reaching the blood stream. The study had three main aims: firstly 
determination of the biocompatibility of the implant in vivo, secondly the 
determination of the release characteristics of the implant in vivo in the rat model and 
thirdly the effect of ice on the release profile of drug from the implant.  
 
7.2. Materials and Methods 
 
7.2.1. Materials 
Ortho-phosphoric acid (H3O4P) (85-90%) purchased from Fluka (Sigma-Aldrich 
Chemie GmbH, Steinheim, Switzerland), Methanol 215 (ROMIL-SpSTM Super Purity 
Solvent (MeOH), Assay>99.9%) and Acetonitrile 200 (ROMIL-SpSTM Super Purity 
Solvent (CH3CN), Assay>99.9%) was purchased from Romil Pure Chemistry 
132 
 
(Cambridge, Great Britain) and double de-ionized water was obtained from a Milli-Q 
water purification system (Milli-Q, Millipore, Billerica, MA, USA). Liquid Nitrogen was 
purchased from Afrox, South Africa. Phosphate buffered saline tablets, formaldehyde 
(4%v/v), methotrexate (Mw= 431g/mol) and pyrazinamide (Mw=123.1g/mol) were 
purchased from Sigma Aldrich, Steinheim, Germany. Trypton Soya Agar and Blood 
Agar was purchased from Oxiod (UK) and was sterilised and then poured into sterile 
petri dishes until use. 
 
7.2.2. Receipt, marking and treatment of animals 
 Healthy Sprague Dawley rats (200-250g ± 5g) were obtained from the WITS Central 
Animal Service. On receipt, each animal was marked at the base of the tail with the 
number assigned to it, weighed and placed in a cage with 4 other animals. Animals 
were maintained on a 12 hour light/dark cycle and fed commercially available rat 
chow and allowed access to food and water ad libitum. 
 
7.2.3. Biocompatibility studies in rats 
Rats received the drug-loaded implant on Day 1 and were sacrificed after 1 hour, 4 
hours and then on days 2, 4, 6, 8 and 10. The area around the implant including skin 
and underlying muscle was resected. The flank opposite to the side of implant 
implantation was utilised as the control. The samples were persevered in 
formaldehyde (4%v/v) were sent to IDEXX laboratories where they were analysed 
using routine histopathological methods. Briefly, sections of the samples were 
processed in an automated tissue histological processor according to a routine 
standard operating procedure. Following overnight tissue processing, wax blocks 
were prepared and 5µm slides were cut on a microtome before the sections were 
mounted on a microscope slide. These sections were stained with the Haematoxylin 
and Eosin staining method and mounted before microscopy was performed. 
 
7.2.4. In vivo studies on the rat model 
In vivo studies comprised two parts. Firstly, the release of the drug over 10 
consecutive days from the ISFI needed to be determined and the secondly the 
release of drug in response to the application of ice. An application to the University 
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of the Witwatersrand Animal Ethics Screening Committee (AESC) was made. A copy 
of the approval of the study (AESC clearance number: 2009/37/05) and the 
subsequent approval of modification to the study can be found in Appendix C. 
 
7.2.4.1. Sterile preparation of formulations 
As described in chapter 4, PMVE solutions were autoclaved. Due to the thermal 
sensitivity of methotrexate, the drug was added to the formulation under sterile 
conditions. Briefly, formulations were prepared under a horizontal laminar flow unit 
(Labotec®, Midrand, South Africa) fitted with a HEPA filter in a sterile room. Sterile 
settle plates of Trypton Soya Agar were placed at the corners of the laminar flow unit 
in order to determine the presence of possible contaminating micro-organisms. 
These plates were incubated at 37˚C and 25˚C for 24 hours to determine the 
presence of bacteria and fungi respectively.  A small amount of the final formulation 
was also streaked onto a nutrient rich blood agar plate and incubated at 37˚C for 24 
hours to determine if the formulation was sterile.  
 
7.2.4.2. Determination of thermally responsive drug release from the implant into the 
bloodstream and monitoring of body temperature of animals: pilot study 
In order to determine the release of drug from the implant in response to the 
application of ice and hence the cooling of the implant a pilot study was conducted. 
Anaesthesia was induced using a 1:4 xylazine and ketamine (Anaket®) mixture 
(0.1mL/100g). Four animals were injected with the MTX-loaded implants (12mg/kg) 
delivered in 0.4mL formulation. As this was the pilot study, a higher dose of drug was 
used as the animals were to be sacrificed on the day of implantation of the ISFI and 
hence there were no concerns of toxicity. Due to concerns of hypothermia in the 
animals, body temperature was monitored in two ways. Firstly body temperature was 
monitored using a rectal thermometer (World Precision Instruments Inc, Florida, 
USA) and secondly a temperature probe (Physitemp Instruments Inc, New Jersey, 
USA) was inserted at the site of the injection to monitor local decreases in 
temperature. A lag time of 15 minutes was implemented following implantation before 
the application of ice. In order to determine the time taken for the MTX to cross over 
into the blood following the application of ice, animals were sacrificed at the following 
intervals: 15 mins, 1 hour, 2 hours and 3 hours. Blood samples were withdrawn via 
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cardiac puncture and were analysed using ultra performance liquid chromatography 
as subsequently described in Chapter 7, Section 7.2.7.3.  
 
7.2.4.3. Determination of drug release from the ISFI over 10 days and the effect of 
the application of ice on the release of MTX from the ISFI 
The main study involved the application of an ice pack to the area of implantation of 
the ISFI to determine the release of the entrapped drug from the implant in response 
to temperature. Animals were divided into 2 main study groups: baseline animals and 
ice treatment animals (group 1), and three control groups (groups 3, 4 and 5) as 
summarised in Figure 7.1 and Figure 7.2.  
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118 Rats 
*Sampling was conducted 
on 15 rats at fixed time 
intervals: Days 2, 4, 6, 8 
and 10 post implantation of 
the ISFI.  
Tissue samples were taken for histopathological studies. 
Group 1: (75 Rats) 
 
On Day 1, all rats were 
injected subcutaneously 
with the ISFI containing 
MTX, following 
anaesthesia with 
intramuscular KETAMINE 
HCL (100mg/kg) and 
XYLAZINE HCL (5mg/kg). 
Group 4: (8 Rats) 
 
Blood samples were stored at -70
 o
C 
until UPLC was performed to determine 
the concentration of MTX in the blood. 
 
Biochemistry tests were run on the 
blood samples to determine if any 
organ damage had been caused by 
MTX. 
 
Group 2: (25 Rats) 
 
Blood samples were collected via cardiac puncture from the rats. At these time points, animals were 
euthanized using sodium pentobarbital. 
Group 3: (10 Rats) 
 
Animals received no 
treatment. (Blood required 
for UPLC method 
development, and blank 
samples for VetTest 
comparison) 
*Sampling was conducted 
on all rats on Day1.  
On Day 1, all rats received 
a bolus i.p. dose of the 
MTX only. Repeated on 
day 5. 
On Day 1, all rats were 
injected subcutaneously 
with the ISFI containing no 
drug, following 
anaesthesia with 
intramuscular KETAMINE 
HCL (100mg/kg) and 
XYLAZINE HCL (5mg/kg).  
*Sampling was conducted 
on 5 rats at fixed time 
intervals: Days 2, 4, 6, 8 
and 10.  
*Sampling was conducted 
on 2 rats at fixed time 
intervals: Days 2, 4, 6, 8 
and 10.  
Figure 7.1: Flow diagram showing overall design of in vivo studies (*Sampling procedure is 
elaborated on in Figure 7.2). 
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5 Rats: 
Baseline 
concentr-
ation 
5 Rats: 
Ice pack 
applied 
for 2 
mins 
5 Rats: 
Ice pack 
applied 
for 5 
mins 
After 1 hour 
animals are 
sacrificed 
Animals are 
sacrificed 
immediately 
Day 1: All 75 animals receive an injection of the implant containing MTX loaded microparticles following anaesthesia with 
intramuscular KETAMINE HCL (100mg/kg) and XYLAZINE HCL (5mg/kg). 
5 Rats: 
Baseline 
concentr-
ation 
5 Rats: 
Ice pack 
applied 
for 2 
mins 
5 Rats: 
Ice pack 
applied 
for 5 
mins 
After 1 hour 
animals are 
sacrificed 
Animals are 
sacrificed 
immediately 
5 Rats: 
Baseline 
concentr-
ation 
5 Rats: 
Ice pack 
applied 
for 2 
mins 
5 Rats: 
Ice pack 
applied 
for 5 
mins 
After 1 hour 
animals are 
sacrificed 
Animals are 
sacrificed 
immediately 
5 Rats: 
Baseline 
concentr-
ation 
5 Rats: 
Ice pack 
applied 
for 2 
mins 
5 Rats: 
Ice pack 
applied 
for 5 
mins 
After 1 hour 
animals are 
sacrificed 
Animals are 
sacrificed 
immediately 
5 Rats: 
Baseline 
concentr-
ation 
5 Rats: 
Ice pack 
applied 
for 2 
mins 
5 Rats: 
Ice pack 
applied 
for 5 
mins 
After 1 hour 
animals are 
sacrificed 
Animals are 
sacrificed 
immediately 
Day 2: 15 animals Day 4: 15 animals Day 6: 15 animals Day 8: 15 animals Day 10: 15 animals 
Group 1 (75 Rats) 
Figure 7.2: Flow diagram depicting the treatment each of the experimental groups (i.e. Both Group1 and Group 2) were to undergo. 
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7.2.4.3.1. Control animals 
Positive control animals (group 2, Figure 7.2) received intra peritoneal injections of 
MTX as per the flow diagram (Figure 7.1) MTX solutions were prepared from a stock 
solution of Arbitrexate® (Pharmachemie, Netherlands) (50mg/2mL) which was diluted to 
an appropriate concentration of 2mg/mL under sterile conditions as described in 
Chapter 6, Section 6.2.2.1 of this chapter. Each animal received 0.5mL injections i.p. 
using a 1mL syringe and a 25G needle on Day 1 and then on Day 5, hence delivering a 
dose of 8mg/kg/10 days. Negative control animals (group 3, Figure 7.2) received an 
implant (0.4mL) containing no drug on day 1. 
 
7.2.4.3.2. Baseline animals 
Animals (25 SD rats) were injected with a dose of 8mg/kg/10 days in order to match the 
dose given to the control animals. The ISFI was aseptically prepared and injected into 
the flank area of the rats as depicted in Figure 7.3. The dose of 8mg/kg was delivered 
in a 0.4mL formulation. Five rats were sacrificed on each of the following days: day 2, 
4, 6, 8 and 10.  
 
 
Figure 7.3: a) Sketch showing the proposed area of implantation of the ISFI in the 
flank of the animal b) Digital image showing the actual site of implantation and c) digital 
image showing the injection of the ISFI into the flank of the rat. 
 
a) b)
c)
Heart rate monitor
Syringe filled with ISFI
Injection into the flank area
O2 supply
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7.2.4.3.3. Animals receiving application of ice to region of implantation of the ISFI 
As shown in the flow diagram (Figure 7.2) 50 animals were to receive ice treatment 
with 10 animals being sacrificed every two days. However, as discussed in the results 
section of this chapter (Section 7.3.2.4.1) some animals in the baseline group began 
experiencing toxic side-effects after day 6. Hence the ice study was conducted on 
twenty animals only. These twenty animals were injected the ISFI delivering a dose of 
8mg/kg on day 1. On day 2, 5 animals received an application of ice to the area for 2 
minutes and 5 animals received an application of ice to the area for 5 minutes. 
Information obtained from the pilot study was utilised to determine the time point after 
application of ice that the animal would be sacrificed and hence animals were 
sacrificed 1 hour after application of the ice and bloods were collected via cardiac 
puncture. The same procedure was repeated on day 4.  
 
7.2.5. Evaluation of the toxicity of the drug in vivo 
7.2.5.1. Weighing of animals and cage activity 
Animals were weighed daily and animals that had lost more than 15% of their weight 
were to be removed from the study. Cage activity was observed twice a day on the day 
of implantation of the ISFI and then once a day thereafter.  
 
7.2.5.2. Analysis of blood obtained from treated animals 
In order to determine the toxicity of methotrexate on the animals that received doses 
over the period of 10 days, blood was extracted from two animals on day 2, 4, 6, 8 and 
10 from baseline animals and positive control group animals via cardiac puncture. The 
blood sample, approximately 1mL was allowed to clot in a tube and then centrifuged 
using an IDEXX StatSpin VT centrifuge (Westwood, USA). The serum was collected 
and analysed using a VetLab Station (IDEXX Laboratories, Netherlands) and VetTest 
Kits (General Profile, IDEXX Laboratories, Netherlands). In order to assess liver 
function, ALKP (Alkaline phosphatase), ALT (aspartate transaminase); creatinine levels 
were examined. As the formulation contained a high concentration of CaCl2, blood 
concentrations of calcium needed to be determined.  In addition the following tests 
were also undertaken: glucose, total bilirubin, total protein, urea, phosphate, albumin, 
cholesterol and amylase mostly to test possible toxicity of MTX on the liver and 
kidneys. Further, bloods from these animals were sent to IDEXX laboratories 
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(Johannesburg, South Africa) for a full blood count in order to determine haemotogical 
toxicity, if any.  
 
7.2.6. Visualisation of the ISFI utilising ultrasound imaging 
Ultrasound or sonography imaging utilises sound waves to produce images of 
underlying tissues. It is a topographic modality and as such it offers of non-invasive 
method of examination of a cross-sectional area of soft tissue (Anderson and Trahey, 
2006). Ultrasound imaging involves the generation of a sound wave typically of 
between 2-20MHz from an electric pulse by a transducer and transmission of the 
sound wave through the tissue. Sound is reflected partially through the underlying 
layers and totally reflected by denser objects such as bone. Some of these reflections 
or echos return to the transducer and are converted from sound waves into electric 
pulses and relayed to the ultrasonic scanner for interpretation and conversion into 
digital images. The length of time required for return of the echo allows the deduction of 
the depth of the underlying tissue whereas the strength of the echo allows deduction of 
the density of the underlying tissue (Anderson and Trahey, 2006).  
 
The animal was anaesthetised using xylazine and ketamine (1:4 mixture, 0.1mL/100g). 
It was placed on the stage fitted with a heating pad. A rectal thermometer was inserted 
to monitor the temperature of the animal. A tube delivering oxygen was placed over the 
snout of the animal. Following the disappearance of plantar reflexes, ultrasound gel 
was applied the area of implantation and the area was examined using an ultrasound 
imager (Vevo® 2100, VisualSonics Inc., Toronto, Ontario, Canada) and a 15Hz  
transducer to visualise the presence of the implant. To estimate the size of the ISFI, the 
transducer was fixed in position and a scan of the area of implantation was conducted.  
 
7.2.7. Utilization of Ultra Performance Liquid Chromatography in the 
determination of the methotrexate concentration in blood and tissue samples 
obtained from rats 
Chromatography is often utilised in the quantitative determination of separated 
substances and involves separation based on polarity. Liquid chromatography utilises a 
stationary phase and a mobile phase with the analyte of interest and other possible 
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contaminating substances being able to pass through the stationary phase and be 
eluted with the mobile phase at retention times in accordance with their affinity for 
either the mobile or the stationary phase. The retention time of the analyte of interest 
can be determined from a standard solution previously run and hence differentiated 
from other substances. As both height and peak areas vary linearly with an increase in 
concentration, the peak height or the peak area of the analyte can be used in 
comparison with a set of standards and hence can be used to quantify analyte 
concentrations in any sample (Skoog et al, 1992).  
 
Both high performance liquid chromatography (HPLC) and ultra performance liquid 
chromatography (UPLC) ultilise short columns which are densely packed with 
stationary phase particles and use pumps to pump the mobile phase through the 
column rather than gravity. UPLC (a specialised HPLC, first produced, marketed and 
trademarked by Waters®) differs from HPLC in that the packing particles are often less 
than 2μm and hence the pressures are much higher in UPLC (1000atm) whereas 
HPLC columns often have particles sizes of 5μm or greater, with pressures of 400atm 
(Nováková et al., 2006). While both these chromatography methods offer the 
advantages of high resolution and short elution times, UPLC is superior (Wren and 
Tchlitcheff, 2006; Dongre et al, 2008). 
 
Normal phase chromatography utilises a polar stationary phase with a non polar mobile 
phase whereas reverse phase chromatography, as used in this dissertation, consists of 
a non-polar stationary phase and a moderately polar mobile phase. The analyte of 
interest determines the type of chromatography to be used as the analyte is usually of 
similar polarity to the stationary phase with the mobile phase being of opposite polarity 
(Skoog et al. 1992). This is to ensure that the analyte is retained on the column for a 
sufficient period of time rather than being eluted as soon as the mobile phase is run 
through the column. As methotrexate is a non polar drug, reverse chromatography was 
chosen to be used in the quantitative analysis of MTX.  
 
Stationary phases in reverse chromatography are often silica coated with a thin 
chemically or physically bonded organic phase to create the non polar phase and are 
named according to the number of carbons that are attached. In the analysis of MTX as 
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described in this dissertation, an Acquity UPLC® BEH Shield RP18 column 
(2.1x100mm, 1.7µm particle size) was successfully employed. This column consists of 
hybrid particles composed of bridged ethylsiloxane/silica as pure silica materials do not 
provide the mechanical strength or efficiency required in UPLC (Grumbach et al., 
2005).  
 
Besides the strength of interactions with the stationary phase, analyte retention times 
also depend on factors such as the ratio and composition of solvents used and the flow 
rate of the mobile phase used. Isocratic elution is the use of a single mobile phase 
whereas gradient elution utilises atleast two mobile phases, often differing significantly 
in polarity. For the purposes of this study, gradient elution was used as it was found to 
improve separation efficacy.  
 
Lastly due to the errors than can occur in sample preparation and equipment, the use 
of an internal standard is recommended.  An internal standard is a substance added to 
all samples and standards in a fixed quantity and concentration and allows high 
precision as errors especially with injection volumes are accounted for (Skoog et al, 
1992). Pyrazinamide (PYZ) was used as an internal standard in this study.  
 
7.2.7.1. UPLC analysis 
Analysis was conducted on an Acquity® Ultra Performance Liquid Chromatography 
system (Waters®, Milford, MA, USA) fitted with an Acquity UPLC® BEH Shield RP18 
1.7µm VanGuard precolumn (2.1x5mm) and an Acquity UPLC® BEH Shield RP18 
column (2.1 x100mm, 1.7µm particle size). The purpose of the guard column as the 
name implies was to prevent proteinaceous material from reaching the column.  
Samples were run for 2 minutes and an injection volume of 15μL for plasma samples, 
or 10μL for tissue samples and implant samples was injected onto the column. 
Detection was via a photoiodide UV/Vis detector (PDA Detector). This allowed the 
recording of the full UV/Vis absorption spectra and determination of the highest 
absorption of the methotrexate as shown in Figure 7.4. Using this information, a 
wavelength of 310nm was used for the detection of methotrexate and pyrazinamide.  
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Figure 7.4: PDA plot showing the absorbance of MTX (retention time= 1.5mins) and 
PYZ (retention time= 1.1.mins). 
 
7.2.7.2. Preparation of weak and strong washes and mobile phases 
Considering the packing nature of the column, it can be easily understood that any 
particulate material in the system can cause blockages which would increase 
pressures and hence lead to failure of equipment. For this reason all solutions were 
prepared using double deionised water (DDW) (Milli-Q Gradient, Millipore, MA, USA, 
electrical conductivity 18.2MΩ.cm at 25˚C) and all solutions were freshly prepared daily 
and filtered under vacuum using Durapore® membrane filters (Millipore, Ireland). 
Gloves were worn at all times to minimise contamination. Priming solutions consisted 
of a weak wash (10%v/v acetonitrile) and a strong wash (90%
v/v acetonitrile). Gradient 
elution was achieved using acetonitrile and phosphoric acid (0.1%v/v) as mobile phases 
in a method described in Table 7.2.   
 
Table 7.2: UPLC method for the elution of methotrexate and internal standard 
pyrazinamide. 
Time (min) Flow Rate(mL/min) % Phosphoric Acid % Acetonitrile 
Initial 0.400 95 5 
0.5 0.400 85 15 
1.0 0.400 75 25 
1.5 0.400 65 35 
1.6 0.400 95 5 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
A
U
0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00
Minutes
300.00
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Precision and accuracy were determined by replicate injections of three concentrations 
of MTX. Intraday accuracy and precision was determined by multiple injections (n=3) of 
the three concentrations of MTX during the period of analysis on one day and inter-day 
accuracy and precision were determined by injecting the same three concentrations of 
MTX over 3 non-consecutive days (n=3). Peak area and retention time were noted for 
each of the analyte runs. In order to determine the precision, the % RSD (Equation 7.1) 
for retention time and peak area was calculated. Accuracy was determined by 
comparing the obtained amount with the theoretical quantity. 
 
 %RSD= 
std dev x 100%
mean
.....................................................................................Equation 7.1 
 
7.2.7.3. Drug content in the blood 
7.2.7.3.1. Obtaining blood samples 
On the day of termination, animals were sedated using a 1:4  xylazine and ketamine 
mixture (0.1mg/100g). Deep plantar reflexes were tested and when no response was 
obtained, a 22G needle attached to a 5mL syringe (flushed with Heparin-Sodium 
Fresenius, Bodene) was slipped into the heart via the intercostal space and 5mL of 
blood was drawn.  
 
7.2.7.3.2. Treatment of blood samples following collection 
Blood samples obtained from the cardiac puncture were collected in heparinised tubes 
(Improve® Improvacuter® Lithium Heparin collection tubes, GmbH, Hamburg, 
Germany). Bloods were immediately centrifuged at 3000rpm for 15minutes using a 
desktop centrifuge (Model TD5A-WS, Shanghai Luxiangyi Centrifuge Intrument Co., 
Ltd., Shanghai, China). Plasma was collected and stored at -70˚C until analysis.  
 
7.2.7.3.3. Determination of the optimal method of extraction of drug from plasma 
samples 
Before samples of blood can be injected onto the UPLC column, proteins must be 
removed. Two methods exist for achieving this: liquid-liquid extraction and solid phase 
extraction. Liquid-liquid extraction was chosen as solid phase extraction showed low 
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levels of MTX in the final elute. Methanol was selected as the deproteinising agent in 
this study as other agents such as acetonitrile and perchloric acid proved unsuccessful.   
 
7.2.7.3.3.1. Determination of the optimal ratio of deproteinating agent 
Extraction yield was determined by spiking 400μL blank plasma samples with fixed 
quantities of drug sample (100μL of a 0.1mg/mL MTX solution). To these samples 
differing quantities of methanol was added and UPLC analysis conducted on these 
samples was compared with samples of the drug solution (100μL of a 0.1mg/mL MTX 
solution) in the same quantity of methanol.  
 
Comparison of these allowed the determination of the best recovery method, i.e. the 
amount of methanol that should be added to the plasma sample to recover the greatest 
amount of drug. The ratio of plasma to methanol in order to obtain a recovery of 99% 
was found to be 1:4.2, and subsequently plasma samples were treated in this way. 
Although recovery obtained was good, concern over the low amounts of drug in the 
actual plasma samples necessitated the concentration of samples. For this reason 
plasma samples were dried completely under a gentle stream of nitrogen gas and 
reconstituted in 500μL methanol or samples were dried to 500μL in a vacuum oven 
(Trade Raypa® Digital drying oven, Barcelona, Spain maintained at 50˚C, -0.6bar). 
Comparison of these two samples determined that the samples dried to 500μL showed 
better recovery. 
 
7.2.7.3.3.2. Treatment of actual plasma samples 
Using the obtained ratio of 1:4.2, 400μL samples of blood were pipetted into suitable 
centrifuge tubes and 1800μL of methanol was then added. The samples were vortexed 
(Vortex-Genie 2, Scientific Industries Inc., Bohemia, NY, USA) for 15 seconds to 
ensure adequate mixing of the methanol with the plasma. The samples were then 
centrifuged at 1500rpm for 5 minutes (Model TG16-WS, Shanghai Luxiangyi Centrifuge 
Intrument Co., Ltd., Shanghai, China) in order to precipitate the proteins. Supernatants 
were then decanted into Eppendorf microtubes (Eppendorf AG, Hamburg, Germany), 
placed in a vacuum oven and evaporated to 500μL. Samples were filtered using a 
0.2μm filter (GHP Acrodisc filter, Pall Life Sciences, NY, USA). Pyrazinamide was used 
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as an internal standard and 2μL of a 0.5mg/mL solution was added to each sample 
before analysis.  
 
7.2.7.3.3.3. Construction of a calibration curve in order to quantify amounts of drug in 
actual plasma samples 
A calibration curve was generated in order to quantify the amount of drug in the plasma 
samples. Briefly, blank plasma samples were spiked with known quantities of MTX and 
the procedure outlined above was followed.  The ratio of the area under the (AUC) of 
the chromatogram of drug to the internal standard was plotted against the 
corresponding drug concentrations (μg/500μL). The least squares method was used to 
determine the linearity equation and correlation coefficient (r2). The limit of 
quantification (LOQ) was defined as the concentration which produces 
chromatographic peaks with heights at least 3 times that of the baseline noise. 
 
7.2.7.4. Determination of the residual drug in ISFIs 
From day 4 and 10 animals, the area surrounding the implant was resected and the 
implant was dissected out (Figure 7.5). Care was taken to ensure that all visible implant 
was removed. The implant was then dissolved in phosphate buffered saline (PBS, pH 
7.4). Samples were twice filtered through a 0.22μm Cameo Acetate membrane filter 
(Millipore Co., Bedford, Massachusetts) and a 500μL sample was placed in the sample 
vial for analysis. Pyrazinamide (0.5mg/mL) was used as the internal standard and 2μL 
was added to each sample.  
 
7.2.7.4.1. Construction of a calibration curve in PBS 
A calibration curve of MTX in PBS was also conducted. The ratio of the area under the 
(AUC) of the chromatogram of the drug to internal standard was plotted against the 
corresponding drug concentrations expressed in μg/mL. The least squares method was 
used to determine the linearity equation and correlation coefficient (r2). 
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Figure 7.5: Digital images showing the resected tissue surrounding the implant with a) 
showing the implant in situ as indicated by the black arrow and b) shows the resected 
implant with some of the implant still remaining as indicated by the black arrow. This 
area was then scraped using a scalpel to collect the remaining implant. 
 
7.2.7.5. Determination of the drug content in surrounding tissue 
Tissue immediately surrounding the implant was collected from day 4 and day 10 rats 
following removal of the ISFI as described in Section 7.2.7.4 of this chapter. As shown 
in Figure 7.6 the entire area surrounding the implant was resected (approximately 
4mm), yielding a sphere like sample. The sphere was cut open and the entire implant 
removed. Care was taken to ensure that all the implant was removed and the tissue 
was rinsed with PBS to ensure there was no drug that had diffused out of the implant 
and onto the tissue post removal. The implant was treated further as described in 
Section 7.2.7.4 of this chapter. The samples of tissue surrounding the implant were 
rinsed with PBS and then accurately weighed and cut into thin pieces using surgical 
scissors and/or a scalpel and placed in a mortar. Liquid nitrogen was then added to the 
mortar and a pestle was used to crush the tissue to a powder. PBS (5mL) was then 
added to the powder and the solution was homogenised for 15 seconds using a 
homogeniser (Polytron®, Kinematica Inc, Bohemia, NY, USA).  The obtained solution 
was centrifuged at 3000rpm for 10 mins and the supernatant was collected and filtered 
using filter paper (Whatman filter paper, Kent, England) to remove any remaining 
pieces of flesh or fatty tissue and then refiltered using 0.22μm filters. To remove protein 
from the samples, 400μL of the obtained filtrate was treated with 800μL of methanol. At 
this ratio of methanol to tissue sample, protein precipitation was observed. Samples 
were then vortexed for 15 seconds and centrifuged for 5 minutes. Following final 
filtration of the supernatant through a 0.22μm filter into vials (Waters® LCMS certified 
vials with a pre-slit screw top, Waters, Milford, MA, USA) samples were injected onto 
the column. 
a) b)
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Figure 7.6: Digital image showing the resected implant with surrounding tissue.   
 
7.2.7.5.1. Construction of a calibration curve in methanol 
A calibration curve of MTX in methanol was also conducted. The ratio of the area under 
the (AUC) of the chromatogram of the drug to internal standard was plotted against the 
corresponding drug concentrations expressed in μg/mL. The least squares method was 
used to determine the linearity equation and correlation coefficient (r2). 
 
7.3. Results and Discussion  
 
7.3.1. Biocompatibility of the ISFI in the rat model 
7.3.1.1. Implantation site and tissue necrosis 
After one hour of implantation of the ISFI, no inflammation was observed. Minimal to 
acute inflammation was detected 4 hours after implantation of the ISFI. The 
inflammatory response then varied from acute in the 2, 4- and 6- day specimens to 
subacute in the 8- and 10-day implantation sites. This is the expected response of the 
tissue to a foreign body. Chronic inflammation generally follows and is generally part of 
the healing process. It is persistent inflammation that presents a problem (Anderson 
and Langone, 1999). The inflammation was regarded as minimal to mild and no severe 
exudative inflammatory response could be detected as shown in Figure 7.7.  
 
However, tissue necrosis, especially in the subcutaneous fatty tissue, was observed in 
almost all of the implantation sites. Poly(methyl vinyl ether) is reported by Nurkeeva et 
al. (2005) to be biocompatible and poly(methyl vinyl ether-co-maleic anhydride) 
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(PMVE/MA) has been used in a number of formulations (Orienti et al., 1998; Finne et 
al., 1989 and Cerchiara et al., 2005).  In addition, some salts of PMVE/MA have been 
approved for use in the cosmetic industry (Burnett, 2011). PMVE/MA crosslinked by 1,9 
decadiene, was tested in rabbits eyes and was found to be only a slight irritant (ISP 
(Australasia) ,1993). The same report by ISP also showed low toxicity of the polymer 
on the skin and had an oral lethal dose of more than 5g/kg. A locally available product, 
Correga®: a denture fixative, also contains PMVE/MA.  However, to date reports of 
PMVE/MA or PMVE used as an implant system have not been found. This study 
however clearly shows necrosis associated with the ISFI. While the reports of safety 
associated with the copolymer seem promising and indicate that the polymer itself is 
not the likely cause of toxicity, the polymer needs to be examined further. It is a 
possibility that the polymer is safe and the high calcium content of the ISFI is then most 
likely the causation of the necrotic regions. Further investigation is this regard is 
warranted. 
 
7.3.1.2. Tissue mineralization 
Dystrophic calcification was found in most of the specimens and was likely the result of 
tissue damage and necrosis. It could also be attributed to the presence of CaCl2 in the 
formulation. However, it was not severe and resorption was thought possible.  
 
7.3.1.3. Granulomatous inflammation and fibroplasia 
The granulomatous response appeared minimal to mild with only early fibroplasia and 
encapsulation observed in one of the sections (a day 8 animal). No well-developed 
capsule or any collagen formation could be detected in any of the specimens.  
 
7.3.1.4. Focal skin ulceration 
Some of the implantation sites showed foci of superficial skin necrosis and ulceration. It 
was the opinion of the pathologist (Dr WS Botha, IDEXX Laboratories) that this was 
most likely secondary induced by licking or biting at the implantation site based on the 
morphological findings. It was therefore regarded as an incidental observation and the 
biting may well have been associated with sensitivity and pain at the implantation site. 
However, several animals in the placebo group also experienced the skin ulceration 
and another possible explanation was the decrease in blood flow to the region due to 
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subcutaneous damage caused by the presence of the implanted material. Again the 
high concentrations of calcium in the implant must be questioned. Calcium is an 
important ion in the clotting of the blood (Hilgard, 1973). Hilgard (1973) investigated 
hypercalcaemia on clotting time and found a reduction in clotting time in vitro. In vivo 
and further in vitro experimentation revealed that hypercalcaemia may play a part in the 
formation of thrombi in vivo in the presence of other trigger mechanisms (Hilgard, 
1973). Hence it is possible that the elevated concentrations of calcium may have 
caused coagulation of blood in the region inhibiting blood flow to the dermal layers and 
hence resulting in secondary ulceration. 
 
 
Figure 7.7: Histopathological analysis of local tissue surrounding the area of 
implantation of the implant in a) non-treated animal b) after 2 days of implantation c) 
after 6 days of implantation and d) after 10 days of implantation. 
 
7.3.2. In vivo testing of the ISFI 
7.3.2.1.  Sterile preparation of ISFI 
After incubation of the plates (settle plates and streaked formulation plate) for 24 hours, 
plates were examined visually to determine the presence of growth. None of the plates 
showed any growth indicating the sterility of the formulation prepared. 
 
a) b)
c) d)
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7.3.2.2. Construction of a calibration curve in order to quantify the amount of 
methotrexate in blood and tissue samples and precision and accuracy of the UPLC 
method 
Figure 7.8 shows the typical chromatograms obtained for the drug, methotrexate and 
the internal standard, pyrazinamide. As shown in Figure 7.9, a calibration curve with a 
high coefficient of determination was obtained. Table 7.3 shows the calculated 
precision and accuracy of the method when three replicate injections of three samples 
with known concentrations were made on the same day and on three non-consecutive 
day. As should be noted the accuracy remained high even between days and %RSD 
remained relatively low indicating that the method had good precision and accuracy. 
The limit of quantification was determined to be 0.50ng/mL. 
 
 
Figure 7.8: Typical chromatogram obtained for methotrexate (retention time=1.408min) 
and internal standard, pyrazinamide (retention time=0.932min) 
 
151 
 
 
Figure 7.9: Calibration curve obtained of Methotrexate in blank plasma 
 
Table 7.3: Inter- and intra- day precision and accuracy of the method were determined 
(only one set of interday data is shown). 
 %RSD  
(TR) 
%RSD 
(AUC) 
Accuracy 
Intraday    
1 0.154 0.583 99% 
2 0.143 0.433 99% 
3 0.166 0.494 99% 
Interday    
1 0.61 0.290 97% 
2 0.54 0.540 98% 
3 0.49 0.667 96% 
%RSD= Percentage relative standard deviation;TR= Retention Time; AUC= Area under the curve 
 
7.3.2.3. Observations and findings of the pilot study 
The pilot study determined two things: firstly the effect of the application of ice to the 
region on the body temperature was determined. Table 7.4 summarises the effect of 
ice on the temperature (body and at the site) of the rats. 
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Table 7.4: Table showing the effect of the application of ice on the rats on the local and 
systemic temperatures. 
 Rat 1 Rat 2 Rat 3 Rat 4 
Weight 234g 237g 227g 219g 
Temp at site     
Before (˚C) 33.0 33.9 32.8 31.6 
After (˚C) 26.7 28.0 24.1 23.7 
Body Temp       
Before (˚C) 32.7 34.3 34.5 33.2 
After (˚C) 30.7 33.7 32.4 32.7 
Temp at site: Temperature at the site of implantation, Body temp: Body Temperature 
 
As can be noticed, the body temperature (measured with the rectal thermometer) did 
not change by many degrees (the largest difference in temperature is 2.1˚C). However, 
the temperature at the site decreased sufficiently. This was the desired outcome as it 
showed that the application of ice to the region for up to 5 minutes would not cause 
hypothermia in the animals. 
 
Secondly, the pilot study was used to determine the time of sacrifice of the animals. 
Plotted in Figure 7.10 are the concentrations of MTX in the blood sacrificed 15 minutes, 
1 hour, 2 hours or 3 hours after the application of ice for 5 minutes. 
 
 
Figure 7.10: MTX levels in the blood of the pilot study animals clearly showing the 
peak of drug at 1 hour following the application of ice to the area  
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Hence, for studies that followed, animals were sacrificed 1 hour following the 
application of ice as this was when the highest concentration of drug was obtained. 
This was possibly the time of diffusion of the drug from the site of implantation to the 
blood stream. Following this, the amount of drug in the blood stream decreased due to 
diffusion to other tissues or excretion. 
 
7.3.2.4. Main study 
7.3.2.4.1. Baseline Animals 
Animals were injected with a dose of 8mg/kg/10 days in order to equalize the dose 
given to the control animals. Animals were labelled as described in the flow chart 
(Figure 7.11)  
 
Figure 7.11: Flow chart demonstrating the numbering of the experimental animals.  
 
Day 2 animals showed no toxicity and were sacrificed. However in the Day 4, 6, 8 and 
10 groups, Rats 32, 33, 37, 40, 41, 47 and 49 developed diarrhoea and of these four 
animals, one animal (Rat 41) developed enterohaemorrhagic diarrhoea and 
subsequently died on the 8th day following implantation. Post mortem examination of 
the animal revealed severe haemorrhaging in the gastrointestinal tract and severe 
dehydration. In addition, all animals in the main and ice treatment branches of the 
study lost weight throughout the study. The weight loss and the diarrhoea were not 
Control Group  
Day 2: Rats 
1-5  
Day 4: Rats 
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Day 8: Rats 
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Day 8: Rats 
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Ice Treatment 
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Ice Treatment 
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Day 2: Rats 
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63 and 64 
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Day 8: Rats 
67 and 68 
Day 10: Rats 
69 and 70 
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observed in animals that received the non-drug loaded placebo (Rats 61-70) and 
animals in the control group (Rats 1-25).  
 
The significance of these observations is that the animals receiving the implant 
developed side effects and loss of weight indicating the toxic levels of drug were 
reached. Animals in the control group receiving intraperitoneal injections of the drug did 
not experience these side effects indicating that high levels of drug were not obtained 
in these animals. Animals receiving the placebo implant also did not develop these side 
effects, indicating that these were likely to have been drug induced and could not have 
been due to the polymeric material composing the implant. 
 
7.3.2.4.2. Analysis of the toxicity of MTX in vivo 
7.3.2.4.2.1. Analysis of blood biochemistry 
Analysis of the blood revealed some toxicity in the animals. Several animals in the 
baseline study group showed a decrease in blood  phosphate levels. When levels of 
calcium increase in the blood, one of the action of parathyroid hormone is to decrease 
the resorption of phosphate ions from the kidney tubules. This leads to a decrease in 
phosphate levels (Vander et al., 1990). Hence the drop in phosphate levels could be 
due to the increase in calcium levels due to the high calcium content in the implant. 
The parathyroid hormone is responsible for maintaining calcium homeostasis in the 
body. Calcium blood levels remained within normal limits over the period of study. 
Normal levels of phosphate and calcium were noted in the control animals. One animal 
in the Day 10 group of the baseline study showed an elevated urea concentration, 
which could be a result of kidney toxicity. Such an observation was made by Heringou 
et al. (1989) where rats treated with a cement delivering MTX over a prolonged period 
developed severe nephropathy with necrosis of the epithelium and the convoluted 
tubules. All other tests were marked as within normal ranges. 
 
Full blood counts revealed low levels of haemoglobin in all animals, both the control 
group and the baseline animals. Some animals in each group also showed a decrease 
in platelet counts and white cell counts. Baseline animals also showed unsatisfactory 
readings for Red Blood Cell (RBC) counts. Some animals showed a decrease in the 
RBC count while others an elevated count. A high RBC count can easily explained by 
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the dehydration observed in several of the animals in the baseline study and is 
attributed to the diarrhoea experienced by the animals. Low RBC counts when coupled 
with low white cell counts could be indicative of bone marrow suppression. None of the 
animals in the control group showed a decrease or increase in RBC counts. Once 
again this could be indicative of the higher levels of MTX obtained in the animals 
receiving the implant and hence indicative of the release of drug from the implant. 
 
7.3.2.4.3. Analysis of blood samples 
7.3.2.4.3.1. Baseline animals and control animals 
Control animals (n=25) received a dose of 8mg/kg/10 days of MTX in two divided 
doses. Blood levels of the drug fell below the LOQ and could not be determined except 
in one animal that showed a concentration of 56.6ng/mL on Day 6, the day following 
the i.p. injection of MTX. However, it was the only animal in the group to show a 
reading. 
 
 
Figure 7.12: Blood methotrexate concentrations in baseline animals (SD< 0.034) 
 
Figure 7.12 shows the drug content of the blood in the baseline animals. While n=5 for 
day 2 and day 4,  it should also be noted that the final three values are obtained from 3 
animals only as the other two animals in each group had levels of drug that were below 
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the LOQ. Further the final concentration was approximately the same as the LOQ and 
it is difficult to say with confidence that these values are accurate. Nevertheless it can 
be said that the amount of MTX in the blood is very low almost below quantifiable 
amounts when utilising standard UPLC methods. This could be indicative that the 
majority of the drug being released at later stages was retained at the site of 
implantation rather than distributing into the blood.   
 
There was large variation in the blood concentration observed between animals. 
Possible reasons for this could be that the implant was not injected in one single depot 
area or the site of injection (subcutaneous versus subdermal) could have differed 
between animals. Certainly both of these are possible as the injections were not all 
performed by the same individual and the rat is a small animal, making distinguishing 
between subdermal and subcutaneous areas difficult. Further unlike during in vitro 
testing where the implant clumped together within the dialysis tubing regardless of 
method of injection due to the relatively large volume of the fluid within the tubing. In 
vivo this is not possible as there is spreading of the implant due to the pressure from 
the tissue surrounding the implant. Another reason for the variation between animals 
could be the temperature. During the pilot study the temperature of animals at the site 
of implantation was noted (Table 7.4). One animal showed a temperature reading of 
31.6˚C which is below the gelation temperature of the ISFI. It is possible that the 
implant released the drug faster in some animals due to the lower temperature.   
 
The side-effect (diarrhoea) experienced by the animals was possibly the result of the 
sustained release of drug from the implant compared to the quick clearance of the MTX 
when the drug was given intraperitoneally to the control group. This is possibly due to 
an initial damage of the gastrointestinal tract (GIT) tissue due to the burst effect of the 
implant which is consistent with the high drug quantity in the blood observed on Day 2. 
The toxicity of MTX on the GIT as has been reported by Bajin-Katić et al., 2004. 
Although the exact mechanisms of the damage are unknown, damage to the precursor 
crypt cells occur and hence once mature cells are sloughed off, there are no cells to 
replace them leaving the intestinal tissue exposed to biliary salts and pancreatic 
secretions and hence autodigestion occurs. A similar toxicity profile has been reported 
in rats receiving MTX delivered by a surgically implanted acrylic cement implant 
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(Heringou et al.,1989). The rats in this study also developed gastrointestinal toxicity 
characterised by gastrointestinal haemorrhage after 4-6 days following implantation.  
 
After Day 2 however, the drug concentration in the blood is extremely low indicating 
perhaps very little blood reaching the blood stream as desired. In a tumor bearing 
animal such a side-effect may not have been seen as the burst release of the drug 
would have been utilised by the rapidly growing tumor. However, this is a merely a 
hypothesis and must be confirmed in further work on tumor bearing animals.  
 
7.3.2.4.3.2.  The effect of the application of ice 
As shown in Figure 7.13, application of ice to the region did cause an enhanced 
release of drug. However once again there was much variation between the implants, 
once again possibly due to different injection patterns in the animals. On day 4, the 
implant did not appear as responsive to ice as on day 2 following the implantation. This 
was as observed in vitro. 
 
 
Figure 7.13: The effect of application of ice to the region of implantation (SD<0.06) 
 
7.3.2.4.4. Analysis of methotrexate concentration remaining in implant and in 
surrounding tissue 
Figure 7.14(a) and (b) show the calibration curves obtained for PBS and methanol 
respectively. Figure 7.14(c) shows the amount of drug remaining in recovered implants. 
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The two day 10 rats (Rats 49 and 50) show very different results. Rat 49 has very little 
drug remaining while Rat 50 has a quarter of the drug initially implanted, still present. 
Although to some degree this can be compared with the weight loss shown by the 
animals, the amount of variation between animals makes the observation of trends 
difficult. All animals (placebo and main study) lost weight on the day following injection 
of the implant. However, thereafter, placebo animals gained weight or eventually 
exceeded the original weight. It should be noted that Rat 70 (Figure 7.14(e)) suffered 
muscle injury during the administration of the anaesthetic before ultrasound imaging on 
Day 6 and as result appeared to have lost weight in the days following the procedure. 
However, it did regain the weight it had lost. Rat 67, a placebo animal sacrificed after 8 
days shows the typical profile of weight gain showed by the animals (Figure 7.14(e)). It 
is worthy noting that Rat 50 gained weight after day 7 whereas Rat 49 continued to 
lose weight Figure 7.14(f). This is perhaps due to the increased release of drug from 
the implant in Rat 49 whereas the ISFI in rat 50 did not release as much MTX. This 
explains both the high amount of residual drug in the implant as well as the lack of 
weight loss observed in Rat 50. In addition, Rat 49 also presented with diarrhoea but 
Rat 50 did not.  Of animals from day 4 to day 10 from the baseline study (n=20), 13 
rats showed a loss of weight and 7 showed a gain of weight. The day 4 rats also 
showed low amounts of drug remaining in the implants and the animals examined had 
also lost weight over the 4 days and both suffered from diarrhoea. Hence animals that 
lost weight and developed diarrhoea had low levels of drug remaining in the implant 
while animals that did not develop diarrhoea showed higher amounts of drug remaining 
in the implant. This indicates that in some animals drug release from the implant 
occurred more rapidly than others. Once again this may be due to the lower 
temperature at the site in these animals or a variation in injection technique. 
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Figure 7.14: a) Calibration curve of MTX in PBS b) calibration of MTX in methanol c) 
remaining drug in the implant over 4 or 10 days and after the application of ice to the 
region d) drug in the surrounding tissue after 4 or 10 days and after the application of 
ice e) weight loss in rats carrying the MTX loaded implants for 10 days and f) weight 
loss in placebo receiving rats. 
 
The area around the implant (Figure 7.14(d)) showed relatively high amounts of drug 
after the application of ice and as shown drug was still present at the site after 10 days 
even in animals with low amounts of drug remaining in the implant. Interestingly, 
although the application of ice showed higher amounts of drug in the blood with the 
application being for 5 minutes, the application of ice for 2 minutes appears to show 
higher amounts of MTX in the surrounding tissues. Further investigation is required in 
order to determine possible reasons for this occurrence. 
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7.3.2.4.5. Ultrasound imaging of the ISFI in vivo 
Ultrasound imaging conducted revealed a solid mass in the subcutaneous tissue as 
shown in Figure 7.15. Note the absence of the mass in the placebo animal (a).    
 
 
Figure 7.15: Ultrasound imaging showing a) the absence of the implant in a placebo 
rat and b) the presence of the ISFI in an animal from the main study. 
 
The scan of the area of implantation in the rat was used to calculate the approximate 
volume of the implant. Figure 7.16 shows the images obtained during three 
dimensional plotting of the area of the implant. The area of the implant was determined 
to be 25mm3 in the animal examined. 
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Figure 7.16: a) Image obtained using 2 dimensional ultrasound b) three-dimensional 
image obtained from scan of implant area showing the medial and saggital planes and 
c) and d) three-dimensional plotting of the area of the implant. Note the tapering of the 
implant indicating the point of withdrawal of the needle from the flank leaving a “trail” of 
the implant. 
 
7.4. Concluding Remarks 
In conclusion, the ISFI while promising in vitro, has shown less promising results in 
vivo. In vivo results revealed that the ISFI formulation was able to deliver drugs to the 
site over a period of ten days. Animals receiving the implant showed side effects 
related to the chemotherapeutic drug indicating that doses of the drug were being 
delivered and maintained in vivo. This was confirmed by the blood levels of the drug 
determined using UPLC. Animals receiving the drug intraperitoneally did not show the 
same side-effects and blood levels of the drug were so low they could not be 
determined even at Day 2 indicating that the delivered drug was quickly cleared in vivo. 
Animals receiving the placebo implant also did not show this side-effect indicating that 
it was a side-effect of the drug and not of the implant material itself. While this indicates 
the superiority of the ISFI over the intraperitoneal delivery of drug, it was not 
considered likely that the ISFI would be able to deliver drug over a period of three 
months as envisaged.  
a)
c)
b)
d)
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CHAPTER 8  
CONCLUSIONS AND RECOMMENDATIONS 
8.1. Conclusions 
Considering the burden of cancer and the numerous problems associated with the 
systemic treatment of solid tumors in particular, the development of an in situ forming 
implant capable of delivering chemotherapeutics directly to tumors is certainly required. 
In order to formulate an ideal in situ forming implant, preformulation studies were 
conducted and the thermoresponsive polymer, PMVE in combination with CaCl2 was 
selected for use in the development of an in situ forming implant. Statistical 
optimization utilizing a Face-Centered Central Composite design was employed for 
determining the optimal ISFI capable of being easily injectable into the body, forming 
an implant at the site of injection and of releasing the entrapped chemotherapeutic over 
a long period of time. The optimized formulation was found to comprise of 16.87%w/v of 
PMVE and 0.1482M of CaCl2. Optimization of formulated pH-responsive microparticles 
was also conducted. Due to difficulty in injecting the formulations as a result of particle 
agglomeration, particles were only tested in vitro against cell lines. Microparticles were 
not tested in vivo. 
 
Optimized ISFI formulations were prepared and release fractions tested for activity 
against cancer cell lines. In vivo testing of the implant was conducted in Sprague-
Dawley rats. Results showed that several animals that received the ISFI loaded with 
methotrexate developed diarrhea. Animals in the control group receiving methotrexate 
intaperitoneally did not show this side-effect. Hence the side-effects were indicative of 
prolonged release of drug from the implant compared to the intraperitoneal delivery of 
methotrexate which was cleared rapidly. This was confirmed by the blood levels found 
in the animals receiving the implant.  In addition, animals receiving the placebo implant 
did not show this side-effect either indicating that the diarrhea was a side-effect of the 
drug and not of the implant material itself. 
 
In conclusion, in vitro work showed promising results with the release of drug from the 
implant exceeding a month while in vivo results revealed that further work is required to 
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improve the biocompatibility of the ISFI and to prolong the release of drug from the 
implant in vivo.  
 
8.2. Recommendations 
To date there is very little data on the pharmaceutical use of PMVE. It is recommended 
that the polymer be investigated further. The ISFI should be formulated without the 
addition of CaCl2, in order to provide basis to the possibility that CaCl2 may be 
responsible for the local necrosis caused. In addition, it is recommended that should 
such a study be conducted, organs of each animal be collected for tracing of 
methotrexate concentrations.  
 
A tumor bearing animal will also provide a more realistic model for testing rather than 
healthy animals. Tumor bearing models will offer two advantages: firstly the drug when 
released from the implant will be delivered to the cancerous tissue. This will allow the 
researcher to monitor the size of the tumor as a measure of drug release. Secondly the 
microenvironment of a solid tumor differs from that of a healthy animal. In vitro studies 
conducted attempted to mimic the solid tumor environment. It is possible that different 
results would be seen in a tumor bearing model.  
 
Assuming that the ISFI is successfully formulated without the addition of the CaCl2, a 
different animal model should be selected. The peripheral temperature at the site of 
implantation in the rat model may have impacted the release behaviour of the drug 
from the implant due to a smaller body surface area.    
 
Further, studies of PMVE in different pharmaceutical embodiments is also 
recommended. Utilization of PMVE for the formation of micro- or nano- particles among 
other uses may prove interesting. 
 
Considering the calcification of tissues caused and the slow in vivo degradation of the 
implant, the implant (as currently formulated) is perhaps also suited for the potential 
delivery of cells (such as osteoblasts) to areas where bone formation is required.  
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APPENDIX B (I) 
Formulation approaches for interactive pH-responsive nanoparticles 
Farhana Ravat, Ameena Wadee, Viness Pillay*, Yahya E. Choonara and Lisa C. du Toit 
University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, Parktown, 2193, 
Johannesburg, South Africa 
*Correspondence: viness.pillay@wits.ac.za 
Introduction 
To compare the particle sizes, zeta potential and drug entrapment efficiency of nanoparticles comprising various 
polymeric permutations and utilizing different nanoparticle preparation approaches. Furthermore, the effect of pH on the 
zeta potential of the nanoparticles was also explored. 
Methods 
Two approaches of forming chitosan (CHT) nanoparticles were investigated namely, a coacervation/precipitation (CP) 
and an emulsion-droplet (ED) method. In each case the stabilizer used was polyvinyl alcohol (PVA) at a concentrations 
ranging from 1-5%
w
/v. The effect of Span 80 was also investigated. Methacrylic acid nanoparticles were produced using 
a  nano-precipitation method with PVA (0.4%
w
/v or 1%
w
/v) used as stabilizers. Diphenhydramine (DPH) was used as the 
model drug to investigate the drug entrapment efficacy (DEE) within the nanoparticles. The particle size distribution and 
zeta potential were measured using a ZetaSizer NanoZS (Malvern Instruments, UK).  
Results 
Using the CP method for preparing CHT nanoparticles mean particle sizes ranged between 499.7d.nm (Pdi=0.404) and 
530d.nm (Pdi=0.373) with the use of 1%
w
/v and 5%
w
/v PVA respectively. The ED approach using CHT produced 
nanoparticles with a mean particle size ranging between 408nm (Pdi=0.436), 531nm (Pdi=0.711) and 166nm 
(Pdi=0.364) with the use of either 1%
w
/v PVA, 5%
w
/v PVA or Span 80 as a stabilizer respectively. Methacrylic acid 
nanoparticles had a mean particle size of 338nm (Pdi=0.141 at 0.4%
w
/v PVA) and 384nm (Pdi=0.112 at 1%
 w
/v PVA). 
The zeta potential values for all nanoparticle formulations varied between 0.236mV to -0.162mV regardless of the 
stabilizer or the pH of the suspending fluid used. DEE for CHT using the CP approach had values of 9.20% (1%
w
/v PVA) 
and 27.00% (5%
w
/v PVA). DEE values for CHT using the ED method revealed values of 8.12 % (1%
w
/v PVA), 6.99% 
(5%
w
/v PVA) and 14.66% (Span 80). DEE values for the methacrylic acid nanoparticles were 2.47% (0.4%
w
/v PVA) and 
1.88% (1%
w
/v PVA) for the w/o/w approach. The nanoparticle sizes varied significantly between the various approaches 
adopted and the type of stabilizer used. An increase in the stabilizer concentration yielded larger particles with greater 
polydispersity indices that were suggestive of agglomeration and the large particle size variation. 
Conclusions 
The CP method of preparing CHT nanoparticles displayed the most stability and efficiency in terms of entrapping highly 
soluble drugs such as DPH.  
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APPENDIX B (II) 
The effect of CaCl2 and Gum Arabic on the physicomechanical properties and drug release profile of 
thermoresponsive poly(methyl vinyl ether) gels 
Ameena Wadee, Viness Pillay*, Yahya E. Choonara, Lisa C. Du Toit 
University of the  Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road,   Parktown, 2193, 
Johannesburg, South Africa, University of the Witwatersrand 
*Correspondence: viness.pillay@wits.ac.za 
Purpose: 
To determine the effect of Gum Arabic on gel strength and drug release profile of thermosensitive poly(methyl vinyl 
ether) (PMVE) hydrogels. Further, to determine the interactions occurring between the polymers by means of FTIR. As 
the implant formed is intended for the prolonged treatment of solid tumors, conditions chosen mimic those found at a 
tumor site. 
Methods: 
Preparation of solutions: PMVE solutions were diluted to a 0.25% w/v solution. CaCl2 was added to 20mL of PMVE in 
concentrations of 0.05M, 0.1M, 0.2M and 0.3M with or without the addition of Gum Arabic (4%). 
Textural Analysis: Phosphate buffered solution(pH 6.75) was heated to 37˚C± 0.5˚C and 3mL of the polymeric blend 
being tested was immersed for 10 seconds. Gel strength and compressibility were then determined using a textural 
analyser (TA.XTplus Texture Analyser, StableMicroSystems, England) and the following parameters: Probe diam: 
10mm; pre test speed: 1mm/s, test speed: 2mm/s; post test speed: 3mm/s; depth of compression: 2mm; trigger force: 
0.001mN. All tests were conducted in triplicate. 
Fourier Transformed Infrared (FTIR): Polymeric blends were examined using a FTIR Spectrphotometer (Perkin Elmer, 
USA). 
Drug release: Folic acid -as the model drug- was added to prepared polymeric blends in the concentration of 1mg/mL. 
Solutions were stirred until the folic acid was evenly suspended in the solution.  5mL of the formulation was injected into 
a dialysis bag (MWCO: 2kDa) which had been prefilled with 3mL of phosphate buffer solution (pH6.75). The dialysis bag 
was then immersed in a jar containing 60 mL phosphate buffer solution (pH 6.75) and placed in an orbital shaker bath 
(37˚C± 0.5˚C; 25 rpms). 4mL samples were drawn at 0.5 hours, 1.5 hours, 3 hours, 4.5 hours, 6 hours, 24 hours, 36 
hours and 60 hours and replaced with prewarmed buffer to maintain sink conditions. Drug content was assayed by UV 
spectroscopy at 280nm. 
Results: 
Textural analysis: The CaCl2 containing gels were harder and the area under the curve for these gels were greater 
than those of PMVE gels without any additives. The addition of Gum Arabic to the CaCl2 containing gels resulted in gels 
that were weaker. 
FTIR: The profiles for the combinations of polymers showed no interaction between either the polymers, or polymer-
salt or polymers-drug combinations. 
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Drug Release: Sustained release of folic acid was achieved from all the formulations. The PMVE-CaCl2 gels released 
drug more slowly than the PMVE gels and release was slowed even further with the addition of Gum Arabic. Less than 
20% of drug was released from the PMVE-CaCl2 and PMVE-CaCl2-GumArabic implants after 20 hours and 
approximately 35% of drug had been released from the PMVE gels at the same time point.  
Conclusions: 
The addition of CaCl2 to PMVE formed gels that were harder and released drug more slowly than the PMVE gels with 
no additives. The addition of Gum Arabic to CaCl2-PMVE gels retarded drug release further but the gels formed were 
weaker indicating that the hardness of the gels does not correlate with drug release from the implant. 
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APPENDIX B (III) 
An Injectable In Situ Forming Implant for the Treatment of Solid Tumors Utilizing a Central Composite Design 
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Purpose:  
Poly(methylvinyl ether) (PMVE) is a thermoresponsive polymer which when exposed to an increase in temperature 
converts from a solution to a gel. This can be exploited in the development of an injectable, in situ forming implant (ISFI) 
for the treatment of solid tumors.  
Methods: 
A two-factor face-centered central composite design (FCCCD) was employed to obtain an optimal ISFI formulation which 
was easily injectable, able to gel around body temperature and capable of delivering a chemotherapeutic over prolonged 
periods of time. PMVE solutions (15-30%
w
/v) were diluted and CaCl2 (0.08-0.5M) was added in accordance with 14  ISFI 
formulations generated by a FCCCD. In order to determine the response of the ISFI to increases in temperature, a 
Rheometer System was used to expose samples to fixed strain and oscillation (18Pa, 10Hz) while the temperature of the 
sample was increased. Model drug, folic acid, was added to ISFI formulations at a concentration of 5mg/mL. Drug 
release studies were performed and samples were drawn every 3 days for 30 days. Drug content was assayed by UV 
spectroscopy. A Textural Analyzer was utilized to determine the injectability of the ISFI formulations by comparing the 
maximum force required to depress the plunger of a syringe filled with a formulation to that of a water filled syringe.  
Results:  
ISFI formulations showed gelation temperatures of below 36˚C with the formulation with the highest concentration of 
CaCl2(0.5M) showing the lowest gelation temperature 32.1˚C (±0.6˚C). Prolonged release of folic acid was achieved 
from all of the ISFI formulations (≤ 45% of the drug over 30 days) with formulations containing higher amounts of salt 
(0.2-0.5M) showing lower initial burst release profiles. Lower polymer concentrations (15%
w
/v) in the formulation resulted 
in easily injectable formulations.  
Conclusion:  
Utilization of a statistical design of the experiments has assisted in obtaining an optimal implant formulation which 
possesses the required properties and which may provide sustained release of entrapped chemotherapeutics.  
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APPENDIX B (IV) 
The development of an in situ forming implant for the treatment of osteosarcoma: Autoclaving as a 
sterilization method 
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Poly(methyl vinyl ether) (PMVE) is a thermoresponsive polymer which at increased temperatures converts 
from a solution to a gel. This can be exploited in the development of an injectable, in situ forming implant 
for the treatment of osteosarcomas and other solid tumors. A sterilization method which does not alter the 
gelation properties is required. MATERIALS AND METHODS: 1) Preparation of solutions: PMVE solutions 
were diluted to 35%
w
/v solutions and CaCl2 (0.5M) was added. Solutions were autoclaved at 121˚C for 
15mins and compared with unsterilized solutions. 2) Rheology: A Haake Modular Advanced Rheometer 
System (ThermoFisher Scientific, Germany) was used to expose samples to fixed strain and oscillation 
(18Pa, 10Hz) while the temperature of the sample was increased. 3) FTIR: A Fourier Transformed Infrared 
Spectrophotometer (PerkinElmer, USA) was used to determine the effect of autoclaving on the chemical 
structure of the polymer. 4) Drug release: Model drug, folic acid, was added to polymer solutions in the 
concentration of 5mg/mL. Drug release studies were carried out and samples were drawn every 3days for 
30days. Drug content was assayed by UV spectroscopy. RESULTS: The gelation temperature of the 
autoclaved formulations remained the same at 33.6˚C. FTIR revealed no change in the spectra. However, 
release of folic acid from the autoclaved formulation was slightly faster as 32% of the drug was released 
after 32 days (unsterilized formulations: 27%). CONCLUSIONS: Autoclaving does not appear to have 
changed the thermogelation properties. Observed differences between the unsterilized polymer and the 
autoclaved one can be explained by the incorrect making up to volume of the solution following 
autoclaving.  
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APPENDIX B (V) 
The development of an in situ forming implant for the treatment of solid tumors: 
Determination of the effect of methotrexate release on colon carcinoma cells and 
in vivo studies in the rat model 
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Purpose: 
    An implant which forms at the site of a tumor and releases drug in situ provides many benefits. High 
local concentrations of drug at the site can be achieved as well as a reduction in systemic side-effects. 
Poly(methylvinyl ether) is a biocompatible, thermoresponsive polymer which converts from a solution to a 
solid with a change in temperature. As a result the polymer in solution form can be injected at the site of 
the tumor and will form a solid implant in situ due to its response to the increase in temperature. This study 
sought to determine whether the release of the entrapped chemotherapeutic, methotrexate (MTX) 
occurred over a month and whether the amount of drug being delivered was sufficient to cause cancer cell 
death. A pilot study in the non-tumor bearing rat model was also conducted.  
Methods:  
   Preparation of implant formulations: Optimized formulations of poly(methylvinyl ether) (20%
w
/v, Calcium 
Chloride: 0.125M) were prepared and loaded with MTX at a concentration of 5mg/mL. Formulations 
prepared for animals were prepared from autoclaved polymer and drug was added to the formulation 
under aseptic technique. 
   Determination of the release of MTX from the implant: Drug release studies were performed and 
samples were drawn every 3 days for 30 days. Drug content was assayed using UV spectroscopy. Drug 
elutes collected were also utilized to determine whether MTX was being released in sufficient quantities to 
inhibit the growth of cells.  
   Utilization of flow cytometry and an MTT assay for the determination of cell viability: Colon carcinoma 
cells (HT29) which were used as the model for solid tumors, were grown in Dulbecco’s Modified Essential 
Medium (supplemented with 10% FBS and 1%Pen-Strep) to 75% confluency. Elutes collected from the 
drug release studies on days 1, 7, 15 and 30 were then added to cells and incubated over 24 hours. Flow 
cytometry and MTT assays were then conducted on the treated cells to determine cell viability. 
   Determination of the release of MTX in the rat model: Sprague-Dawley rats (200-250g) were divided into 
two groups of 25 rats each. Animals were followed over a period of 10 days. Control animals received two 
intraperitoneal injections (on days 1 and 5) delivering a total dose of MTX 2mg/rat/10 days, whereas the 
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study group received a once-off implant delivering a dose of 2mg/rat/10 days. Rats were monitored for 
toxicity throughout the study.  
Results and Conclusions: 
  Release of MTX exceeded 30 days with mean fractional drug release after 30 days of 25% of the 
entrapped drug. The MTT assay showed that a significant percentage of cells were non-viable after 
treatment with elutes from the implant. This was confirmed by flow cytometry. Rats in the control group did 
not develop any significant toxicity as a result of the intraperitoneal injection possibly due to the rapid 
clearance of the MTX. Rats that received the implant began to develop significant toxicity to MTX after 6 
days. This indicated that MTX was being released in sufficient quantities and in a sustained manner and 
shows promise for utilization of this formulation as an in situ forming implantable system delivering 
chemotherapeutics to the site of solid tumors.  
**Ethics approval for in vivo studies obtained from WITS Animal Ethics Screening Committee, AESC 
Number: 2009/37/05. 
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